---
document_datetime: 2023-09-21 18:57:28
document_pages: 134
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/jentadueto-epar-public-assessment-report_en.pdf
document_name: jentadueto-epar-public-assessment-report_en.pdf
version: success
processing_time: 148.6913697
conversion_datetime: 2025-12-30 12:38:03.584903
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Assessment report

## Jentadueto

linagliptin / metformin hydrochloride

Procedure No.:

EMEA/H/C/002279

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone

+44 (0)20 7418 8400

Facsimile

+44 (0)20 7418 8613

E-mail info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| Note ............................................................................................................1     | Note ............................................................................................................1     | Note ............................................................................................................1   |
|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| 1.                                                                                                                     | ............................................5 Background information on the procedure                                  |                                                                                                                      |
| 1.1.                                                                                                                   | Submission of the dossier....................................................................................          | 5                                                                                                                    |
| 1.2. Manufacturers ................................................................................................... | 1.2. Manufacturers ................................................................................................... | 6                                                                                                                    |
| 2. ..............................................................................6 Scientific discussion               | 2. ..............................................................................6 Scientific discussion               |                                                                                                                      |
| 2.1.                                                                                                                   | .................................................................................................... Introduction      | 6                                                                                                                    |
| 2.2.                                                                                                                   | Quality aspects                                                                                                        | ................................................................................................ 9                   |
| 2.2.1.                                                                                                                 | ................................................................................................. Introduction         | 9                                                                                                                    |
| 2.2.2.                                                                                                                 | Active Substance                                                                                                       | .......................................................................................... 9                         |
| 2.2.3.                                                                                                                 | ............................................................................ Finished Medicinal Product                | 11                                                                                                                   |
| 2.2.4.                                                                                                                 | .......................... Discussion on chemical, pharmaceutical and biological aspects                               | 13                                                                                                                   |
| 2.2.5.                                                                                                                 | ................... Conclusions on the chemical, pharmaceutical and biological aspects                                 | 14                                                                                                                   |
| 2.3.                                                                                                                   | ........................................................................................ Non-clinical aspects          | 14                                                                                                                   |
| 2.3.1.                                                                                                                 | Introduction                                                                                                           | ............................................................................................... 14                   |
| 2.3.2.                                                                                                                 | ............................................................................................. Pharmacology             | 14                                                                                                                   |
| 2.3.3.                                                                                                                 | ........................................................................................ Pharmacokinetics              | 18                                                                                                                   |
| 2.3.4.                                                                                                                 | ................................................................................................. Toxicology           | 25                                                                                                                   |
| 2.3.5.                                                                                                                 | ..................................................... Ecotoxicity/environmental risk assessment                        | 41                                                                                                                   |
| 2.3.6.                                                                                                                 | ................................................................. Discussion on non-clinical aspects                   | 46                                                                                                                   |
| 2.3.7.                                                                                                                 | ............................................................ Conclusion on the non-clinical aspects                    | 47                                                                                                                   |
| 2.4.                                                                                                                   | .............................................................................................. Clinical aspects        | 47                                                                                                                   |
| 2.4.1.                                                                                                                 | ............................................................................................... Introduction           | 48                                                                                                                   |
| 2.4.2.                                                                                                                 | ........................................................................................ Pharmacokinetics              | 51                                                                                                                   |
| 2.4.3.                                                                                                                 | ..................................................................................... Pharmacodynamics                 | 64                                                                                                                   |
| 2.4.4.                                                                                                                 | ............................................................... Discussion on clinical pharmacology                    | 68                                                                                                                   |
| 2.4.5.                                                                                                                 | ............................................................. Conclusions on clinical pharmacology                     | 68                                                                                                                   |
| 2.5.                                                                                                                   | .............................................................................................. Clinical efficacy       | 69                                                                                                                   |
| 2.5.1.                                                                                                                 | ................................................................................. Dose response studies                | 69                                                                                                                   |
| 2.5.2.                                                                                                                 | ............................................................................................... Main studies           | 72                                                                                                                   |
| 2.5.3.                                                                                                                 | .......................................................................114 Discussion on clinical efficacy             |                                                                                                                      |
| 2.5.4.                                                                                                                 | ................................................................116 Conclusions on the clinical efficacy               |                                                                                                                      |
| 2.6.                                                                                                                   | ...............................................................................................117 Clinical safety     |                                                                                                                      |
| 2.6.1.                                                                                                                 | Discussion on clinical safety                                                                                          | .........................................................................123                                         |
| 2.6.2.                                                                                                                 | ..................................................................125 Conclusions on the clinical safety               |                                                                                                                      |
| 2.7.                                                                                                                   | Pharmacovigilance                                                                                                      | ........................................................................................125                          |
| 2.8.                                                                                                                   | User consultation                                                                                                      | ..........................................................................................129                        |
| 3. Benefit-Risk Balance                                                                                                | 3. Benefit-Risk Balance                                                                                                | .........................................................................129                                         |
| 4. Recommendations.............................................................................134                     | 4. Recommendations.............................................................................134                     |                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ALD

Approximate Lethal Dose

ALT

Alanine aminotransferase (plasma)

AP

Applicant's Part (or Open Part) of a DMF

API

Active Pharmaceutical Ingredient

AR

Assessment Report

ASM

Active Substance Manufacturer

ASMF

Active Substance Master File = Drug Master File

AST

Aspartate aminotransferase (plasma)

AUC0-24h,ss

Area under the plasma-concentration-time curve from zero to 24 hours steady state

BA

Bioavailability

BCS

Biopharmaceutical Classification System

BE

Bioequivalence

BI 1356

Linagliptin

bid

Twice daily (bis in die)

BP

British Pharmacopoeia

CEP

Certificate of Suitability of the European Pharmacopoeia

CFU

Colony Forming Units

Cmax,ss

Maximum plasma level, steady state

CMS

Concerned Member State

CoA

Certificate of Analysis

Crl:CD(SD)

Charles River Labs strain of rats (Sprague Dawley rats)

Crl:WI(Han)

Charles River Labs Wistar strain of rats (Wistar Han rats)

CRS

Chemical Reference Substance (official standard)

CYP

Cytochrome P450

DPP-4

Dipeptidyl Peptidase 4

DMF

Drug Master File = Active Substance Master File

DoE

Design of Experiments

DP

Drug Product

DS

Drug Substance

DSC

Differential Scanning Calorimetry

EDQM

European Directorate for the Quality of Medicines

f

Female(s)

GD

Gestation Day

GLP

Good Laboratory Practice

GLP-1

Glucagon-Like Peptide-1

h

Hour(s)

HCl

Hydrochloric acid

HDPE

High Density Polyethylene

HsdHan: Wist   Harlan Ltd Wistar strain of rats (Han Wistar rats)

IPC

In-process control

IR

Infrared

IU

International Units

JP

Japanese Pharmacopoeia

KF

Karl Fischer

LDPE

Low Density Polyethylene

LOA

Letter of Access

LOD

Limit of Detection

LOQ

(1) Limit of Quantification, (2) List of Questions

m

Male(s)

MA

Marketing Authorisation

MAH

Marketing Authorisation Holder

MATE

Multidrug And Toxin Extrusion Antiporter

MEB

Medicines Evaluation Board

MRHD

Maximum Recommended Human Dose

MS

Mass Spectrometry

MTD

Maximum Tolerated Dose

ND

Not detected

NLT

Not less than

nM

Nanomolar (nmol/L)

NMR

Nuclear Magnetic Resonance

NMT

Not more than

NOAEL

No Observed Adverse Effect Level

No. (Animal)

number

OCT

Organic Cation Transporter

oGTT

Oral Glucose Tolerance Test

OOS

Polychlorotrifluoro ethylene

PDE

Permitted Daily Exposure

PE

Polyethylene

Ph.Eur.

European Pharmacopoeia

PIL

Patient Information Leaflet

PK

Pharmacokinetic

PMAT

Plasma Membrane Monoamine Transporter

PP

Polypropylene

PVC

Polyvinyl chloride

PMAT

Plasma Membrane Monoamine Transporter

QOS

Quality Overall Summary

RH

Relative Humidity

RMS

Reference Member State

RP

Restricted Part (or Closed Part) of a DMF

RRT

Relative retention time

RSD

Relative standard deviation

RVG #

Marketing Authorisation number in NL

SPC

Summary of Product Characteristics

UV

Ultraviolet

USP/NF

United States Pharmacopoeia/National Formulary

XRPD

X-Ray Powder Diffraction

<div style=\"page-break-after: always\"></div>

* This is a general list of abbreviations. Not all abbreviations will be used.

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Boehringer Ingelheim International GmbH submitted on 29 June 2011 an application for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMA)  for  Jentadueto,  through  the centralised  procedure  falling  within  the  Article  3(1)  and  point  3  of  Annex  of  Regulation  (EC)  No 726/2004.  The  eligibility  to  the  centralised  procedure  was  agreed  upon  by  the  EMA/CHMP  on  21 January 2010.

The applicant applied for the following indication: For patients with type 2 diabetes mellitus:

Jentadueto  is  indicated  as  an  adjunct  to  diet  and  exercise  to  improve  glycaemic  control  in  adult patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of linagliptin and metformin.

Jentadueto is  indicated  in  combination  with  a  sulphonylurea  (i.e.,  triple  combination  therapy)  as  an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC  -  complete  and independent application.

The  application  submitted  is  composed  of  administrative  information,  complete  quality  data,  nonclinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or  bibliographic  literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant  to  Article  7  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/3/2010 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Not applicable.

## Market exclusivity

Not applicable.

## Scientific Advice/Protocol Assistance

The  applicant  received  Scientific  Advice  from  the  CHMP  on  22-25  September  2008.  The  Scientific Advice pertained to non-clinical and clinical aspects of the dossier.

## Licensing status

A new application was filed in the following countries: USA, Switzerland, Indonesia, Korea, Argentina, Brazil, Columbia, Mexico and Peru.

The product was not licensed in any country at the time of submission of the application.

<div style=\"page-break-after: always\"></div>

## 1.2. Manufacturers

## Manufacturer responsible for batch release

Boehringer Ingelheim Pharma GmbH &amp; Co. KG Binger Strasse 173 D-55216 Ingelheim am Rhein Germany

## Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Pieter de Graeff Co-Rapporteur: Karsten Bruins Slot

1. The application was received by the EMA on 29 June 2011.
2. The procedure started on 20 July 2011.
3. The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  07  October 2011.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  07 October 2011.
4. During  the  meeting  on  14-17  November  2011,  the  CHMP  agreed  on  the  consolidated  List  of Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the applicant on 18 November 2011.
5. The applicant submitted the responses to the CHMP consolidated List of Questions on 12 January 2012.
6. The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 24 February 2012.
7. During the CHMP meeting on 12-15 March 2012, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
8. The applicant submitted the responses to the CHMP List of Outstanding Issues on 20 April 2012.
9. The Rapporteurs circulated the Joint Assessment Report on the applicant's written responses to the List of Outstanding Issues to all CHMP members on 7 May 2012 and 21 May 2012.
10. During the meeting on 21-24 May 2012, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Jentadueto on 24 May 2012.

## 2. Scientific discussion

## 2.1. Introduction

## Problem statement

Type 2 diabetes mellitus (T2DM) is a disease affecting more than 180 million people worldwide and particularly in the industrialised countries the incidence of this disorder is increasing. The prevalence is expected to rise to 300 million people by the year 2025. T2DM is characterised by multiple metabolic

<div style=\"page-break-after: always\"></div>

abnormalities involving insulin resistance, impaired insulin secretion, and increased glucose production. Morbidity  and  mortality  associated  with  T2DM  is  caused  by  macrovascular  complications  such  as cardiovascular disease and microvascular complications such as retinopathy, neuropathy, and nephropathy. In addition to diet and exercise, a number of medications are available to lower blood sugar levels. However, all of the established therapies have limitations including a range of safety and tolerability issues, limited extent and/or durability of efficacy, and inconvenience in dosing. The most common adverse events associated with currently used agents are hypoglycaemia (with sulfonylureas, meglitinides, insulin), weight gain (with sulfonylureas, meglitinides, insulin, thiazolidinediones [TZDs]), and gastrointestinal intolerance (with metformin, alpha-glucosidase inhibitors). Dipeptidyl-dipeptidase4  (DPP-4)  inhibitors  are  generally  well  tolerated;  treatment  with  the  currently  marketed  DPP-4 inhibitors  (sitagliptin,  saxagliptin,  vildagliptin)  was  however  associated  with  elevated  incidences  of infections and  gastrointestinal disorders (compared  with  placebo). Sitagliptin, vildagliptin,  and saxagliptin are either not indicated in patients with moderate to severe renal impairment or require dose adjustments in this patient population.

## About the product

Jentadueto is a fixed dose combination of linagliptin and metformin hydrochloride.

Linagliptin (BI 1356) is a selective, orally administered, xanthine-based inhibitor of dipeptidylpeptidase-4  (DPP-4)  with  a  50%  Inhibitor  Concentration  (IC50)  of  1  nM.  DPP-4  inhibitors  are antidiabetic agents that lower blood glucose by extending the short half life of glucagon-like peptide 1 (GLP-1),  which  is  secreted  by  intestinal  L-cells  in  response  to  a  meal,  and  glucose-dependent insulinotropic peptide (GIP), both of which exert glucose-dependent insulinotropic effects and thereby contribute  to  the  maintenance  of  post-meal  glycaemic  control.  GLP-1  lowers  blood  glucose  by increasing  the  glucose-stimulated  insulin  release  and  by  limiting  glucagon  secretion  to  slow  gastric emptying and to induce satiety. DPP-4 inhibitors maintain long-term β -cell  function, which has been demonstrated in animal models. Inhibition of DPP-4 bears little risk of hypoglycaemia in patients with diabetes  mellitus  because  GLP-1  activity  ceases  when  plasma  glucose  concentration  falls  below 55 mg/dl. Linagliptin is predominantly excreted unchanged via the faeces. Renal excretion is a minor pathway  of  elimination  of  linagliptin  at  therapeutic  doses.  A  Marketing  Authorisation  for  linagliptin (Trajenta 5mg) was granted in the EU by the EC on the 24 th of August 2011.

<div style=\"page-break-after: always\"></div>

Metformin  has  been  used  in  Europe  for  over  50  years  and,  together  with  lifestyle  modification,  is recommended by the European Association for the Study of Diabetes (EASD) as the first-line treatment for T2DM. The immediate release dosage forms are widely approved with tablet strengths of 500 mg, 850 mg and 1000 mg approved in several countries. Although its mechanism of action is not yet fully understood, metformin lowers blood glucose levels primarily by suppressing hepatic gluconeogenesis. It is believed that this is achieved through metformin-induced activation of adenosine monophosphateactivated protein kinase, an energy-regulating enzyme in the liver. Furthermore, metformin improves the  insulin  sensitivity  of  peripheral  tissues,  decreases  gastrointestinal  tract  glucose  absorption,  and acts  as  an  insulin  sensitiser  without  exerting  any  direct  effect  on  pancreatic β -cell  insulin  secretion. Through these mechanisms, metformin therapy typically leads to substantial reductions in glycosylated HbA1c but it does not promote weight gain or increase the risk of hypoglycaemia.

The combination of linagliptin with metformin may provide clinically meaningful treatment benefits by lowering glucose and reducing glycosylated haemoglobin (HbA1c) further than monotherapy with either component at corresponding doses. Combining linagliptin with metformin hydrochloride simplifies the antidiabetic  therapy  by  decreasing  the  number  of  tablets  to  be  taken  and  is  expected  to  improve patients'  compliance  with  medication;  fixed-dose  combination  therapy  has  resulted  in  improved compliance in patients previously treated with oral antidiabetics.

The Applicant applied for the following strengths: 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/ 1000 mg. The recommended starting dose of Jentadueto for patients not adequately controlled on metformin alone is 2.5 mg of linagliptin twice daily (5 mg daily dose) plus the dose of metformin already being taken. For patients switching from co-administration of linagliptin and metformin, Jentadueto should be initiated at the dose of linagliptin and metformin already being taken. The applicant therefore proposed to recommend a starting dose of Jentadueto for patients inadequately controlled on dual combination therapy  with  the  maximal  tolerated  dose  of  metformin  and  a  sulphonylurea  is  2.5  mg  of  linagliptin twice daily (5 mg total daily dose) and a dose of metformin similar to the dose already being taken. When  linagliptin  plus  metformin  is  used  in  combination  with  a  sulphonylurea,  a  lower  dose  of  the sulphonylurea may be required due to the risk of hypoglycaemia. For the different doses of metformin, Jentadueto  is  available  in  strengths  of  2.5 mg  linagliptin  plus  850 mg  metformin  hydrochloride  and 2.5 mg linagliptin plus 1,000 mg metformin hydrochloride.

## Type of Application and aspects on development

The clinical development program of linaglipin/metformin was designed to demonstrate the safety and efficacy  of  linagliptin  as  monotherapy,  metformin  as  monotherapy  and  linagliptin  and  metformin  as FDC in  patients  with  T2DM.  The  program  included  24  phase  I  studies,  4  phase  II  and  9  phase  III studies for linagliptin as monotherapy, 6 phase I, 2 phase II and 4 phase III studies for the FDC. No dedicated studies with metformin as monotherapy were conducted. The pharmacokinetics, safety, and efficacy profiles of metformin as monotherapy are well known and well established in the literature.

The  development  programme  of  linagliptin/metformin  complies  with  the  CHMP  Guideline  'Note  for guidance  on  the  Clinical  Investigation  of  Medicinal  Products  for  the  treatment  of  diabetes  mellitus (CPMP/EWP/1080/00)'. This guideline is currently under revision.

Scientific advice was provided by the CHMP in September 2008 (EMEA/CHMP/SAWP/ 472394/2008) on the non-clinical and clinical aspects of the development program. The CHMP requested a clinical study to show equivalence of twice daily dosing of linagliptin 2.5 mg with once daily dosing of linagliptin 5 mg.  This  study  was  subsequently  conducted  by  the  Applicant  and  its  results  are  presented  in  this Marketing Authorisation application.

A product-specific waiver (P/3/2010) has been agreed for linagliptin/metformin by the PDCO.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

Jentadueto  is  presented  as  film-coated  tablets  containing  two  active  substances  linagliptin  and metformin hydrochloride. Two strengths of the product with the same amount of linagliptin (2.5 mg) but with different amounts of metformin hydrochloride (850 mg or 1000 mg) were developed.

The  tablets  are  oval  and  biconvex.  The  2.5 mg/850 mg  tablets  are  light  orange,  debossed  with \"D2/850\" on one side and the company logo on the other. The 2.5 mg/1000 mg tablets are light pink, debossed with \"D2/1000\" on one side and the company logo on the other.

Excipients used in the formulation of Jentadueto are well known excipients commonly used in tablet formulations, such as arginine, copovidone, magnesium stearate, maize starch and colloidal anhydrous silica.  These  excipients  are  used  to  manufacture  the  tablet  cores  which  are  then  coated  with  film coating  consisting  of  hypromellose,  titanium  dioxide  (E171),  talc,  propylene  glycol  and  iron  oxides, yellow and red (E172) (coating for the 2.5 mg/850 mg strength) or iron oxide, red (E172) (coating for the 2.5 mg/1000 mg strength).

The tablets are packed either in perforated unit dose blisters consisting of an aluminium lidding foil and a  PVC/polychlorotrifluoro  ethylene/PVC  based  forming  foil  (alu/PVC/PCTFE/PVC  blisters),  or  in  highdensity polyethylene (HDPE) bottles with plastic screw caps.

Initially the applicant applied for 3 strengths of the product 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/1000 mg, all to be taken twice daily (bid). However during the evaluation the lowest strength (2.5 mg/500 mg) was withdrawn.

## 2.2.2. Active Substance

## Linagliptin

Linagliptin  is  chemically  designated  as  8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione and has the following structure:

<!-- image -->

It is a white to yellowish crystalline solid substance, slightly hygroscopic. It is very soluble in aqueous media (&gt; 1 mg/ml) over the entire physiological pH range. It is soluble in methanol, sparingly soluble in  ethanol  and  very  slightly  soluble  in  isopropanol  and  acetone.  Linagliptin  is  classified  as  class  III compound according to the Biopharmaceutics Classification System (BCS) due to its incomplete oral systemic bioavailability and the moderate permeability observed in Caco-2 cells.

Linagliptin  has  one  chiral  centre  at  the  3-aminopiperidine  moiety.  The  substance  used  for  the manufacture of Jentadueto tablets is the (R) enantiomer.

<div style=\"page-break-after: always\"></div>

Linagliptin  simultaneously  exists  in  two  polymorphic  forms  The  two  polymorphic  forms  do  not  differ with  regard  to  relevant  physicochemical  properties  and  therefore  the  solid-state  differences  are unlikely to have any impact on bioavailability.

The  chemical  structure  of  linagliptin  has  been  confirmed  by  means  of  UV,  IR, 1 H-  and 13 C-NMR spectroscopy and mass spectrometry (MS). The content of carbon, hydrogen and nitrogen have been determined  by  elemental  analysis.  The  absolute  configuration  of  the  active  substance  at  the  chiral carbon has been determined by means of X-ray crystallography. The solid state properties of linagliptin were  characterised  using  light  microscopy,  thermal  analysis  (TG  and  DSC)  and  X-ray  powder diffraction.

## Manufacture

The synthetic process for linagliptin consists of three steps during which simple commercially available molecules are used as starting materials. The synthesis is followed by milling process.

The manufacturing process has been described in sufficient detail including suitable reaction schemes. The amounts of raw materials, yields, and equipment have been specified, and the in-process controls have  been  well  described.  Appropriate  specifications  for  starting  materials  and  reagents  have  been established.

Potential impurities were well discussed with regards to their origin and characterised. The levels of the impurities  with  an  acceptance  criterion  higher  than  max.0.15%  were  supported  by  the  results  of toxicological studies and appropriate specification limits have been set.

The synthetic process does not involve Class 1 solvents or metal catalysts. The Class 2 solvents and the  Class  3  solvents  used  in  the  synthesis  have  been  shown  to  be  efficiently  removed  during  the process  and  appropriate  specifications  have  been  set  in  accordance  with  the  Note  for  Guidance  on Impurities: Residual Solvents.

## Specification

The  active  substance  specifications  include  tests  with  suitable  limits  for  appearance  (visually), identification (IR, HPLC and melting point), impurities (GC, HPLC, Chiral-HPLC), residual solvents (GC), water content (KF), sulphated ash (weighing), particle size (laser-beam diffraction) and assay (HPLC).

The  analytical  methods  used  have  been  sufficiently  described  and  validated  in  accordance  with  the Note for Guidance on Validation of Analytical Methods.

Batch analysis results have been provided for 14 commercial scale batches manufactured according to the  proposed  synthetic  process.  All  results  were  consistent  from  batch  to  batch  and  demonstrated compliance with the proposed active substance specifications.

## Stability

Stability studies have been performed in accordance with ICH requirements on three commercial scale batches  manufactured  by  the  proposed  route  of  synthesis.  The  samples  were  stored  for  up  to  36 months  under  the  conditions  for  long  term  storage  (25°C/60% RH)  and  up  to  6  months  under accelerated conditions (40°C/75% RH). The stability results presented were satisfactory and supported the proposed retest period.

<div style=\"page-break-after: always\"></div>

In addition, one batch was subjected to forced degradation studies at elevated temperature, humidity, pH, oxidative conditions and light in the solid state and in solution. Photostability testing of the solid active substance was also performed according to ICH guideline Q1B. The results of the stress studies demonstrated that in solid form, the active substance is very stable at elevated temperatures, high humidity and the combined effect of both conditions. During photostability testing, only a slight change in  colour  was  observed,  but  no  change  in  impurity  profile  leading  to  the  conclusion  that  the  active substance is not sensitive to light.

## Metformin hydrochloride

Metformin hydrochloride is chemically designated as 1,1-dimethylbiguanide monohydrochloride according to the IUPAC nomenclature and has the following structure:

<!-- image -->

This active substance is described in the Ph. Eur.

It  is  a  white  or  almost  white  crystalline  powder.  The  substance  is  freely  soluble  in  water,  slightly soluble in ethanol and practically insoluble in acetone and methylene chloride. Metformin hydrochloride is classified as BCS class III compound.

The chemistry, manufacturing and control information on metformin hydrochloride has been evaluated by the EDQM  and  a  European  Certificate of Suitability of the  Monograph  of  the  European Pharmacopoeia (CEP) has been issued. A copy of the CEP has been provided. The CEP includes an additional test for a residual solvent used during the last step of synthesis. The retest period and type of the container for storing the substance are also included in the certificate. In addition holder of the certificate has declared the absence of use of material of human or animal origin in the manufacturing process of the metformin hydrochloride.

Batch analysis data of the five commercial scale batches of metformin hydrochloride were provided. The  results  were  within  the  specification  limits,  consistent  from  batch  to  batch  and  demonstrated compliance with the Ph. Eur. monograph for this substance.

## 2.2.3. Finished Medicinal Product

## Pharmaceutical Development

The objective of the product development was to obtain an immediate release solid oral dosage form. A twice-a-day dosing regimen was chosen due to the pharmacokinetics of metformin hydrochloride. The therapeutic dose of linagliptin of 5 mg once a day was divided into two doses of 2.5 mg each in order to match this dosing regimen.

Initial  compatibility  studies  with  the  active  substances  showed  degradation  of  linagliptin  when combined with metformin hydrochloride. Several concepts to overcome this instability were considered for the final formulation, including physical separation in the pharmaceutical form (bilayer tablets) or addition of a stabilizer. Screening trials with excipients with a potentially stabilising effect on linagliptin were performed in order to find a suitable stabilizer for  the  formulation.  The  selection of  excipients including their corresponding levels in the finished product is based on formulation experiments where

<div style=\"page-break-after: always\"></div>

the  resulting  tablets  were  assessed  with  regard  to  mechanical  tablet  properties,  dissolution,  assay, content uniformity, chemical and physical stability as well as in vivo bioavailability studies.

The manufacturing process is based on a granulation process. Glidant and lubricant are added in a blending  step followed  by  tablet  compression.  The  tablet  cores  are  than  film-coated.  During development of the product the blending time and the tablet compression process were optimised.

The proposed commercial formulation was used practically unchanged from the very beginning of the development.  Only  a  minor  adjustment  was  made  in  the  pigments  in  the  film  coat  to  meet  the requested  colours  prior  to  the  manufacture  of  the  primary  stability  batches,  which  also  served  as supplies for the three pivotal clinical bioequivalence trials. Pivotal clinical studies were performed with combinations of tablets containing linagliptin (2.5 mg and 5 mg) and metformin hydrochloride tablets (500 mg and 1000 mg). The applicant performed bioequivalence studies to compare the mono dose products to the proposed fixed dose combination products for all three strengths. The test products were full scale batches manufactured at the intended commercial manufacturing site. In parallel to the bioequivalence studies, in vitro dissolution of the test and reference products was compared at three pH.  The  dissolution  profiles  were  similar  with  regard  to  linagliptin  and  dissimilar  with  regard  to metformin hydrochloride. As bioequivalence was shown in vivo , this prevailed over the in vitro findings.

## Adventitious agents

None of the excipients used for Jentadueto are of animal or human origin.

Magnesium stearate used is of vegetable origin, arginine is manufactured by fermentation methods.

## Manufacture of the product

Jentadueto film-coated tablets are manufactured using conventional process consisting of granulation, tablet  compression  and  coating.  Operating  parameters  and  in-process  controls  were  studied  to evaluate their effects on the final drug product properties. Based on this analysis, critical steps were identified and IPC acceptance criteria were defined.

Due to the low content of linagliptin per unit dose and in accordance with the NfG on Process Validation, manufacture of this product was regarded as a non standard process for which validation data on fullscale batches are needed. No formal process validation data have been provided by the applicant and only a process evaluation report for all strengths of the finished product. The data presented in the process evaluation report were obtained from process evaluation trials at full production scale based on the  intended  commercial  manufacturing  process  for  the  tablets.  The  results  indicated  that  the manufacturing process was reproducible and provides product that complies with the in-process and finished product specifications.

In  addition  the  applicant  confirmed  that  formal  process  validation  will  be  performed  on  three consecutive  commercial  scale  batches  per  tablet  strength  prior  to  marketing  of  the  product  and provided the validation protocol. This was accepted by the Committee.

<div style=\"page-break-after: always\"></div>

## Product specification

The product specification includes tests for appearance (visual), identification of both active substances and  arginine  (HPLC),  loss  on  drying  (weighing),  dissolution  (HPLC/UV),  uniformity  of  dosage  units: content  uniformity  of  linagliptin  (HPLC)  and  mass  variation  of  metformin  hydrochloride  (weighing), assay (HPLC) and degradation products (HPLC).

The analytical methods used for testing have been adequately described and validated in accordance with ICH guidelines.

Batch  analysis  data  have  been  provided  on  nine  commercial  scale  batches  from  the  proposed commercial manufacturing site, demonstrating compliance with the proposed release specification. In addition,  batch  analysis  data  from  two  smaller  batches  produced  at  the  development  site  were provided.

## Stability of the product

Stability  data  of  three  batches  of  each  strength  2.5  mg/500  mg  and  2.5  mg/1000  mg  film-coated tablets  and  one  batch  of  2.5  mg/850  mg  film-coated  tablets  were  submitted  in  support  of  the application. The batches were packaged in both proposed commercial container/closure system. The stability  studies  have  been  carried  out  according  to  ICH  requirements.  A  bracketing  approach  was applied to different dosage strengths and bottle sizes.

No significant changes were observed during the primary stability studies. Statistical evaluation of the assays of linagliptin, metformin hydrochloride, and arginine supported the proposed shelf-life in both container closure systems.

In  addition  to  the  primary  stability  studies,  the  tablets  were  subjected  to  stress  stability  testing investigating the effects of elevated temperature, humidity, and light. The finished product was stable with  respect  to  elevated  temperature  and  light  and  susceptible  to  humidity.  The  proposed  storage conditions for the blisters and bottles with regard to protection from moisture are therefore justified.

In-use  stability  studies  were  also  performed  for  the  product  packed  in  bottles.  The  largest  bottle contains 180 tablets. Based on a twice daily dosage regimen, this bottle will be kept for 90 days. The in-use stability studies were performed with two primary stability batches of each strength stored at long term conditions for nine and twenty four months prior to the study. No significant changes were observed. Loss on drying increased during storage but remained well within the shelf-life limit. On the basis  of  the  provided  in-use  stability  data,  no  temperature  storage  condition  is  necessary  for  the bottles after opening.

On the basis of the provided stability data, the assigned shelf life and storage conditions as defined in the SmPC is well supported.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The  quality  of  Jentadueto  has  been  adequately  established.  In  general,  satisfactory  chemical  and pharmaceutical  documentation  has  been  submitted  in  support  of the marketing  authorisation application.

The  active  substances  are  well  characterised  and  documented.  Although  linagliptin  simultaneously exists in two polymorphic forms, this does not have an impact on relevant physicochemical properties. The  quality  of  metformin  hydrochloride  is  assured  by  a  European  Certificate  of  Suitability  of  the Monograph of the European Pharmacopoeia (CEP).

<div style=\"page-break-after: always\"></div>

The  excipients  are  commonly  used  in  these  types  of  formulations  and  comply  with  Ph.  Eur. requirements.  The  packaging  material  is  commonly  used  and  well  documented.  The  manufacturing process  of  the  finished  product  is  a  standard  process  that  has  been  adequately  described.  Stability tests indicate that the product under ICH guidelines conditions is chemically stable for the proposed shelf life.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of the product is considered to be acceptable when used in accordance with the conditions defined in the SmPC.  Physicochemical  and  biological  aspects  relevant  to  the  uniform  clinical performance of the product have been investigated and are controlled in a satisfactory manner. There are  no  unresolved  quality  issues,  which  have  a  negative  impact  on  the  Benefit  Risk  balance  of  the product.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

A comprehensive non-clinical development was conducted to support the chronic use of linagliptin in humans. Metformin is considered a well known active substance indicated for treatment of T2DM, with an established non-clinical and clinical safety profile. There is a limited amount of non-clinical data on metformin, and no new original data was submitted. The applicant performed an extensive review of the  literature.  In  the  light  of  the  longstanding  clinical  use  of  metformin,  this  was  considered  to  be acceptable  by  the  CHMP.  Non-clinical  studies  conducted  with  the  combination  of  linagliptin  and metformin were limited to repeat-dose toxicity studies and reproduction toxicity studies in line with the Guideline on the non-clinical development of fixed combinations of medicinal products (EMEA/CHMP/SWP/258498/2005). This was considered acceptable by the CHMP.

Pivotal studies regarding linagliptin and the combination of linagliptin and metformin were performed in compliance with GLP. Metformin is a well-established  substance.  It  is  not  known  whether  published studies with metformin were performed in compliance with GLP.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## Linagliptin

In  vitro ,  linagliptin  potently  and  selectively  inhibited  DPP-4  activity,  whereas  its  main  metabolite, CD1790, was pharmacologically inactive.

In  both  normal  and  diabetic  mice  and  rats,  the  results  of  the  PD  studies  showed  that  oral administration of linagliptin significantly inhibits plasma DPP-4 activity accompanied by improvements in glucose homeostasis and glucose tolerance. In diabetic rats, linagliptin also significantly increased glucose-induced  elevations  of  GLP-1  and  insulin.  Although  efficacious  in  diabetic  animals,  the magnitude  of  decreasing  blood  glucose  is  dependent  on  the  severity  of  insulin  resistance  in  these animals. In Zucker Diabetic Fatty rats, linagliptin reduced less significantly blood glucose levels than in normal animals.

<div style=\"page-break-after: always\"></div>

In Rhesus monkeys and Beagle dogs, linagliptin inhibited DPP-4 activity by &gt;70% within 30 min which was maintained for at least 7 hours. However, no blood glucose levels were measured to strengthen these results. The IC50 values of 0.23 nM for cynomolgus DPP4 and 0.20 nM for the human DPP-4 show  that  potency  is  comparable  in  both  species.  This  demonstrates  the  suitability  of  cynomolgus monkeys as animal model.

Long duration of action in terms of both inhibition of DPP-4 and glycaemic control was, demonstrated in  mice and rats orally dosed with linagliptin. The results of these studies suggest that a once daily dosing  frequency  is  adequate  to  maintain  an  appropriate  degree  of  DPP-4  inhibition  that  exerts therapeutic effects on glucose.

Long-term treatment of diabetic mice reduced fed plasma glucose HbA1c after 14 and 28 days. This improved hyperglycaemia could not be explained by improved insulin sensitivity by linagliptin.

## Metformin

Metformin  belongs  structurally  to  the  biguanides  and  is  an  insulin  sensitizing  drug,  which  improves fasted and postprandial plasma glucose in patients with T2DM. The mechanism of action of metformin is  still  not  fully  elucidated.  However  its  anti-diabetic  action  is  based  on  decreased  hepatic  glucose production  via  suppressed  gluconeogenesis,  decreased  absorption  of  glucose  from  the  intestine  and improved  insulin  sensitivity.  In  addition,  metformin  was  shown  to  increase  GLP-1  release  in  obese patients with or without type 2 diabetes.

The pharmacological action of metformin has minor or no effect on insulin secretion, but reduces the demand of insulin due to its insulin sensitizing effect by increasing peripheral uptake of glucose. The pharmacological actions of metformin are, therefore, targeted towards the liver, the muscle and the adipose tissue. Further, metformin is not associated with an increased risk of hypoglycaemic episodes.

## Linagliptin/metformin

The pharmacodynamic effects of the combination of linagliptin and metformin were studied in  vitro . This study, which was not performed with the fixed-dose combination product, was conducted in order to evaluate additive or synergistic effects of the free combination of linagliptin and metformin. Male db/db  mice  were  orally  dosed  once  daily  for  one  week  with  either  vehicle,  linagliptin  (1  mg/kg), metformin (200 mg/kg), or a combination of linagliptin (1 mg/kg) and metformin (200 mg/kg). An oral glucose  tolerance  test  (oGTT)  was  performed  16  h  after  the  last  compound  administration.  The baseline  values  for  fasting  glucose  before  the  glucose  challenge  were  lower  in  all  treatment  groups than in the control group (-25% with linagliptin; -40% with metformin; - 44% with the combination). To  assess  the  effect  of  the  different  treatments  on  glucose  excursion,  the  baseline  value  was subtracted from all glucose measurements and an AUC was calculated. The AUC for glucose excursion was  reduced  by  13%  with  linagliptin  and  by  19%  with  metformin.  The  combined  treatment  of linagliptin and metformin resulted in a significant reduction of the AUC for glucose excursion by 37%.

No  additional  primary  pharmacodynamic  studies  were  submitted  for  the  fixed  dose  combination linagliptin/metformin which was considered acceptable.

<div style=\"page-break-after: always\"></div>

## Secondary pharmacodynamic studies

## Linagliptin

Secondary pharmacodynamic studies (non-GLP) were performed to investigate neurological, cardiovascular,  pulmonary,  gastrointestinal  and  renal  effects.  Single  doses  were  given.  A  modified Irwin test was performed in mice at oral dosages of up to 30 mg/kg for testing potential effects of linagliptin  on  the  Central  Nervous  System  (CNS).  No  compound-induced  effect  was  seen  suggesting the absence of any influence of linagliptin on overt behaviour at the tested dosages.

For assessing effects on renal function and clinical chemistry parameters, rats were treated orally with a  dose  of  3,  10  or  30  mg/kg  linagliptin.  Based  on  the  endpoints  of  the  study  linagliptin  did  not influence kidney function or integrity.

## Metformin

No  secondary  pharmacodynamic  assays  were  performed  with  metformin.  These  studies  were  not considered necessary in view of the extensive clinical experience accumulated over the many years on the market.

## Linagliptin/metformin

No secondary pharmacodynamic studies were performed on the fixed dose combination linagliptin/metformin based on the data available for each compound which was considered acceptable.

## Safety pharmacology programme

## Linagliptin

The core battery studies (ICHS7A and ICHS7B) were all conducted according to GLP except for the in vitro assays. Single doses were given if not stated otherwise.

Potential effects on the CNS were investigated in rats after oral administration of 6, 60 or 600 mg/kg linagliptin.  In  a  modified  Irwin  study,  no  marked  or  consistent  behavioural  or  physiological  changes were seen. In addition, no significant effects on body temperature or spontaneous locomotor activity were observed.

<div style=\"page-break-after: always\"></div>

A comprehensive cardiovascular profiling was performed both in vitro and in vivo .  Linagliptin had no effect  on  the  hERG-mediated  potassium  current  at  concentrations  up  to  10 μ M.  In  the  Guinea  pig papillary muscle assay, concentrations up to 10 μ M did not affect resting membrane potential, action potential  amplitude  and  overshoot,  and  maximal  upstroke  velocity.  There  was  a  concentration dependent shortening of the action potential beginning at 0.3 μ M that increased up to a 7% shortening (of APD90) at 10 μ M. These in vitro studies indicated that linagliptin has a low proarrhytmic potential based  on  a delayed ventricular repolarization. Potential in vivo effects of linagliptin on the cardiovascular system were studied in the telemetered Cynomolgus monkey at dosages of 12, 60 and 150 mg/kg. High plasma concentrations of up to 18900 nM (1703x clinical Cmax) were reached at a dose of 150 mg/kg. There were no relevant treatment-related changes in the ECG (lead II) at doses up to 150 mg/kg. Cardiovascular investigations were also conducted in repeat-dose toxicity studies. In the 4-week toxicity study in Beagle dogs, doses up to 9 mg/kg/day (210x clinical Cmax) were free from any  relevant  effect  of  linagliptin  on  blood  pressure,  heart  rate  and  ECG.  Changes  seen  at  45 mg/kg/day  (955x  clinical  Cmax)  were  considered  to  be  pseudo-allergy  related.  In  Cynomolgus monkeys, which did not show any signs of pseudo-allergy after oral administration with linagliptin, no treatment-related changes were detected in the ECG and blood pressure measurements in the toxicity studies up to 12 months duration and at dosages up to and including 300 mg/kg/day (2523x clinical Cmax). In conclusion, the preclinical safety data did not indicate any linagliptin-related cardiovascular risk.

Effects  on  respiratory  function  were  tested  in  rats  given  oral  dosages  of  0,  6,  60  or  600  mg/kg linagliptin.  Oral  dosages  of  6  or  60  mg/kg  produced  no  effect  on  respiratory  rate,  tidal  volume  and minute volume. At a dosage of 600 mg/kg, a statistically significant increase in tidal volume and a significant decrease in respiration rate and minute volume at 30 min post-dose were seen. A dose level of  600  mg/kg was associated with a plasma level of 3099x clinical Cmax. Therefore, the slight and isolated  respiratory  effects  seen  at  600  mg/kg  are  considered  to  be  without  relevance  for  human safety.

In  conclusion,  the  safety  pharmacology  assessment  of  neurological,  cardiovascular  and  respiratory effects supports the clinical development of linagliptin.

## Metformin

No formal safety pharmacology studies have been performed on metformin. These studies were not considered necessary by the CHMP in view of the extensive clinical experience accumulated over the many years on the market.

## Linagliptin/metformin

No safety pharmacology studies were performed on the fixed dose combination linagliptin/metformin based on the data available for each compound which was considered acceptable as well.

## Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies were submitted for the combination linagliptin/metformin based on the data available for each compound which is considered acceptable.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacokinetics

## Methods of analysis

## Linagliptin

The  HPLC-MS/MS  assay  for  the  quantification  of  linagliptin  has  been  validated  adequately  in  rat plasma. Acceptable linearity, precision, accuracy and specificity of linagliptin were observed over the concentration range 0.100 to 100 nmol/L.

## Metformin

The  HPLC-MS/MS  method  for  the  measurement  of  metformin  has  been  validated  adequately  in  rat plasma. Acceptable linearity, precision, accuracy and specificity of metformin were observed over the concentration range 50 to 25000 nM.

## Absorption

## Linagliptin

In  vitro studies  showed  that  linagliptin  is  a  moderately  permeable  drug  and  a  substrate  for P-glycoprotein.  Linagliptin  is  a  substrate  for  OATP8,  OCT2,  OAT4,  OCTN1  and  OCTN2,  suggesting  a possible  OATP8-mediated  hepatic  uptake,  OCT2-mediated  renal  uptake  and  OAT4-,  OCTN1-  and OCTN2-mediated renal secretion and re-absorption of linagliptin in vivo .

Oral bioavailability of linagliptin appeared to be moderate in mice (18-44%), rats (51-55%), monkeys (41-69%) and humans (30%). Maximum blood concentrations of linagliptin  were  generally  reached between 5 minutes and 1 h post-dose in mice, rabbits and monkeys. In the rat, the maximum blood concentration was between 0.5 and 4 h post-dose following oral administration. After oral administration  of 5 or 15  mg/kg  linagliptin  in  mice,  AUC0-∞ and  Cmax  increased  more  than proportionally with dose. This indicates non-linear mechanisms in the pharmacokinetics of linagliptin in mice in this dose range. Non-linear pharmacokinetic behavior of linagliptin was also observed in rats and rabbits, which may be due to a saturation of P-glycoprotein mediated active secretion and DPP-4 binding.  Food  had  a  moderate  influence  on  the  plasma  profiles  of  linagliptin  but  not  on  the  overall extent of absorption in rats.

## Metformin

Metformin hydrochloride is highly soluble but lowly permeable. Thus, metformin can be classified as BCS class III drug. The oral bioavailability in rats was low to moderate (about 30%) in the dose range between 50 and 200 mg/kg. Passive permeation, active uptake by cation transporters (e.g. PMAT) or other saturable processes may play a role in oral absorption of metformin. This could cause non-linear pharmacokinetics. However metformin showed a linear PK profile between 50 and 900 mg/kg in rats. This may be due to the investigated dose range, where transport mechanisms are already saturated and non-linear PK could be expected at markedly lower doses only. Although the overall contribution of metabolic  transformation  of  metformin  is  low,  a  slight  entero-hepatic  first  pass  metabolism  was suggested in rats. No studies addressing the absorption of metformin have been performed to support this application. The above data are based on published literature and this was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

Table 1. Pharmacokinetic parameters of linagliptin and metformin after multiple oral doses of linagliptin/metformin combination to rats

| Dose of linagliptin/metformin (mg/kg)   | Sex   | Day   | Linagliptin    | Linagliptin         | Metformin      | Metformin           |          |
|-----------------------------------------|-------|-------|----------------|---------------------|----------------|---------------------|----------|
| Dose of linagliptin/metformin (mg/kg)   | Sex   | Day   | C max (nmol/l) | AUC 0-24 (nmol*h/l) | C max (nmol/l) | AUC 0-24 (nmol*h/l) |          |
| 0.5/100                                 | M     | 1     | 6.43           | 103                 | 33600          | 214000              | U09-2243 |
| 0.5/100                                 | F     | 1     | 16.7           | 108                 | 36800          | 191000              | U09-2243 |
| 0.5/100                                 | M     | 14    | 11.2           | 136                 | 44800          | 282000              | U09-2243 |
| 0.5/100                                 | F     | 14    | 19.3           | 141                 | 46600          | 190000              | U09-2243 |
| 1/200                                   | M     | 1     | 18.7           | 156                 | 71800          | 418000              | U09-2243 |
| 1/200                                   | F     | 1     | 24.3           | 195                 | 61600          | 336000              | U09-2243 |
| 1/200                                   | M     | 14    | 33.8           | 274                 | 65100          | 439000              | U09-2243 |
| 1/200                                   | F     | 14    | 69.7           | 332                 | 85100          | 477000              | U09-2243 |
| 2.5/500                                 | M     | 1     | 38.9           | 281                 | 134000         | 1210000             | U09-1632 |
| 2.5/500                                 | F     | 1     | 49.3           | 307                 | 129000         | 1060000             | U09-1632 |
| 2.5/500                                 | M     | 14    | 73.1           | 445                 | 183000         | 1630000             | U09-1632 |
| 2.5/500                                 | F     | 14    | 50.3           | 473                 | 223000         | 1960000             | U09-1632 |
| 5/1000                                  | M     | 1     | 37.4           | 311                 | 175000         | 2220000             | U09-1632 |
| 5/1000                                  | F     | 1     | 74.9           | 512                 | 223000         | 2330000             | U09-1632 |
| 5/1000                                  | M     | 14    | 32.8           | 578                 | 283000         | 3490000             | U09-1632 |
| 5/1000                                  | F     | 14    | 45.9           | 545                 | 313000         | 3760000             | U09-1632 |
| 10/2000                                 | M     | 1     | 44.1           | 391                 | 214000         | 2530000             | U09-1632 |
| 10/2000                                 | F     | 1     | 54.6           | 621                 | 273000         | 3740000             | U09-1632 |
| 10/2000                                 | M     | 14    | -              | -                   | -              | -                   | U09-1632 |
| 10/2000                                 | F     | 14    | -              | -                   | -              | -                   | U09-1632 |
| 0.5/100                                 | M     | 1     | 9.18           | 123                 | 44900          | 272000              | U10-1492 |
| 0.5/100                                 | F     | 1     | 13.9           | 99.7                | 37200          | 147000              | U10-1492 |
| 0.5/100                                 | M     | 88    | 16.1           | 166                 | 51400          | 221000              | U10-1492 |
| 0.5/100                                 | F     | 88    | 20.1           | 149                 | 57400          | 226000              | U10-1492 |
| 2/400                                   | M     | 1     | 39.0           | 251                 | 103000         | 790000              | U10-1492 |
| 2/400                                   | F     | 1     | 64.3           | 313                 | 112000         | 613000              | U10-1492 |
| 2/400                                   | M     | 88    | 37.1           | 308                 | 123000         | 1160000             | U10-1492 |
| 2/400                                   | F     | 88    | 50.5           | 297                 | 198000         | 1200000             | U10-1492 |
| 4/800                                   | M     | 1     | 37.2           | 289                 | 143000         | 1690000             | U10-1492 |
| 4/800                                   | F     | 1     | 63.0           | 407                 | 182000         | 1480000             | U10-1492 |
| 4/800                                   | M     | 88    | 25.3           | 344                 | 198000         | 2330000             | U10-1492 |
| 4/800                                   | F     | 88    | 21.8           | 309                 | 361000         | 4900000             | U10-1492 |
| 2/800                                   | M     | 1     | 18.8           | 201                 | 144000         | 1500000             | U10-1492 |
| 2/800                                   | F     | 1     | 25.2           | 222                 | 183000         | 1360000             | U10-1492 |
| 2/800                                   | M     | 88    | 15.6           | 253                 | 227000         | 3220000             | U10-1492 |
| 2/800                                   | F     | 88    | 16.2           | 218                 | 324000         | 4200000             | U10-1492 |
| 4/0                                     | M     | 1     | 17.7           | 203                 | 170000         | 1610000             | U10-1492 |
| 4/0                                     | F     | 1     | 25.4           | 208                 | 178000         | 1300000             | U10-1492 |
| 4/0                                     | M     | 88    | 38.5           | 265                 | 219000         | 2770000             | U10-1492 |
| 4/0                                     | F     | 88    | 99.4           | 457                 | 305000         | 3870000             | U10-1492 |

<div style=\"page-break-after: always\"></div>

Toxicokinetic  studies  with  linagliptin/metformin  combination  administration  in  rats  showed  that  the exposure  to  linagliptin  increased  less  than  dose-proportional,  whereas  the  exposure  to  metformin increased dose proportionally between 500 and 1000 mg/kg but less than dose proportionally between 1000 and 2000 mg/kg. The dose-proportionality of linagliptin is in contrast with earlier findings after administration  of  linagliptin  alone,  where  the  exposure  increased  more  than  dose-proportional.  The CHMP agrees with the Applicant that  this  could  be  explained  by  the  different  dose  ranges  used.  At doses lower than 10 mg/kg, the disposition of linagliptin is mainly determined by saturable binding to plasma and tissue DPP-4. However, it should be noted that in case of high doses or overdosing of the linagliptin/metformin combination the AUC may increase more than dose-proportional.

No effect of linagliptin on metformin kinetics was observed. However, co-administration with metformin did affect linagliptin kinetics: the AUC of linagliptin was higher (1.4- to 2-fold) with metformin (800 mg/kg) compared to administration without metformin at day 1 in both male and female rats.

It was shown in rats that the feeding status only influenced the shape of the plasma level time curve and  not  the  oral  absorption  of  linagliptin.  The  exposure  (AUC)  to  linagliptin  was  unaffected  by  the feeding conditions. As stated in the SmPC, food decreases the extent and slightly delays the absorption of metformin hydrochloride. Some accumulation (up to a factor 1.9) of both linagliptin and metformin was  observed  after repeated doses  in the 2-week  combination  toxicity study in rats, while accumulation was not consistently found in the 13-week combination toxicity study in rats. Thus, some accumulation of linagliptin in rat plasma after repeated dosing can not be excluded.

## Distribution

## Linagliptin

The distribution of linagliptin was dominated by the binding to its target DPP-4 in plasma and tissues at low  doses.  A  pronounced  concentration-dependency  was  observed  in  the  plasma  protein  binding  of linagliptin.  A  very  high  binding  percentage  of  about  99%  at  concentrations  up  to  about  1  nM  was observed.  At  concentrations  beyond  about  30  nM,  the  plasma  protein  binding  was  constant  with  a moderate  bound  fraction  between  70  and  80%.  The  concentration  dependency  was  shown  to  be caused by high affinity saturable binding to soluble DPP-4 in plasma. Thus, the plasma concentration of soluble  DPP-4  may  have  an  influence  on  the  pharmacokinetics  of  linagliptin  and  changes  in  plasma protein  binding  are  expected  at  therapeutic  plasma  levels  in  humans  (Cmax,ss  of  11.1  nM). Additionally,  it  should  be  noted,  that  plasma  concentrations  achieved  in  toxicology  studies  were generally in a range where DPP-4 binding of linagliptin in plasma is saturated. Thus, plasma protein binding  of  linagliptin  in  toxicology  studies  was  lower  than  in  humans  during  therapeutic  treatment adding an additional safety margin in terms of unbound exposure.

<div style=\"page-break-after: always\"></div>

Extensive tissue distribution was indicated by high volumes of distribution in all species (&gt;4 l/kg). This was confirmed by whole body autoradiography in rats. Linagliptin is extensively distributed into tissues and long retention times are observed in DPP-4 containing tissues, in particular the kidneys and the liver. Alike plasma protein binding, also tissue distribution of linagliptin is dominated by DPP-4 binding as shown in mice and rats. Kidney and liver were shown to contain the major fraction of total body DPP-4 in mice and rats and therefore the high and persistent tissue levels of linagliptin even at low doses  are  due  to  high-affinity  binding  to  DPP-4.  Once  DPP-4  is  saturated,  tissue  concentrations increased linearly with dose due to nonspecific binding. This is in line with the still high volumes of distribution  observed  in  DPP-4  deficient  rats  which  indicate  DPP-4  independent  tissue  distribution. Complete saturation of DPP-4 in tissue can be assumed in all toxicology studies and high exposure to linagliptin was demonstrated in Cynomolgus monkey liver and kidney tissue sampled from the animals of the 52 week toxicity study. Despite the long residence times in tissues and the long terminal half-life in plasma, steady state is achieved quickly after repeated dosing and only a limited accumulation in tissues  occurs.  Thus,  during  chronic  use  of  low  doses  of  linagliptin,  steady  state  in  tissue  will  be achieved  quickly  once  DPP-4  is  saturated.  Traces  of  covalently  bound  radioactivity  were  found  in plasma  of  animals  and  humans,  which  were  regarded  as  of  negligible  importance  considering  the exceptionally low levels and the low therapeutic dose of linagliptin.

Linagliptin crosses the placenta barrier in rats and rabbits. Foetal exposure in rats reached about 50% of  the  maternal  exposure,  whereas  2-5%  was  found  in  foetuses  of  rabbits.  Foetal  exposure  differs between rats and rabbits, but the foetal exposure in humans is unknown. Placental transfer in humans is expected based on the results in rats and rabbits.

## Metformin

The plasma protein binding of metformin is very low. In rat plasma, only about 15% were reported to be protein bound in vitro . In addition, a bound fraction of about 10% was determined in a solution of 4% human serum albumin.

In rat blood, metformin is distributed slightly more into plasma than into or onto blood cells. The mean plasma-to-blood  cell  partition  ratio  was  reported  to  be  about  1.3  independent  of  concentrations between 1 and 20 μ g/mL (7.7-230 μ M) metformin. Metformin showed a slow association but also a slow disappearance from erythrocytes.

Metformin showed a moderate to high volume of distribution (2-3 l/kg) in rats, indicating extensive tissue distribution. This was confirmed experimentally by dosing [14C]radiolabelled metformin to mice and rats. High radioactivity concentrations were found in the gastrointestinal tract, kidneys, liver and the salivary glands at concentrations higher than in blood. Lower levels were observed in the heart, skeletal muscle, white fat and brain, the latter indicating that metformin and/or metabolites may cross the blood brain barrier. Liver concentrations of metformin in rats were about 3 - 4 times higher than plasma concentrations of metformin. The distribution into the isolated perfused rat liver was shown to be  permeability  limited  and  that  in  the  organic  cation  transporter  OCT1  knockout  mice  the  liver concentrations were about 30 times lower than in wild type mice (study R10-2435). Thus, OCT1 was suggested to be responsible for hepatic uptake of metformin. The same study also demonstrated that OCT1  was  also  involved  in  the  intestinal  uptake  of  metformin.  In  a  comparative  study,  it  was demonstrated that the tissue uptake clearance of metformin in rats is markedly higher in the kidney than in the liver. It was concluded that metformin transport by renal OCT2 plays a dominant role for its pharmacokinetics whereas OCT1, which is expressed in both liver and kidney in rats and expressed in human liver is of subordinate importance.

Metformin crosses the blood-placenta-barrier in humans and the foetus is exposed to metformin.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

No distribution PK studies were performed on the fixed dose combination linagliptin/metformin which was considered acceptable based on the data provided for the individual compounds.

## Metabolism

## Linagliptin

The  elimination  of  linagliptin  in  mice,  rats  and  female  rabbits  was  governed  by  non-metabolic mechanisms. Unchanged parent compound was the most abundant component in urine, faeces, bile and  plasma  of  animals  except  for  Cynomolgus  monkeys.  In  monkey  bile  and  faeces  metabolites  of linagliptin dominated. Linagliptin is metabolised by CYP3A4 in humans. There was no indication for a contribution of other CYP enzymes  in the metabolism of linagliptin. After oral dosing, the pharmacologically  inactive  metabolite  CD1790  was  the  only  circulating  metabolite  with  a  systemic exposure in human plasma of &gt;10% of parent compound systemic exposure at steady state. CYP3A4 is involved  into  formation  of  CD1790  in  humans.  Thus,  co-administered  inhibitors  of  CYP3A4  may influence the pharmacokinetics of linagliptin and decrease formation of CD1790. Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes.

Linagliptin is not an inducer of hepatic cytochrome P450. However, linagliptin weakly inhibited CYP3A4 activity  in  human  liver  microsomes  competitively.  Additionally,  weak  to  moderate  mechanism  based (irreversible)  inhibition  of  CYP3A4  by  linagliptin  was  observed  (IC50=36.3 μ M  (testosterone  6ßhydroxylation); IC50=41.6 μ M (erythromycin N-demethylation); IC50&gt;100 μ M (midazolam 1hydroxylation and nifedipine oxidation)). Considering the very low plasma concentrations of linagliptin in  humans  (Cmax,ss of  11.1  nM)  and  its  high  plasma  protein  binding  at  therapeutic  plasma  levels  in humans, it is very that linagliptin interacts on the pharmacokinetics of co-administered drugs.

## Metformin

No  relevant  inhibition  of  CYPs  by  metformin  was  observed.  The  overall  contribution  of  metabolic transformation of metformin to its elimination is low. However, in a recent study it was shown that metformin  is  metabolized  via  CYP2C11,  2D1  and  3A1/2  in  rats.  A  slight  first  pass  metabolism  was observed in rats. Thus, although excretion of unchanged parent compound is the determining route of elimination,  additional  metabolic  transformation  of  metformin  is  indicated.Co-administration  with CYP3A4 inhibitors or inducers could affect the pharmacokinetics of linagliptin. There was no indication of a mechanism-based inhibition of CYP3A4 by metformin. Therefore, metabolic interactions between linagliptin and metformin, based on inhibition of CYP3A4 are not expected.

## Linagliptin/metformin

Metabolism of the FDC  linagliptin/metformin is described below under Pharmacokinetic drug interactions.

<div style=\"page-break-after: always\"></div>

## Excretion

## Linagliptin

Across species, the dominant excretion route was via the faeces. The urinary excretion was shown to be  dose-dependent  in  mice  and  rats.  At  an  oral  dose  of  1  mg/kg,  less  than  1%  of  the  dose  was excreted  in  urine,  whereas  up  to  about  20%  of  the  dose  was  excreted  with  urine  at  30  mg/kg.  As demonstrated in mice, the dose-dependency of renal excretion can be attributed to a saturable binding of linagliptin to its target DPP-4 in tissue and plasma. Biliary excretion is prominent and P-glycoprotein was shown to be involved into elimination with bile. Despite a prominent biliary excretion of parent drug, the entero-hepatic recirculation of linagliptin was lower than expected. This was attributed to a negative effect of bile on its absorption in anaesthetised rats. Besides the biliary excretion (about 80% within  6  hours  after  iv  administration  of  1  mg/kg  linagliptin),  about  12%  of  the  dose  was  directly secreted into the intestinal lumen, independently of biliary excretion. It is likely that P-gp mediated efflux  is  involved  into  active  secretion  of  linagliptin  from  the  blood  into  the  gut  lumen  in  rats.  In comparison  to  biliary  excretion,  direct  secretion  into  gut  represents  a  minor  route  of  elimination. Nevertheless, it may become more important in case of hepatic (and renal) elimination impairment.

## Metformin

The by far dominating excretion pathway is renal elimination of unchanged parent compound. Active secretion involving hMATE2-K and hOCT2 in the proximal tubules of the kidney is suggested in addition to  glomerular  filtration.  Biliar  excretion  was  low.  As  mentioned  previously,  the  compound  is  mainly excreted unchanged.

## Linagliptin/metformin

No excretion PK studies were performed on the fixed dose combination linagliptin/metformin which was considered acceptable.

## Pharmacokinetic drug interactions

## Linagliptin

No in  vivo drug-drug  interaction  studies  were  performed  in  animals.  For  drug  transporters  or  drug metabolizing enzymes where linagliptin was identified as inhibitor, relevant inhibition only occurs in the micromolar range. Considering the very low plasma concentrations of linagliptin in humans (Cmax,ss of 20  nM)  and  its  high  plasma  protein  binding  at  the  therapeutic  plasma  levels  in  humans,  it  is  very unlikely, that linagliptin interacts on the pharmacokinetics of co-administered drugs. The same applies for the main metabolite CD 1790.

Linagliptin is a substrate for P-gp. In addition, linagliptin undergoes a minor metabolism in humans and the main metabolite CD 1790 is formed by CYP 3A4. Thus, co-administered drugs which act on P-gp and/or CYP 3A4 may have an influence on the pharmacokinetics of linagliptin.

## Metformin

Metformin  is  mainly  excreted  unchanged  via  urine.  However,  it  was  shown  that  metformin  is metabolized via CYP2C11, 2D1 and 3A1/2 in the rat. Several rat studies demonstrated pharmacokinetic interactions  with  metformin  and  co-administered  drugs  which  are  substrates  for  CYP3A1/2  e.g. telithromycin  or  DA-8159  leading  to  decreased  metformin  clearance  in  rats.  In  addition,  altered pharmacokinetics of metformin were described in disease models, where hepatic expression levels of these CYPs are changed, e.g. streptozotocin induced diabetes in rats  or challenge of E. coli LPS in rats.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

## Metabolism by CYP enzymes

In vitro , it was demonstrated that metformin does not inhibit any of the investigated CYP isoforms in vivo .  Thus,  as  the  only  CYP  isoform  involved  into  the  metabolism  of  linagliptin  is  CYP3A4,  coadministration  of  metformin  should  not  alter  the  metabolism  of  linagliptin.  This  was  confirmed  in  a clinical  study  where  no  clinical  meaningful  interaction  was  observed.  The  contribution  of  metabolic transformation to the overall elimination of metformin in human is very low if at all present. Linagliptin was  shown  to  be  a  moderate  to  poor  mechanism  based  (irreversible)  inhibitor  of  CYP3A4 in  vitro. However,  in  a  clinical  study  no  clinically  relevant  interaction  was  observed  between  linagliptin  and simvastatin, a known model substrate for CYP3A4. No consistent or relevant interactions have been observed in the toxicokinetic studies, where also supratherapeutic doses of both compound were dosed repeatedly in rats. Thus, drug-drug-interactions between linagliptin and metformin on a CYP level are extremely unlikely to occur.

## Binding to plasma proteins

Metformin  does  not  bind  notably  to  plasma  proteins  in  rats  and  humans  and  therefore,  linagliptin cannot  influence  metformin  pharmacokinetics  by  interaction  on  the  plasma  protein  binding  level.  In addition, the plasma protein binding of linagliptin at therapeutic doses is characterised by a very high affinity and high specifity as it binds to soluble plasma DPP-4. On the other hand, it was shown that metformin does not inhibit DPP-4 in vitro and in vivo . Taken together, drug-drug interactions between metformin and linagliptin with respect to plasma protein binding are unlikely.

## Transport by drug-transporters

Linagliptin  and  metformin  are  both  substrates  for  OCTs.  In  addition,  linagliptin  was  identified  as  an inhibitor of OCT1 with and IC50 value of 47.2 μ M. Thus, upon oral administration of 5 mg linagliptin local  intestinal  concentrations  in  the  range  of  the  IC50  might  be  produced.  However,  such  high concentrations of linagliptin in the gut would only be present for a transient period and thus, OCT1 inhibition in the gut would be limited if at all present. In all other tissues where OCT1 is expressed and also  in  plasma,  the  unbound  concentrations  of  linagliptin  are  far  below  the  IC 50 value  for  OCT1 inhibition, considering the low therapeutic plasma levels. Finally, the role of OCT1 mediated transport of metformin is recognized as of minor importance. In addition, in particular OCT2, which is expressed on the basolateral membrane of the renal proximal tubule cells, was shown to play a central role in renal  elimination  of  metformin.  Due  to  low  therapeutic  plasma  concentration  of  linagliptin  and linagliptin  being  not  an  inhibitor  of  OCT2,  a  competitive  inhibition  of  OCT2  mediated  metformin transport  by  linagliptin  in  the  kidney  can  be  excluded  although  linagliptin  was  shown  to  distribute extensively into kidneys.

Metformin is reported to be a substrate of MATE and PMAT which are expressed on the brush boarder membrane of renal proximal tubule cells. Kidney distribution of linagliptin is due to high affinity binding to  kidney  DPP-4.  Thus,  even  in  tissues  with  high  concentrations  of  total  linagliptin,  only  a  very  low unbound concentration can be expected as most of the compound is bound tightly to DPP-4. Hence, a competitive inhibition of MATE and PMAT mediated metformin transport by linagliptin in the kidney can be excluded. On the other hand, the high doses of metformin may theoretically lead to a competitive inhibition of uptake or efflux transporters for linagliptin. However, no indications were found, that an active uptake is involved in the gastrointestinal absorption of linagliptin.

<div style=\"page-break-after: always\"></div>

Furthermore, it  was  demonstrated  in  rats,  that  oral  absorption  and  biliary  excretion  of  linagliptin  is influenced by P-gp. However, metformin most likely is neither a substrate nor an inhibitor of P-gp and therefore P-gp mediated interactions are not expected.

In addition, linagliptin was shown to be a substrate for OCT2 (but not OCT1). Thus, metformin could theoretically  influence  the  pharmacokinetics  of  linagliptin  by  competing  for  OCT2  in  the  kidney decreasing  the  renal  clearance  of  linagliptin.  However,  renal  excretion  of  linagliptin  is  of  almost negligible  importance  for  its  elimination.  Thus,  clinically  relevant  pharmacokinetic  interactions  at  an OCT2  mediated  mechanism  are  not  expected,  which  was  confirmed  in  the  clinical  study.  Taken together,  based  on  the  available  non-clinical  data,  clinically  relevant  pharmacokinetic  interaction between metformin and linagliptin at the respective therapeutic dose levels is not expected in humans.

## 2.3.4. Toxicology

The  toxicity  of  linagliptin  has  been  evaluated  in  an  extensive  non-clinical  program.  The  toxicology program included single-dose and repeat-dose toxicity studies in mice, rats, dogs and monkeys, in vivo and in vitro genotoxicity studies, reproduction and developmental toxicity studies and carcinogenicity studies.  Although  metformin  has  been  marketed  for  many  years,  there  are  only  limited  non-clinical data  available  in  published  literature.  Therefore,  the  general  and  reproductive  toxicity  of  metformin was  investigated  in  additional  rat  studies.  Repeat-dose  toxicity  studies  and  reproduction  toxicity studies  were  conducted with the FDC linagliptin/metformin. This is in line with the Guideline on the non-clinical development of fixed combinations of medicinal products (EMEA/CHMP/SWP/258498/2005).

## Single dose toxicity

## Linagliptin

Table 2. Single dose toxicity studies with linagliptin

| Study ID   | Species/ Sex/Number/ Group   | Dose/Route                           | Observed max non-lethal dose, mg/kg   | Major findings                                                          |
|------------|------------------------------|--------------------------------------|---------------------------------------|-------------------------------------------------------------------------|
| U05-1899   | Mouse M+F/3                  | 1000 and 2000 mg/kg Oral             | 1000                                  | 1000: piloerection 2000: 1M+1F dead. Stasis of liver, spleen and kidney |
| U05-1902   | Mouse M+F/3                  | 1000 and 2000 mg/kg Oral             | < 1000                                | 1000: 1M dead. Reduced motor activity, piloerection                     |
| U05-1938   | Mouse M+F/3                  | 10, 30 and 60 mg/kg Intravenous      | 60                                    | No treatment- related findings                                          |
| U05-1901   | Rat M+F/3                    | 1000 and 2000 mg/kg Oral             | 1000                                  | 2000: 1F dead. Piloerection, blood in lung, fluid in uterus             |
| U05-1903   | Rat M+F/3                    | 1000 and 2000 mg/kg Oral             | 2000                                  | 1000: piloerection                                                      |
| U05-1936   | Rat M+F/3                    | 10, 30, 60 and 120 mg/kg Intravenous | 60                                    | 120: 2F dead. Stasis of liver and kidneys                               |

<div style=\"page-break-after: always\"></div>

Oral acute toxicity studies in mice and rats were repeated with a different batch of linagliptin due to differences in the impurity profile between the batches used in early toxicological investigations and the one produced for an early clinical study. The acute toxicity of linagliptin in mice and rats was low as indicated by a maximum non-lethal dose of ≤ 1000 mg/kg.

## Metformin

Acute toxicity of metformin was not studied in single-dose studies, but information about this endpoint was  obtained  from  short-duration  toxicity  studies  in  rats.  These  data  indicated  that  the  ALD  of metformin is above 1000 mg/kg.

## Linagliptin/metformin

No  single  dose  toxicity  studies  were  performed  on  the  fixed  dose  combination  linagliptin/metformin which was considered acceptable based on the data available for each compound.

## Repeat dose toxicity

## Linagliptin

Table 3. Repeat-dose toxicity studies with linagliptin

| Study ID   | Species / Sex/ Number / Group   | Dose/Route mg/kg/day                | Duration   | NOEL/ NOAEL (mg/kg/day )   | Major findings                                                                                                                                                                                |
|------------|---------------------------------|-------------------------------------|------------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U06-2122   | Mouse M+F/5                     | 0, 100, 300, 1000 Oral (diet)       | 2 weeks    | Not defined                | 1000: Body weight gain decrease                                                                                                                                                               |
| U06-1784   | Mouse M+F/6                     | 0, 60, 120, 300, 600 Oral (gavage)  | 4 weeks    | Not defined                | 120: Hyperkeratosis, epithelial hyperplasia in stomach 600: Hunched posture, piloerection. F: Liver, thymus weight decrease                                                                   |
| U07-1536   | Mouse M+F/12                    | 0, 100, 300, 600 Oral (gavage)      | 3 months   | 100                        | 300: ALP, ALT, AST increase Hyperkeratosis and epithelial hyperplasia in stomach 600: 3F+1M dead. Ovary weight decrease, renal weight increase, Tubular hypertrophy and basophilia in kidneys |
| U08-1887   | Rat M+F/5                       | 0, 100, 300, 1000 Oral (diet)       | 2 weeks    | Not defined                | 1000: decreased body weight gain, food consumption decrease Piloerection, size of stomach, cecum and colon increase                                                                           |
| U04-1714   | Rat M+F/10                      | 0, 30, 100, 300, 1000 Oral (gavage) | 2 weeks    | Not defined                | 300: Spleen weight decrease, Thymus apoptosis, excretory duct atrophy of submandibular salivary glands 1000: Not tolerated; necropsy on day 6 or 8. Histological changes in many organs       |

<div style=\"page-break-after: always\"></div>

| Study ID   | Species / Sex/ Number / Group   | Dose/Route mg/kg/day              | Duration   |   NOEL/ NOAEL (mg/kg/day ) | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------|---------------------------------|-----------------------------------|------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U05-1937   | Rat M+F/10                      | 0, 6, 60, 600 Oral (gavage)       | 4 weeks    |                         60 | 600: 1F dead. Piloerection, emaciation, hairless patches, decrease body weight, food consumption decrease, AST, ALT, GLDH, aldolase, bilirubin increase, Triglyceride decrease, Liver and kidney weight increase, Thymus, prostate, ovaries, pituitary weight decrease Necrosis and hyperplasia in liver, tubulus degeneration in kidneys, phospholipidosis in lung, lymph nodes, thymus, spleen and bone marrow. Atrophic salivary gland, apoptosis in prostate and |
| U06-1874   | Rat M+F/10                      | 0, 10, 30, 100, 300 Oral (gavage) | 3 months   |                         30 | lymphatic organs 100: Kidney, adrenals, thyroid weight increase, Aggregation of alveolar macrophages in lung. Glycogen accumulation in liver 300: Body weight gain decrease ALP, ALT, AST, bilirubin, creatinine, urea increase, Liver weight increase, Follicular cell hypertrophy in thyroid                                                                                                                                                                       |
| U07-1910   | Rat M+F/20                      | 0, 7, 30, 100, 300 Oral (gavage)  | 6 months   |                         30 | 100: Locomotor activity decrease ALT, GLDH increase 300: AST increase Liver, kidneys weight increase Tubular damage in kidneys, glycogen storage in liver incerase Hyperplasia of bile ducts. Phospholipidosis in lung. Mucosal irritation in stomach. Microfollicular hypertrophy in thyroid. Changes in ovaries, vagina and prostate                                                                                                                               |
| U06-1236   | Rat M+F/5                       | 0, 30, 60, 100 IV                 | 1 week     |                         30 | 60: Iliac lymph nodes weight increase, Thymus weight decrease 100: 1M dead. Prone, pale, breathing rate increase, Irritation at injection site                                                                                                                                                                                                                                                                                                                       |
| U06-1301   | Rat M+F/10                      | 0, 2.5, 10, 50 IV                 | 2 weeks    |                         10 | 50: Adrenal weight decrease                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Study ID   | Species / Sex/ Number / Group   | Dose/Route mg/kg/day         | Duration   | NOEL/ NOAEL (mg/kg/day )   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------------|---------------------------------|------------------------------|------------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U04-2187   | Dog M+F/2                       | 0, 15, 45, 150 Oral (gavage) | 2 weeks    | Not defined                | 15: Pseudo-allergic reactions, vomiting 45: Collapsis, histamine increase Apoptosis and inflamitory infiltration in bile duct, degeneration of seminiferous epithelium in testis. Lung weight increase 150: 1M dead, necrosis myocardium                                                                                                                                                                                                                                       |
| U05-1944   | Dog M+F/3                       | 0, 1, 3, 9, 45 Oral (gavage) | 4 weeks    | 9                          | 45: Pseudo-allergic reactions, vomiting, hypotension, tachycardia, QTc-prolongation, histamine increase, inflammatory infiltration in bile duct, tubuloepithelial apoptosis/necrosis in kidney, atrophy in seminiferous tubules                                                                                                                                                                                                                                                |
| U05-1978   | Monkey M+F/3                    | 0, 10, 30, 100 Oral (gavage) | 2 weeks    | 100                        | No findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| U05-1950   | Monkey M+F/1                    | 300 Oral (gavage)            | 2 weeks    | Not defined                | 300: Post-dose emesis                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| U05-2481   | Monkey M+F/3                    | 0, 10, 60, 300 Oral (gavage) | 4 weeks    | 10                         | 60: Salivation. Kidney weight increase Ovary, uterus weight decrease, Follicular development decrease, Thymus weight decrease Atrophy in vagina, sternal marrow and thymus 300: 1M dead. Emesis. ALT, AST, bilirubin, creatinine increase, Protein in urine increase Liver weight increase Hepatocyte glycogen increase Epithelial hypertrophy and peribiliary inflammation in bile ducts and gall bladder. Germinal centre development in lymph nodes decrease Thymus atrophy |

<div style=\"page-break-after: always\"></div>

| Study ID   | Species / Sex/ Number / Group   | Dose/Route mg/kg/day                                      | Duration                      | NOEL/ NOAEL (mg/kg/day )   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------|---------------------------------|-----------------------------------------------------------|-------------------------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U07-1072   | Monkey M+F/3                    | 0, 4, 25, 150 Oral (gavage)                               | 3 months                      | 4                          | 25: Epithelial hypertrophy/ hyperplasia, glandular degeneration, inflammatory cell infiltrate in stomach. 150: Body weight decrease Emesis, salivation. Creatinine, globulin increase, Albumin decrease, Chol, TG increase, Urinary protein increase Urinary Na and Cl decrease, Kidney weight increase, Thymus weight decrease Uterus, cervix weight decrease Cellularity in thymus and spleen decrease, Germinal centre development in madibular and mesenteric |
| U08-1185   | Monkey M+F/4                    | 0, 1, 10, 100 Oral (gavage)                               | 12 months                     | 10                         | lymph nodes decrease 100: 1F dead. Vomiting, salivation. Body weight decrease, Ovary weight decrease, Islet cell proliferation, hypoproteinemia, Urinary protein increase                                                                                                                                                                                                                                                                                         |
| U08-2215   | Monkey M+F/1                    | Staircase phase: 1, 2.5, 10, 25, 50 Constant phase: 40 IV | 3 days per dose level 2 weeks | Not defined                | 50 (staircase): Shallow breathing, lethargy 40 (2 weeks constant phase): Underactive behavior                                                                                                                                                                                                                                                                                                                                                                     |
| U10-1202   | Monkey M+F/3                    | 0, 1, 5, 40 IV                                            | 2 weeks                       | 5                          | 40: Swollen lips, muzzle and groin, shallow breathing, reddening facial skin, ECG: PG, QRS increase, Systolic blood pressure decrease                                                                                                                                                                                                                                                                                                                             |

Liver, kidneys and gastrointestinal tract were identified as the principal target organs of toxicity in mice and rats at high doses of linagliptin at repeat doses ( ≥ 100  mg/kg/day,  &gt;300x  Maximum Recommended  Human  Dose  (MRHD)  based  on  AUC).  In  rats  also  effects  on  reproductive  organs, thyroid  and  the  lymphoid  organs  were  seen  ( ≥ 60  mg/kg/day,  &gt;150x  MRHD).  No  relevant  and consistent gender differences were observed.

Strong  pseudo-allergic  reactions  were  observed  in  dogs  at  medium  doses  ( ≥ 15  mg/kg/day,  450x clinical  Cmax),  secondarily  causing  cardiovascular  changes,  which  were  considered  dog-specific. Therefore, no further repeat-dose testing has been performed with dogs.

At  high  doses  of  linagliptin  (&gt;1000x  MRHD,  based  on  AUC)  liver,  kidneys,  stomach,  reproductive organs, thymus, spleen, and lymph nodes were target organs of toxicity in Cynomolgus monkeys. At medium  dose  (&gt;100x  MRHD)  irritation  of  the  stomach  is  the  major  finding.  No  important  gender difference is observed. Necrotic skin lesions, which were observed after administration of other DPP-4 inhibitors, were not seen. The NOAEL of the longer oral toxicity studies in Cynomolgus monkeys is 10 mg/kg/day (40-66x MRHD).

<div style=\"page-break-after: always\"></div>

Intravenous administration of linagliptin to Cynomolgus monkeys at high dose (40 mg/kg/day), was associated with first degree atrioventricular block and signs indicative of pseudo-allergy. Because there was  no  relationship  between  the  signs  of  pseudo-allergy  and  histamine  plasma  concentrations,  this effect was not as clear as in dogs. Also this route of administration will not be used in human therapy; therefore, these findings will not be relevant for human use.

## Metformin

## Table 4. Repeat-dose toxicity studies with metformin

| Study ID     | Species/Sex/ Number/Group   | Dose/Route (mg/kg/day)   | Duration   |   NOEL/ NOAEL (mg/kg/day) | Major findings                                                                                                                                                                                                                                                                                                                        |
|--------------|-----------------------------|--------------------------|------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U09-2246 GLP | Rat M + F/10                | 0, 100, 200, 1000 Oral   | 2 weeks    |                       200 | 1000: Body weight gain ↓ Heart: Organ weight ↑ , hypertrophy of myocardium Liver: Organ weight ↑ Adrenals: Organ weight ↑ , vacuolation medulla Pituritary: Organ weight ↑ , hyperplasia Thymus: Organ weight ↓ , size reduction cortical areas Salivary glands (infiltration, inflammation) Pancreas (depletion of zymogen granules) |

The exposure increased almost proportionally with dose. Mean metformin plasma AUC0-24h values at dose levels of 100, 200 or 1000 mg/kg/day were 178, 374 and 2790 μ M·h. The respective Cmax values were 38.2, 70.1 or 204 μ M. There was no gender related effect.

No  adverse  findings  were  seen  at  100  and  200  mg/kg/day  (2.4x  MRHD)  metformin.  At  1000 mg/kg/day (17.5x MRHD), body weight gain was slightly decreased (terminal body weight 0.9x relative to control). The organ weights of the heart (1.3x relative to control), liver (1.3x) and adrenals (1.2x) were increased. In addition, a statistically significant increase in pituitary weights (1.2x) was noted in females.  Thymus  weights  were  reduced  (0.8x).  In  correlation  with  the  increased  heart  weights,  a concentric  hypertrophy  of  the  ventricle  myocardium  was  observed.  The  adrenal  medulla  (zona fasciculata) was affected by a minimal to slight cytoplasmic vacuolation. Hyperplasia of the pituitary gland (pars distalis) was found in females, atrophy of the seminal vesicles was seen in males. There were  also  alterations  of  the  parotid  salivary  gland  and  size  reduction  of  the  cortical  areas  of  the thymus.  In  addition,  depletion  of  pancreatic  zymogen  granules  was  found,  a  finding  which  often correlates with under nutrition.

At  high  dose  (17.5  x  MRHD)  the  target  organs  of  metformin  in  the  rat  are  heart,  liver,  adrenals, pituitary and thymus. The NOAEL is found at 200 mg/kg (2.4 x MRHD).

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

Table 5. Repeat-dose toxicity studies with the linagliptin/metformin combination

| Study ID          | Species/Sex/ Number/Group   | Dose/Route (mg/kg/day)                               | Duration   | NOEL/ NOAEL (mg/kg/day)   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------|-----------------------------|------------------------------------------------------|------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| U09-1632 Non-GLP* | Rat M + F/5                 | 0/0 2.5/500 5.0/1000 10.0/2000 Oral                  | 2 weeks    | Not defined               | 2.5/500 mg/kg: Heart, adrenals: Organ weight ↑ 5/1000 mg/kg: Body weight gain ↓ Heart: Organ weight ↑ , hypertrophy of myocardium Liver: Organ weight ↑ , cytoplasmic vacuolation Adrenals: Organ weight ↑ , vacuolation medulla Thymus: Organ weight ↓ Salivary glands: Vacuolation Pancreas: Depletion of zymogen granules                                                                                                                                                     |
| U09-2243 GLP      | Rat M + F/10                | 0/0 0.5/100 1/200 Oral                               | 2 weeks    | 1/200                     | No findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| U10-1492 GLP      | Rat M + F/10                | 0/0 0.5/100 2.0/400 4.0/800 2.0/800 4.0/0 0/800 Oral | 13 weeks   | 0.5/100                   | 2.0/400 mg/kg: Body weight gain ↓ Heart, liver, kidneys, adrenals: Organ weight ↑ Thymus: Organ weight ↓ Salivary glands: Hypertrophy of epithelium Ovaries: Number of corpora lutea ↑ 4.0/800 mg/kg, 2.0/800 mg/kg, and 0/800 mg/kg: As lower dose in addition: Mortality (4) Heart: Myocardium: Hypertrophy, fibrosis Liver: Hepatocellular hypertrophy Kidneys: Basophilic tubules, tubulus dilatations Uterus and/or Cervix: Atrophy Stomach: Erosions of the gastric mucosa |

* This non-GLP study has been designed to comply with international guidelines on repeated dose toxicity studies, e.g. 'Note for Guidance on Repeated Dose Toxicity', CPMP/SWP/1042/99 and Directive 2001/83/EC.

## Oral 2-week dose range finding study in rats

At the 2.5/500 mg/kg/day dose level (2.9x MRHD for linagliptin, 11x MRHD for metformin), increases in heart weight (1.3x relative to control) and adrenals weight (1.2x) were observed. Histopathological changes  were  seen  in  heart  (inflammation),  the  thymus  (apoptosis),  adrenal  gland  (cytoplasmic vaculoation) and parotid salivary gland (vacuolation).

Dosages  of  5/1000  mg/kg/day  linagliptin/metformin,  led  to  slight  decrease  in  body  weight  gain (terminal body weight 0.9x relative to control). The weights of the heart (1.4x relative to control), liver (1.3x)  and  adrenals  (1.5x)  were  increased.  Thymus  weights  were  reduced  (0.6x).  Histopathological changes  were  noted  in  heart  (hypertrophy  of  the  myocardium),  liver  (cytoplasmic  vacuolation  in females), salivary glands (vacuolation), thymus (apoptosis), adrenal medulla (cytoplasmic vacuolation), seminal vesicles (atrophy), and pancreas (depletion of zymogen granules).

<div style=\"page-break-after: always\"></div>

Linagliptin/metformin given at dosages of 10/2000 mg/kg/day exceeded the MTD. Mortality occurred already after a single administration and the remaining animals were prematurely sacrificed.

## Oral 2-week toxicity study in rats

There  were  no  drug  related  findings  in  all  dose  groups.  In  conclusion,  the  NOAEL  of  the  2-week combination  study  in  rats  was  set  at  1/200  mg/kg/day  linagliptin/metformin  (1.9x  MRHD  for linagliptin/2.8x MRHD for metformin).

## Oral 3-month toxicity study in rats

Linagliptin and metformin showed a different dose-exposure relationship in the tested dose range. The exposure to linagliptin increased less than proportionally with dose between 0.5 and 4.0 mg/kg/day. In contrast,  the  exposure  to  metformin  at  steady  state  increased  more  than  proportionally  with  dose between 100 and 800 mg/kg/day.

At 800 mg/kg/day metformin alone or in combination with linagliptin (linagliptin/metformin at a dosage of 0/800, 2.0/800 or 4.0/800 mg/kg/day, associated with 20.9x, 23.3 or22.8 x MRHD for metformin,) the  organ  weights  of  the  heart  (up  to  1.6x  relative  to  control),  liver  (1.6x),  kidneys  (1.4x),  and adrenals (1.6x) were increased. Thymus weights were reduced (0.6x). The ovarian (1.4x) and pituitary (0.9x) weights were affected in females. Plasma glucose was reduced (0.7x) and ALT slightly increased (up to 1.8x). Histopathological changes were noted in the heart (hypertrophy of the myocardium), liver (hepatocellular  hypertrophy),  kidneys  (basophilic  tubules),  salivary  glands  (hypertrophy),  thymus (apoptosis), adrenals (hypertrophy), ovaries (increased number of corpora lutea), stomach (erosion) and  intestine.  As  the  findings  were  seen  in  a  comparable  grading  in  all  groups  receiving  800 mg/kg/day metformin alone or in combination with linagliptin, all adverse effects were attributable to metformin. This also indicates that there was no enhancement of metformin-related toxicity, which is caused by the co-administration of linagliptin.

The only observed interaction between linagliptin and metformin was related to body weight gain. The decrease of body weight gain induced by metformin was magnified by linagliptin. At 800 mg/kg/day metformin the terminal body weight was 0.9x relative to control. Co-administration of 4.0 mg/kg/day linagliptin  enhanced  this  effect  to  0.8x  relative  to  control.  This  effect  is  considered  not  adverse  but rather an additive pharmacodynamic effect of the two anti-diabetic compounds.

Linagliptin/metformin at 2.0/400 mg/kg/day also decreased body weight gain (terminal body weight 0.9x control). In addition, similar effects on organ weights and histology described for the animals at 0/800, 2.0/800 and 4.0/800 mg/kg/day were seen but at a lower degree.

In conclusion, a NOAEL for linagliptin/metformin of 0.5/100 mg/kg/day (1.0x MRHD for linagliptin, 1.4x MRHD for metformin) was derived. All adverse findings seen in the study were attributed to metformin. The only combination effect attributable to the linagliptin/metformin combination itself was related to body  weight  gain.  There  was  no  enhancement  of  metformin-related  organ  toxicity  due  to  the  coadministration of linagliptin.

<div style=\"page-break-after: always\"></div>

## Genotoxicity

## Linagliptin

## Table 6. Overview of genotoxicity studies

| Type of test/study ID/GLP                                                                            | Test system                                                    | Concentrations/ Concentration range/ Metabolising system   | Results Positive/negative/ equivocal                  |
|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------------|
| Gene mutations in bacteria U04-1756 batch 8460060 GLP                                                | S. typhimurium TA98, 100, 102, 1535, 1537                      | 100 to 5000 μ g/plate +/- S9                               | Negative                                              |
| Chromosome aberration assay U04-1827 batch 8460060 GLP                                               | Human lymphocytes                                              | 10 to 1000 μ g/mL +/- S9                                   | Negative                                              |
| Chromosomal aberrations in vivo (part of 4-week toxicity studies in rats) U04-1847 batch 8460060 GLP | Micronuclei in bone marrow of rats                             | 6, 60 and 600 mg/kg/day                                    | Negative                                              |
| Main metabolite CD 1790 (tested as racemate CD 1750):                                                | Main metabolite CD 1790 (tested as racemate CD 1750):          | Main metabolite CD 1790 (tested as racemate CD 1750):      | Main metabolite CD 1790 (tested as racemate CD 1750): |
| Gene mutations in bacteria U06-1188 batch PAC01750A1 GLP                                             | S. typhimurium TA98, 100, 102, 1535, 1537                      | 30 to 3000 μ g/plate +/- S9                                | Negative                                              |
| Gene mutations in bacteria U07-2080 batch PR4PAC01750A1 GLP                                          | S. typhimurium TA98, 100, 102, 1535, 1537 Preincubation repeat | 30 to 3000 μ g/plate +/- S9                                | Negative                                              |
| Chromosomal aberration assay U06-1585 batch PAC01750A1 GLP                                           | Human lymphocytes                                              | 30 to 1000 μ g/mL +/- S9                                   | Negative                                              |

Linagliptin did not show a genotoxic potential up to toxic concentration or dosage levels when tested in bacterial and mammalian systems.

The potential genotoxicity of the main metabolite CD 1790 of linagliptin was also assessed in the Ames test and in the chromosome aberration assay in human lymphocytes.

No specific in vivo test with CD 1790 was performed as this metabolite is present in all animal species used for toxicological testing. In the rat the plasma level of CD 1790 was about 3-5% compared to the parent  compound  linagliptin  based  on  AUC.  In  the  rat  bone  marrow  micronucleus  test,  in  which dosages of up to 600 mg/kg/day of linagliptin were administered, an exposure of approximately 20000 nM.h  CD  1790  (corresponding  to  1000-fold  clinical  exposure  of  CD  1790)  was  calculated.  It  can therefore be concluded that CD 1790 is also negative in the rat bone marrow micronucleus assay.

<div style=\"page-break-after: always\"></div>

## Metformin

The Ames test, gene mutation test (mouse lymphoma cells), chromosomal aberrations test (human lymphocytes) and in vivo mouse micronucleus tests were negative with metformin.

## Linagliptin/metformin

No  genotoxicity  studies  have  been  performed  for  the  combination  linagliptin/metformin  which  is considered acceptable by the CHMP.

## Carcinogenicity

## Linagliptin

Table 7. Two-year carcinogenicity studies with linagliptin

| Study ID /GLP              | Dose/Route                         | Exposure (AUC, nM.h)       | Species/No. of animals   | Major findings                                   |
|----------------------------|------------------------------------|----------------------------|--------------------------|--------------------------------------------------|
| U10-1500 batch 5060170 GLP | 0, 8, 25, 80 mg/kg/day Oral gavage | 8: 767 25: 5180 80: 38300  | CD-1 mouse M+F/60        | 80F: Malignant lymphoma (probably insignificant) |
| U10-1502 batch 5060170 GLP | 0, 6, 18, 60 mg/kg/day Oral gavage | 6: 1520 18: 8070 60: 66100 | Wistar rat M+F/55        | 60: Phospholipidosis in lung                     |

In a 2-year carcinogenicity mouse study, linagliptin did not induce carcinogenic effects, except for a significant increase in malignant lymphomas in females at 80 mg/kg/day (242x MRHD for linagliptin, 27x MRHD for metabolite CD 1790). This was attributed to a high background of lymphomas in mice, and because linagliptin is not genotoxic, lymphoid hyperplasia in spleen and thymus was not increased in female mice, exposure in females was lower than in males, and occurred only at a very high dose, it was concluded that this finding is not relevant for humans.

Oral administration of linagliptin up to 60 mg/kg/day to Wistar rats for 2 years revealed no evidence of a  carcinogenic  potential.  A  dosage  of  60  mg/kg/day  corresponds  to  418-times  clinical  exposure  for linagliptin and 185-times clinical exposure for the main metabolite CD 1790 at MRHD.

## Metformin

Long-term  carcinogenicity  studies  with  metformin  have  been  performed  in  Sprague  Dawley  rats  at doses  of  150,  300,  and  450  mg/kg/day  in  males  and  150,  450,  900,  1200  mg/kg/day  in  females. These  doses  were  approximately  2,  4,  and  8  times  in  males,  and  3,  7,  12,  and  16  times  the therapeutic exposures based AUC values with the maximum recommended human daily dose of 2000 mg/kg/day. No evidence of carcinogenicity with metformin was found in neither male nor female rats.

## Linagliptin/metformin

The  fixed  dose  combination  of  linagliptin/metformin  contains  two  compounds  assessed  as  non carcinogenic.  The  carcinogenic  potential  is  thus  fully  assessed.  Hence  other  studies  assessing carcinogenic potential with the combination are not needed in accordance with the requirements of the 'Guideline on the Non-Clinical Development of Fixed Combinations of Medicinal Products '(EMEA/CHMP/SWP/258498/2005).

<div style=\"page-break-after: always\"></div>

## Reproduction Toxicity

Table 8. Reproductive toxicity studies with linagliptin, metformin and linagliptin/metformin

| Study type/ Study ID / GLP                                   | Species; Number / group   | Route & dose, mg/kg/day                                      | Dosing period                                              | Major findings                                                                                                                                                                                                                | NOAEL (mg/kg &AUC, nM.h)                                            |
|--------------------------------------------------------------|---------------------------|--------------------------------------------------------------|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Linagliptin                                                  | Linagliptin               | Linagliptin                                                  | Linagliptin                                                | Linagliptin                                                                                                                                                                                                                   | Linagliptin                                                         |
| Male and female fertility, embryo-fœtal development U06-2047 | Rat M+F/24                | Oral gavage 0, 10, 30, 240                                   | M: 29 days before mating F: 15 days before mating till GD6 | 240: Salivation, decrease of weight gain, food consumption decrease                                                                                                                                                           | 30 (parental toxicity) 240 (fertility, embryonic development)       |
| Embryo-fœtal development U05-2124                            | Rat F/10                  | Oral gavage 0, 6, 60, 600                                    | GD 7-16                                                    | 600: Maternal toxicity (decrease of body weight gain, food consumption decrease Resorption, sedation, salivation, bloody vagina) Hysterectomy: 60: Ossification delay 600: Fetal body weight decrease, Malformations increase | Not derived                                                         |
| Embryo-fœtal development U06-1637                            | Rat F/24                  | Oral gavage 0, 10, 30, 240                                   | GD 7-16                                                    | 240: Maternal toxicity (body weight gain, food consumption decrease) Hysterectomy: 240: Resorption rate increase, Skeletal ossification decrease, Rib anomalies increase                                                      | 30 AUC: 7710                                                        |
| Embryo-fœtal development U05-2449                            | Rabbit F/6                | Oral gavage 0, 100, 200, 300 In addition: 1F 400, 600 2F 600 | GD 6-18                                                    | 200: Body weight gain decrease ≥ 300: Maternal death Hysterectomy: 100: Complete resorptions 300: Malformations increase                                                                                                      | Not derived                                                         |
| Embryo-fœtal development U06-1200                            | Rabbit F/16-18            | Oral gavage 0, 4, 25, 150                                    | GD 6-18                                                    | ≥ 25: Body weight gain decrease 150: Food consumption decrease Hysterectomy: 150: Intrauterine death and runts, variations increase                                                                                           | Maternal toxicity: 4 AUC: 339 Embryo-foetal toxicity: 25 AUC: 12400 |

<div style=\"page-break-after: always\"></div>

| Study type/ Study ID / GLP            | Species; Number / group   | Route & dose, mg/kg/day                                        | Dosing period         | Major findings                                                                                                                                                                                                                                                                                                                                                            | NOAEL (mg/kg &AUC, nM.h)                                                                                  |
|---------------------------------------|---------------------------|----------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Peri & postnatal U07-1558             | Rat F/24                  | Oral gavage 0, 10, 30, 300                                     | GD 6 - LD 21          | F0: 300: Maternal toxicity (Salivation, body weight decrease, Food consumption decrease, Post-implantation loss increase) F1: 300: Body weight decrease, Delayed descensus testes, delayed preputial separation                                                                                                                                                           | 30                                                                                                        |
| Metformin                             | Metformin                 | Metformin                                                      | Metformin             | Metformin                                                                                                                                                                                                                                                                                                                                                                 | Metformin                                                                                                 |
| Embryo-fœtal development U10-2386 GLP | Rat 24                    | Oral gavage 0, 200, 500, 1000                                  | GD7-16                | 500 mg/kg: Maternal findings: Body weight gain ↓ , Blood glucose on GD 7 ↓ Hysterectomy: Ossification delays + malformations ↑ 1000 mg/kg: Maternal findings: Body weight gain ↓ , blood glucose ↓ on GD 7, blood glucose ↑ on GD 16 Hysterectomy: Ossification delays + malformations ↑ Unilateral anophthalmia, + polydactylia                                          | Embryo-fetal: 200 (4 x MRHD) AUC(0-24h) on GD 7: 377000 (nmol•h)/L AUC(0-24h) on GD 16: 638000 (nmol•h)/L |
| Linagliptin/metformin                 | Linagliptin/metformin     | Linagliptin/metformin                                          | Linagliptin/metformin | Linagliptin/metformin                                                                                                                                                                                                                                                                                                                                                     | Linagliptin/metformin                                                                                     |
| Embryo-fœtal development U10-2448 GLP | Rat 24                    | Oral gavage 0/0 1.0/200 2.5/500 5.0/1000 2.5/1000 5.0/0 0/1000 | GD7-16                | 1.0/200 mg/kg: Maternal findings: Body weight gain ↓ 2.5/500 mg/kg: Maternal findings: Body weight gain ↓ , blood glucose ↓ on GD 7 Hysterectomy: Ossification delays + malformations ↑ 0/1000, 2.5/1000 and 5.0/1000 mg/kg: Maternal findings: Body weight gain ↓ , blood glucose ↓ on GD 7 Hysterectomy: Ossification delays + malformations ↑ 5.0/0 mg/kg: No findings | Embryo-fetal: 1/200 (1.5x/ 3.3x MRHD) Mean AUC(0- 24h): 238/528 nM·h/ μ M·h                               |

<div style=\"page-break-after: always\"></div>

## Fertility and early embryonic development

## Linagliptin

In rat studies on fertility and early embryonic development, a NOAEL of 30 mg/kg/day (49x MRHD) was derived for paternal and maternal toxicity. No effects on early embryonic development, mating, fertility  and bearing live young were observed up to and including the high dosage group given 240 mg/kg/day (943x MRHD).

## Metformin

Fertility of male or female rats was not affected by metformin when administered at dose up to 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.

## Linagliptin/metformin

No  fertility  and  early  embryonic  development  studies  have  been  performed  for  the  combination linagliptin/metformin which is considered acceptable by the CHMP.

## Embryo-foetal development

## Linagliptin

No teratogenic effects occurred in Wistar rats up to and including the high dose of 240 mg/kg/day linagliptin (943x MRHD). The NOAEL for both maternal toxicity and embryo-foetal toxicity was 30 mg/kg/day (49x MRHD).

No teratogenic effects were observed in Himalayan rabbits up to and including the high dose of 150 mg/kg/day (1943x MRHD). A NOAEL of 25 mg/kg/day (78x MRHD) was derived for embryo-foetal toxicity. For maternal toxicity the NOAEL was 4 mg/kg/day (2.1x MRHD).

## Metformin

Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day, which represent 3 and 6 times the maximum recommended human daily dose of 2000 mg based on body surface area comparison for rats and rabbits, respectively.

Maternal findings: data from GD 7 demonstrated a trend for dose related decrease of glucose levels 4, 8 and 24 h after treatment with doses of 500 mg/kg and 1000 mg/kgThe data from GD 16 did not provide an indication for a trend to changed glucose levels in the 200 and 500 mg/kg dose groups at any time point. In the 1000 mg/kg dose group mean body weight during treatment period fluctuated on a slightly lower level than in the Control group. Mean body weight gain of the 200, 500 and 1000 mg/kg dose groups was decreased.Fetal data: In the viscera shortened truncus brachiocephalicus and small  kidney  at  1000  mg/kg  were  seen.  The  skeleton  showed  delayed  ossification  indicating developmental retardation. Most variations occurred at 1000 mg/kg and three (parietal bone partly not ossified, orbitosphenoidal bone not ossified and calcaneus not ossified) at 500 mg/kg. At 1000 mg/kg split sternebra lateral axis, flat and thickened rib (unilateral and bilateral), and rib z-shaped (bilateral) as  well  as  single  unilateral  anophthalmia  and  single  unilateral  polydactylia  were  seen.  Flat  and thickened rib (bilateral) were also seen at 500 mg/kg. Scapula bent inwardly at 500 and 1000 mg/kg at  increased  incidence  and  in  all  cases  in  combination  with  flat  and  thickened  rib.  At  1000  mg/kg additionally combination with rib z-shaped was seen.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

The exposure to linagliptin increased less than proportionally with the dose between 1 and 5 mg/kg linagliptin.  The  AUC0-24h  of  metformin  increased  dose  proportionally  on  GD  7  and  more  than proportionally on GD 16. The mean exposure to metformin on GD 16 at 5/1000 mg/kg/day was about 30 % higher than at 0/1000 mg/kg/day.

Treatment with linagliptin alone showed no changes in blood glucose levels. In contrast, reduction of blood glucose concentrations (up to 0.6x relative to control) was noted at all exposures to formulations containing 500 and 1000 mg/kg metformin.

In  all  dose  groups  treated  with  1000  mg/kg/day  metformin alone or in combination with linagliptin, means  of  body  weight  gain  were  significantly  decreased.  In  the  metformin  mono  group  (0/1000 mg/kg/day), this effect was less  pronounced than in the 2.5/1000 and  5/1000  mg/kg/day linagliptin/metformin combination groups. This indicates an additive pharmacodynamic effect on body weight gain induced by the administration of the two antidiabetic compounds.

Findings at hysterectomy: There was no effect on the mean number of corpora lutea, implantations, viable fetuses, resorptions as well as fetal sex and group means of preimplantation loss and resorption rate. Mean fetal body weight was significantly decreased in the 5/1000 mg/kg/day linagliptin/metformin dose group, but the individual weights were still within the spontaneous historical range. In some fetuses with ossification delay in the groups given 2.5/1000 and 0/1000 mg/kg/day linagliptin/metformin,  individual  fetal  body  weights  were  slightly  decreased.  Most  skeletal  variations seen at 1000 or 500 mg/kg/day metformin alone or in combination with linagliptin were ossification delays pointing to developmental retardation which is regularly balanced during later development.

At  a  dosage  of  1000  mg/kg/day  metformin  given  alone  or  in  combination  with  linagliptin  (animals dosed with linagliptin/metformin at 0/1000, 2.5/1000 and 5.0/1000 mg/kg/day, associated with 23.1x, 24.1x and 30.3x MRHD for metformin), skeletal malformations (cleft thoracal vertebral body, flat and thickened  rib  and  scapula  bent  inwardly,  thickened  rib,  rib  zshaped)  were  observed.  Most  skeletal malformations  and  findings  without  classification  occurred  at  lower  incidences  than  in  the  1000 mg/kg/day metformin mono group of the associated embryo-foetal development study. All treatment related  adverse  effects  on  the  embryo  were  attributed  to  the  administration  of  1000  mg/kg/day metformin  and  there  was  no  indication  of  an  additive  teratogenic  effect  attributed  to  the  coadministration of 2.5 or 5.0 mg/kg/day linagliptin. One single visceral malformation, hydronephrosis, was  diagnosed  in  the  linagliptin/metformin  group  given  5.0/1000  mg/kg/day.  The  relationship  to treatment  is  uncertain.  Incidences  of  treatment  related  changes  in  the  linagliptin/metformin  group given 2.5/500 mg/kg/day were low. The comparison of this group with the 500 mg/kg/day metformin mono group of the associated embryo-foetal study did not reveal any differences which would suggest an additive adverse effect of linagliptin. No relevant foetal alterations and no teratogenicity occurred in animals  dosed  with  linagliptin/metformin  at  a  dosage  of  1.0/200  mg/kg/day  and  this  combination dosage was considered to be the NOAEL (1.5x MRHD for linagliptin, 3.3x MRHD for metformin). As mentioned previously, dosages of 500 or 1000 mg/kg/day metformin (given alone or in combination with linagliptin) affected blood glucose levels. No effect on blood glucose was seen at 200 mg/kg/day metformin. Therefore, dysglycemia and foetal morphological changes induced by metformin may be connected. No relevant fetal alterations and no teratogenicity occurred in the linagliptin mono group given 5 mg/kg/day (3.0x MRHD).

There were no embryo-toxic findings, which were related to linagliptin. There was no indication of an additive or even synergistic teratogenic effect of both compounds.

<div style=\"page-break-after: always\"></div>

## Prenatal and postnatal development, including maternal function

## Linagliptin

In the pre- and postnatal development study, the NOAELs for maternal and offspring toxicity were 30 mg/kg/day (49x MRHD). Linagliptin produced maternal toxicity at 300 mg/kg/day (1506x MRHD). At this dosage, there was also an influence of linagliptin on body weight and body weight development of the offspring. However, the offspring's fertility was not changed.

Toxicokinetic studies in pregnant rats and rabbits showed that linagliptin and the main metabolite CD 1790 crosses the placenta and is distributed into the embryo and fetus. Linagliptin was also shown to be excreted into maternal milk.

## Metformin

Animal data of excretion of metformin in milk was not provided, but it has been found that metformin is excreted in human milk. The concentrations of metformin in breast milk were generally low and the mean infant exposure to the drug was only 0.28% of the weight-normalized maternal dose. No data regarding pre- and postnatal development after metformin administration are available.

## Linagliptin/metformin

No prenatal and post-natal development studies have been performed for the combination linagliptin/metformin which is considered acceptable by the CHMP based on the data available on both compounds

## Local Tolerance

## Linagliptin

To  evaluate  the  tolerance  for  linagliptin  as  an  injection  solution,  several  studies  were  performed. Injectable  solutions  (0.5  mg/mL)  of  linagliptin  were  well  tolerated  after  a  single  paravenous,  intraarterial,  intravenous,  or  intramuscular  injection.  Linagliptin  was  also  well  tolerated  subsequent  to topical application on rabbit skin. In an ex vivo study, injectable solutions (0.5 mg/mL) of linagliptin induced no relevant hemolysis in human blood.

## Metformin

No local tolerance studies have been performed with metformin. As Jentadueto is only intended for oral use this is considered acceptable by the CHMP.

## Linagliptin/metformin

No  local  toterance  studies  have  been  performed  for  the  combination  linagliptin/metformin  which  is considered acceptable by the CHMP.

## Other toxicity studies

## Immunotoxicity

## Linagliptin

All relevant toxicity studies for linagliptin have been performed. Antigenicity/immunotoxicity measurements were included in toxicological studies and no cause for concern was identified.

## Metformin

No antigenic / immunotoxicity potential is known for metformin.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

In  accordance  with  the  'Note  for  Guidance  on  Immunotoxicity  Studies  for  Human  Pharmaceuticals' (CHMP/167235/2004), no additional information is considered necessary for the fixed dose combination linagliptin/metformin as the individual components show no cause for concern.

## Studies on impurities

## Linagliptin

In the proposed drug substance specification, the acceptance criteria of the linagliptin impurities were set  at  levels  above  the  qualification  threshold.  These  impurities  were  qualified  before  in  general toxicity, carcinogenicity and genotoxicity studies, and found negative.

In  the  proposed  drug  product  specification,  the  acceptance  criteria  of  a  degradation  product  of linagliptin, was set at a level above the identification threshold. Although formally not needed, toxicity studies were performed to demonstrate the biological safety of this degradation product.

## Overview of new genotoxicity studies of a degradation product

| Type of test/study ID/GLP                | Test system                               | Concentrations/ Concentration range/ Metabolising system   | Results Positive/negative/ equivocal   |
|------------------------------------------|-------------------------------------------|------------------------------------------------------------|----------------------------------------|
| Gene mutations in bacteria U10-1029 GLP  | S. typhimurium TA98, 100, 102, 1535, 1537 | 10 to 1000 μ g/plate +/- S9                                | Negative                               |
| Chromosome aberration assay U10-1648 GLP | Human lymphocytes                         | 10 to 200 μ g/mL +/- S9                                    | Negative                               |

The new gene mutation study of the degradation product caused neither base-pair substitutions nor frameshift mutations in different strains of S. typhimurium in the presence and absence of metabolic activation when tested up to insoluble concentrations. Based on these results it was concluded, that the test substance is \"Ames negative\".

The degradation product, using the chromosomal aberration test in human lymphocytes in vitro ,  did not  induce  an  increase  in  the  number  of  structural  and  numerical  chromosomal  aberrations  when tested  up  to  cytotoxic  and  insoluble  concentrations  in  the  presence  and  absence  of  metabolic activation.  Based  on  these  results  it  was  concluded,  that  the  test  substance  is  negative  in  this chromosomal aberration test.

In  a  13-week  toxicity  study  in  the  rat,  the  degradation  product  was  spiked  in  at  a  concentration  of 2.93%. The NOAEL derived in the study was 0.5 mg/kg/day linagliptin and a safety margin to human use of 35 for the degradation product was derived.

<div style=\"page-break-after: always\"></div>

## Metformin

For  metformin  hydrochloride,  the  Applicant  makes  reference  to  a  CEP  from  the  manufacturer  of metformin hydrochloride. Metformin hydrochloride used for the manufacture of linagliptin/metformin hydrochloride film coated tablets is released in accordance with the Ph. Eur. monograph as well as the CEP. There were no impurities in Meformin DS or DP which had to be qualified.

## 2.3.5. Ecotoxicity/environmental risk assessment

The Environmental Risk Assessment (ERA) submitted for Jentadueto was prepared in compliance with the Guideline on the Environmental Risk Assessment of Medicinal Products for  Human  Use (EMEA/CHMP/SWP/4447/00). The two active substances linagliptin and metformin have been assessed separately. Predicted environmental concentrations exceeded the threshold value of 0.01 μ L, triggering a Phase II - Tier A for both active substances.

## Linagliptin

A Phase I environmental risk assessment was performed to evaluate potential environmental risks of linagliptin. The log Kow was determined according to study OECD 122 with a value of 1.7. Based on the log  K ow value  being  below  3,  linagliptin  is  not  expected  to  be  a  bio-accumulative  substance.  A PECsurfacewater of  0.025  µg/L  was  calculated  using  the  default  Fpen  of  0.01.  Since  the  PEC surfacewater exceeded the threshold value of 0.01 μ g/L, a phase II ERA was performed.

The outcome of the phase II assessment shows that the PEC/PNEC ratios for all three compartments are clearly below the trigger values of 1 and 0.1, respectively (see table below).

Table 9. PEC and PNEC values for linagliptin

| Compartment           | PEC         | PNEC          | PEC/PNEC ratio   |   Trigger for Tier B |
|-----------------------|-------------|---------------|------------------|----------------------|
| Surface water         | 0.025 μ g/L | 320 μ g/L     | 7.8 x 10 -5      |                  1   |
| Microorgansisms (STP) | 0.025 μ g/L | 21000 μ g/L   | 1.2 x 10 -6      |                  0.1 |
| Groundwater           | 0.006 μ g/L | 320 μ g/L     | 7.8 x 10 -5      |                  1   |
| Sediment              | 1.57 μ g/kg | 125000 μ g/kg | 1.3 x 10 -5      |                  1   |

Therefore,  the  use  of  linagliptin  as  active  ingredient  with  the  use  pattern  as  given  above  can  be considered to result in insignificant environmental risk for the three aquatic compartments. Thus, an extended  environmental  fate  and  effects  analysis  for  the  three  compartments  in  Tier  B  is  not considered to be necessary.

Since  the  log  K ow of  the  undissociated  compound  was  determined  to  be  below  3,  linagliptin  is considered to have no potential to bio-accumulate. Therefore, bio-concentration does not have to be considered in Tier B.

<div style=\"page-break-after: always\"></div>

The OECD 106 adsorption study was conducted with three different soils and two sewage sludges. The study  shows  that  the  normalisation  to  the  organic  carbon  (OC)  content  of  the  soils/sludges  is  not feasible due to the lack of direct correlation between adsorption of the substance and the OC content of the soils/sludges. Therefore, a Kd-trigger for sludge of 3700 L/kg (corresponding to the Koc-trigger of 10000 L/kg assuming a default OC content in sludge) is considered to be more reasonable than the Koc-trigger as proposed in the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00). For the sludges, the OECD 106 adsorption study resulted in a Kd of 190 L/kg. Since this is below the trigger of 3700 L/kg, a terrestrial risk assessment was not considered in Tier B.

The criterion for significant shifting to the sediment (10% of the substance at any time point after or at 14 days is present in sediment) is exceeded for linagliptin. Therefore, effects on sediment organisms were considered in Tier  B  and  a  toxicity  study  on  chironomids  was  conducted.  Since  the  PEC/PNEC ratio is below the trigger of 1, it can be concluded that the use of linagliptin as active ingredient with the use pattern as given above can be considered to result in insignificant environmental risk for the compartment sediment.

Considering the above data, linagliptin is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

Table 10. Summary of main study results

| Substance (INN/Invented Name): Linagliptin CAS-number (if available): 668270-12-0   | Substance (INN/Invented Name): Linagliptin CAS-number (if available): 668270-12-0   | Substance (INN/Invented Name): Linagliptin CAS-number (if available): 668270-12-0                                | Substance (INN/Invented Name): Linagliptin CAS-number (if available): 668270-12-0                                | Substance (INN/Invented Name): Linagliptin CAS-number (if available): 668270-12-0   |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| PBT screening                                                                       |                                                                                     | Result                                                                                                           |                                                                                                                  | Conclusion                                                                          |
| Bioaccumulation potential- log K ow                                                 | OECD122                                                                             | log P ow = 1.7 (undissociated compound)                                                                          | log P ow = 1.7 (undissociated compound)                                                                          | Potential PBT: No                                                                   |
| PBT-assessment                                                                      | PBT-assessment                                                                      | PBT-assessment                                                                                                   | PBT-assessment                                                                                                   | PBT-assessment                                                                      |
| Parameter                                                                           | Result relevant for conclusion                                                      |                                                                                                                  |                                                                                                                  | Conclusion                                                                          |
| Bioaccumulation                                                                     | log K ow                                                                            | log P ow = 1.7 (undissociated compound)                                                                          | log P ow = 1.7 (undissociated compound)                                                                          | not B                                                                               |
| Bioaccumulation                                                                     | BCF                                                                                 | -                                                                                                                | -                                                                                                                | not B                                                                               |
| Persistence                                                                         | DT50 or ready biodegradability                                                      | Not readily biodegradable                                                                                        | Not readily biodegradable                                                                                        | potentially P                                                                       |
| Toxicity                                                                            | NOEC or CMR                                                                         | 3.2 mg/L                                                                                                         | 3.2 mg/L                                                                                                         | not T                                                                               |
| PBT-statement :                                                                     | The compound is not considered PBT nor vPvB                                         | The compound is not considered PBT nor vPvB                                                                      | The compound is not considered PBT nor vPvB                                                                      | The compound is not considered PBT nor vPvB                                         |
| Phase I                                                                             | Phase I                                                                             | Phase I                                                                                                          | Phase I                                                                                                          | Phase I                                                                             |
| Calculation                                                                         | Value                                                                               | Unit                                                                                                             |                                                                                                                  | Conclusion                                                                          |
| PEC surfacewater , default                                                          | 0.025                                                                               |  g/L                                                                                                            |                                                                                                                  | > 0.01 threshold                                                                    |
| Phase II Physical-chemical properties and fate                                      | Phase II Physical-chemical properties and fate                                      | Phase II Physical-chemical properties and fate                                                                   | Phase II Physical-chemical properties and fate                                                                   | Phase II Physical-chemical properties and fate                                      |
| Study type                                                                          | Test protocol                                                                       | Results                                                                                                          |                                                                                                                  | Remarks                                                                             |
| Adsorption-Desorption                                                               | OECD 106                                                                            | Mean of 3 soils: Koc = 19234 L/kg Kd = 286 Mean of 2 sludges: Koc = 726 L/kg Kd = 190 Not ready biodegradable    | Mean of 3 soils: Koc = 19234 L/kg Kd = 286 Mean of 2 sludges: Koc = 726 L/kg Kd = 190 Not ready biodegradable    |                                                                                     |
| Ready Biodegradability Test                                                         | OECD 301A                                                                           | (0% in 28 days)                                                                                                  | (0% in 28 days)                                                                                                  |                                                                                     |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems                    | OECD 308                                                                            | DT 50, water = 0.8d (r), 1.1d (p) DT 50, sediment = 110d (r), 42.2d (p) DT 50, whole system = 5.2d (r), 1.6d (p) | DT 50, water = 0.8d (r), 1.1d (p) DT 50, sediment = 110d (r), 42.2d (p) DT 50, whole system = 5.2d (r), 1.6d (p) | r = river p = pond                                                                  |
| Phase IIa Effect studies Unit                                                       | Phase IIa Effect studies Unit                                                       | Phase IIa Effect studies Unit                                                                                    | Phase IIa Effect studies Unit                                                                                    | Phase IIa Effect studies Unit                                                       |
| Study type                                                                          | Test protocol                                                                       | Endpoin t                                                                                                        | valu e                                                                                                           | Remarks                                                                             |
| Algae, Growth Inhibition Test ( Pseudokirchneriella subcapitata )                   | OECD 201                                                                            | NOEC EC50                                                                                                        | 4.1 49                                                                                                           | growth rate                                                                         |
| Daphnia sp . Reproduction Test                                                      | OECD 211                                                                            | NOEC                                                                                                             | 3.2                                                                                                              |                                                                                     |
| Fish, Early Life Stage Toxicity Test/ Brachydanio rerio                             | OECD 210                                                                            | NOEC                                                                                                             | 12.0                                                                                                             |                                                                                     |
| Activated Sludge, Respiration Inhibition Test                                       | OECD 209                                                                            | EC50 NOEC                                                                                                        | 792 210                                                                                                          |                                                                                     |
| mg/L Phase IIb Studies                                                              | mg/L Phase IIb Studies                                                              | mg/L Phase IIb Studies                                                                                           | mg/L Phase IIb Studies                                                                                           | mg/L Phase IIb Studies                                                              |
| Sediment dwelling organism ( Chironomus riparius )                                  | OECD 218                                                                            | NOEC                                                                                                             | 125                                                                                                              |                                                                                     |

<div style=\"page-break-after: always\"></div>

## Metformin

A Phase I environmental risk assessment was performed to evaluate potential environmental risks of metformin. The log Kow was determined according to study OECD 107 with a value of 1.1 at pH 7. Based  on  the  log  K ow value  being  below  4.5,  metformin  is  not  expected  to  be  a  bio-accumulative substance. Using the default Fpen and the maximum daily dose to be given in humans of 2000 mg of metformin (corrected for molar mass of hydrochloride), a PECsurface water of 7.8 µg/L was calculated.

In  conclusion  of  the  OECD  308  study,  metformin  dissipated  rapidly  from  the  water  phase  via adsorption  to  the  sediment.  Additionally,  metformin  rapidly  degraded  via  the  formation  of  several minor or transient degradation products to CO2. On the basis of the distribution of total radioactivity between the water phase (overlying plus pore water) and the sediment (extractable and nonextractable), Kd-values for sediment can be calculated for each sampling date. From day 1 to day 7, a period with little initial degradation and with levels of about 50% of the applied radioactivity in water and around 50% in sediment, Kd values of in maximum 7.2 (river) and 6.9 (pond) were obtained. These are in line with the low values determined for soil in the adsorption test.

The criterion for significant shifting to the sediment (10% of the substance at any time point after or at 14 days is present in sediment) is exceeded for metformin. Therefore, effects on sediment organisms were considered in Tier B and a toxicity study on chironomids was conducted.

The criterion for significant shifting to the sediment (10% of the substance at any time point after or at 14 days is present in sediment) is exceeded for metformin. Therefore, effects on sediment organisms were  considered  in  Phase  II  Tier  B  and  a  toxicity  study  on  chironomids  was  conducted.  Since  the PEC/PNEC  ratio  is  below  the  trigger  of  1,  it  can  be  concluded  that  the  use  of  linagliptin  as  active ingredient with the use  pattern  as given  above  can  be  considered  to  result  in insignificant environmental risk for the compartment sediment.

Table 11. PEC/PNEC assessments

*EMEA guidance has lowered the trigger value for the STP risk quotient (from 1 to 0.1) rather than calculating a separate PECSTP. In this case, PEC STP equals PECsurface water .

| Environmental compartment   | PEC µg/L    | PNEC µg/L   | PEC/PNEC    |   Trigger value | Conclusion   |
|-----------------------------|-------------|-------------|-------------|-----------------|--------------|
| Surface water               | 7.80        | ≥ 1,000     | ≤ 7.7×10 -3 |             1   | no risk      |
| Groundwater                 | 1.95        | 1,700       | 1.1×10 -3   |             1   | no risk      |
| STP*                        | 7.80*       | 11,000      | 7.1×10 -4   |             0.1 | no risk      |
| Sediment                    | 53.9 μ g/kg | 1250 μ g/kg | 4.3 x 10 -2 |             1   | no risk      |

Considering the above data, metformin is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

Table 12. Summary of main study results

| Substance (INN/Invented Name): metformin CAS-number (if available): 657-24-9   | Substance (INN/Invented Name): metformin CAS-number (if available): 657-24-9   | Substance (INN/Invented Name): metformin CAS-number (if available): 657-24-9                                                                                                                                                                                                                          | Substance (INN/Invented Name): metformin CAS-number (if available): 657-24-9                                                                                                                                                                                                                          | Substance (INN/Invented Name): metformin CAS-number (if available): 657-24-9   |
|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| PBT screening                                                                  |                                                                                | Result                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                       | Conclusion                                                                     |
| Bioaccumulation potential- log K ow                                            | shake flask                                                                    | log D ow = -1.1 (pH 7.4)                                                                                                                                                                                                                                                                              | log D ow = -1.1 (pH 7.4)                                                                                                                                                                                                                                                                              | Potential PBT: No                                                              |
| PBT-assessment                                                                 | PBT-assessment                                                                 | PBT-assessment                                                                                                                                                                                                                                                                                        | PBT-assessment                                                                                                                                                                                                                                                                                        | PBT-assessment                                                                 |
| Parameter                                                                      | Result relevant for conclusion                                                 |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | Conclusion                                                                     |
| Bioaccumulation                                                                | log K ow BCF                                                                   | log D ow = -1.1 at pH 7.4 not determined                                                                                                                                                                                                                                                              | log D ow = -1.1 at pH 7.4 not determined                                                                                                                                                                                                                                                              | not B                                                                          |
| Persistence                                                                    | DT50 or ready biodegradability                                                 | not ready                                                                                                                                                                                                                                                                                             | not ready                                                                                                                                                                                                                                                                                             |                                                                                |
|                                                                                |                                                                                | DT50 water: 9.2 (river) and 7.9 (pond) days. DT50 total system: 22.0 (r) and 22.3 (p) days. At the end of the study (day 79), 7.5% of applied radioactivity (AR) was remaining as parent compound in the total pond system, and in the river system the parent metformin was not observed any longer. | DT50 water: 9.2 (river) and 7.9 (pond) days. DT50 total system: 22.0 (r) and 22.3 (p) days. At the end of the study (day 79), 7.5% of applied radioactivity (AR) was remaining as parent compound in the total pond system, and in the river system the parent metformin was not observed any longer. | OECD 308                                                                       |
| Toxicity                                                                       | NOEC or CMR                                                                    | N.A.                                                                                                                                                                                                                                                                                                  | N.A.                                                                                                                                                                                                                                                                                                  |                                                                                |
| PBT-statement : metformin is not PBT, nor vPvB.                                | PBT-statement : metformin is not PBT, nor vPvB.                                | PBT-statement : metformin is not PBT, nor vPvB.                                                                                                                                                                                                                                                       | PBT-statement : metformin is not PBT, nor vPvB.                                                                                                                                                                                                                                                       | PBT-statement : metformin is not PBT, nor vPvB.                                |
| Phase I Calculation                                                            | Value                                                                          | Unit                                                                                                                                                                                                                                                                                                  | Unit                                                                                                                                                                                                                                                                                                  | Conclusion                                                                     |
| PEC surfacewater , default F pen                                               | 7.8 (metformin base)                                                           | µg/L                                                                                                                                                                                                                                                                                                  | µg/L                                                                                                                                                                                                                                                                                                  | > 0.01 threshold: Y                                                            |
| Other concerns (e.g. chemical class)                                           | unknown                                                                        |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | unknown                                                                        |
| Phase II Physical-chemical properties and fate                                 | Phase II Physical-chemical properties and fate                                 | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                        | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                        | Phase II Physical-chemical properties and fate                                 |
| Study type                                                                     | Test protocol                                                                  | Results                                                                                                                                                                                                                                                                                               | Results                                                                                                                                                                                                                                                                                               | Remarks                                                                        |
| Adsorption-Desorption                                                          | OECD 106                                                                       | K oc =4.8 and 7.5 L/kg                                                                                                                                                                                                                                                                                | K oc =4.8 and 7.5 L/kg                                                                                                                                                                                                                                                                                | 2 sludges, based on K d                                                        |
|                                                                                | OECD 106                                                                       | K oc =283, 2056 and 3209 L/kg                                                                                                                                                                                                                                                                         | K oc =283, 2056 and 3209 L/kg                                                                                                                                                                                                                                                                         | 3 soils; based on K d                                                          |
| Ready Biodegradability Test                                                    | OECD 301                                                                       | not ready                                                                                                                                                                                                                                                                                             | not ready                                                                                                                                                                                                                                                                                             | public literature                                                              |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems               | OECD 308                                                                       | DT50 water: 9.2 (river) and 7.9 (pond) days DT50 total system: 22.0 (r) and 22.3 (p) days At the end of the study (day 79), 7.5% of applied radioactivity (AR) was remaining as parent compound in the total pond system, and in the river system the parent metformin                                | DT50 water: 9.2 (river) and 7.9 (pond) days DT50 total system: 22.0 (r) and 22.3 (p) days At the end of the study (day 79), 7.5% of applied radioactivity (AR) was remaining as parent compound in the total pond system, and in the river system the parent metformin                                | 2 sediments                                                                    |
| was not observed any longer. Phase IIa Effect studies                          | was not observed any longer. Phase IIa Effect studies                          | was not observed any longer. Phase IIa Effect studies                                                                                                                                                                                                                                                 | was not observed any longer. Phase IIa Effect studies                                                                                                                                                                                                                                                 | was not observed any longer. Phase IIa Effect studies                          |
| Study type                                                                     | Test protocol                                                                  | Endpoin t                                                                                                                                                                                                                                                                                             | value Unit                                                                                                                                                                                                                                                                                            | Remarks                                                                        |
| All toxicity test results expressed as mg metformin base / L                   | All toxicity test results expressed as mg metformin base / L                   | All toxicity test results expressed as mg metformin base / L                                                                                                                                                                                                                                          | All toxicity test results expressed as mg metformin base / L                                                                                                                                                                                                                                          | All toxicity test results expressed as mg metformin base / L                   |
| Algae, Growth Inhibition Test P. subcapitata                                   | OECD 201                                                                       | NOEC                                                                                                                                                                                                                                                                                                  | ≥ 78 mg/L                                                                                                                                                                                                                                                                                             |                                                                                |
| Daphnia sp . Reproduction                                                      | OECD 211                                                                       | NOEC                                                                                                                                                                                                                                                                                                  | 17 mg/L                                                                                                                                                                                                                                                                                               | 21 d mortality,                                                                |

<div style=\"page-break-after: always\"></div>

| Test D. magna                                 |                   |                   |                   |                   | reproduction                                                                 |
|-----------------------------------------------|-------------------|-------------------|-------------------|-------------------|------------------------------------------------------------------------------|
| D. magna                                      | OECD 211          | LC50              | 38                | mg/L              | 21 d mortality                                                               |
| D. magna                                      | OECD 211          | LC100             | 55                | mg/L              | 21 d mortality                                                               |
| Fish, Early Life Stage Toxicity Test D. rerio | OECD 210          | NOEC              | ≥ 10              | mg/L              | Result valid for hatching rate, time to hatch, surivival, length and weight. |
| Activated Sludge, Respiration Inhibition Test | OECD 209          | EC10              | 110               | mg/L              | EC50>1000 mg/L                                                               |
| Phase IIb Studies                             | Phase IIb Studies | Phase IIb Studies | Phase IIb Studies | Phase IIb Studies | Phase IIb Studies                                                            |
| Sediment dwelling organism                    | OECD 218          | NOEC              | 125               | mg/kg             | TOC 2.4%                                                                     |

## 2.3.6. Discussion on non-clinical aspects

The combination of the glucose-dependent insulin secretagogue linagliptin with the insulin sensitizing drug metformin is considered a good principle for diabetes therapy in patients with type 2 diabetes. An additive effect on glucose reduction of linagliptin and metformin was shown in a mouse disease model for  diabetes  (diabetic db/db mice).  There  was  no  relevant  pharmacokinetic  interaction  between metformin and linagliptin.

As  shown  in  the  linagliptin  non-clinical  development  program,  signs  of  linagliptin-related  toxicity occurred at doses far in excess of those recommended for therapy. In the 2-week and 13-week toxicity studies  in  the  rat,  the  liver,  kidneys,  thyroid,  lymphoid  organs  and  lungs  were  identified  as  target organs  of  toxicity.  In  the  2-week  rat  toxicity  study,  no  adverse  findings  were  seen  up  to  100 mg/kg/day (associated with an AUC0-24h,ss of 291 times human AUC0-24h,ss at the MRHD = 291x MRHD).  In  the  13-week  rat  toxicity  study  a  NOAEL  of  30  mg/kg/day  (95.6x  MRHD)  was  derived. Linagliptin was not teratogenic in rats up to and including a dosage of 240 mg/kg/day (943x MRHD).

Metformin-related toxicity in the rat was observed in the heart, liver, kidneys, salivary glands, ovaries, thymus,  gastrointestinal  tract  (stomach,  small  and  large  intestine)  and  adrenal  glands  at  dosages associated with an exposure of 7.4x MRHD or higher. In addition, body weight gain was reduced. A NOAEL of 200 mg/kg/day (2.4x MRHD) was derived in the 2-week rat toxicity study. Metformin was not  teratogenic  and  not  embryotoxic  in  the  rat  at  a  dosage  of  200  mg/kg/day  (4.0x  MRHD). Teratogenicity  of  metformin  in  the  rat  was  observed  at  500  mg/kg/day  (10.9x  MRHD,  beginning effects) and 1000 mg/kg/day (23.2x MRHD). At these dosages, blood glucose levels were affected and dysglycaemia and fetal morphological changes induced by metformin in the rat may be connected.

In  all  linagliptin/metformin  toxicity  studies,  linagliptin  and  metformin  were tested  in  clinical  relevant dose ratios of 1:200 and 1:400. In the general toxicity studies, the only observed interaction between linagliptin and metformin was a reduction of body weight gain. This effect is considered not adverse but  rather  an  additive  pharmacodynamic  effect  of  the  two  antidiabetic  compounds.  In  the  13-week combination toxicity study in the rat, a NOAEL for linagliptin/metformin of 0.5/100 mg/kg/day (1.0x MRHD for linagliptin, 1.4x MRHD for metformin) was derived based on metformin related findings. All adverse findings in the combination studies were attributed to metformin at dosages of 400 mg/kg/day (7.4x MRHD) or higher and no linagliptin related toxicity was observed. There was no indication of a teratogenic  effect  attributable  to  the  co-administration  of  linagliptin  and  metformin.  The  individual compounds were shown to be not genotoxic and not carcinogenic.

<div style=\"page-break-after: always\"></div>

## 2.3.7. Conclusion on the non-clinical aspects

Overall,  the  non-clinical  developmental  plan  of  the  combination  linagliptin/metformin  was  limited  to necessary studies. This is considered acceptable. The available non-clinical data including the results obtained  from  the  repeat  dose  toxicity  and  reproduction  toxicity  studies  with  Jentadueto  and  the environmental risk assessment did not identify any new safety issues. The non-clinical safety profile of linagliptin/metformin  appears  to  be  consistent  with  those  established  for  linagliptin  and  metformin when used as monotherapy. Based on the available non-clinical safety data with the two monotherapy compounds, linagliptin and metformin, it is concluded that the FDC should be well tolerated when used in human at the proposed dosage.

## 2.4. Clinical aspects

The Applicant is seeking a Marketing Authorisation for linagliptin/metformin film-coated tablets as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin, also in combination with a sulphonylurea (i.e. triple combination therapy) in patients inadequately controlled on their maximum tolerated dose of metformin and a sulphonylurea. For  patients  switching  from  co-administration  of  linagliptin  and  metformin,  Jentadueto  should  be initiated at the dose of linagliptin and metformin already being taken. The recommended starting dose of  Jentadueto  for  patients  inadequately  controlled  on  dual  combination  therapy  with  the  maximal tolerated dose of metformin and a sulphonylurea is 2.5 mg of linagliptin twice daily (5 mg total daily dose)  and  a  dose  of  metformin  similar  to  the  dose  already  being  taken.  When  linagliptin  plus metformin is  used  in  combination  with  a  sulphonylurea,  a  lower  dose  of  the  sulphonylurea  may  be required due to the risk of hypoglycaemia. For the different doses of metformin, Jentadueto is available in  strengths  of  2.5 mg  linagliptin  plus  850 mg  metformin  hydrochloride  and  2.5 mg  linagliptin  plus 1,000 mg metformin hydrochloride.

The clinical development program of Jentadueto was designed to demonstrate the safety and efficacy of linagliptin, metformin and linagliptin/metformin as FDC in patients with T2DM. No dedicated studies with metformin as monotherapy were conducted. The pharmacokinetics, safety, and efficacy profiles of metformin  as  monotherapy  are  well  known.  The  clinical  development  programs  for  linagliptin  and linagliptin/metformin are presented in table 14 and 15..

Scientific advice was provided by the CHMP in September 2008 (EMEA/CHMP/SAWP/ 472394/2008) on the  clinical  aspects  of  the  development  program.  The  CHMP  requested  a  clinical  study  to  show equivalence of twice daily dosing of linagliptin 2.5 mg with once daily dosing of linagliptin 5 mg. This study  was  subsequently  conducted  by  the  Applicant  and  its  results  are  presented  in  this  Marketing Authorisation application. The advice given has been followed in all essential parts.

<div style=\"page-break-after: always\"></div>

## 2.4.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the applicant. The applicant has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the  community  were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 13. Linagliptin clinical development program

| Study number                             | Type of study                            | Test and reference products; dosage regimen   | Lina (N)                                 | Comparator (N)                           | Healthy subjects (HS) or diagnosis of patients   |
|------------------------------------------|------------------------------------------|-----------------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------------------|
| Phase I studies in healthy subjects      | Phase I studies in healthy subjects      | Phase I studies in healthy subjects           | Phase I studies in healthy subjects      | Phase I studies in healthy subjects      | Phase I studies in healthy subjects              |
| 1218.1                                   | PK/PD                                    | SRD                                           | 48                                       | Placebo:16                               | HS                                               |
| 1218.8                                   | BA                                       | powder and tablets                            | 24                                       | -                                        | HS                                               |
| 1218.10                                  | PK/PD                                    | SRD iv                                        | 0.5-10mg iv: 28                          | Placebo: 8                               | HS                                               |
| 1218.7                                   | PK                                       | 14 C Human ADME iv/oral                       | 5-10 mg iv: 12                           | -                                        | HS                                               |
| 1218.25                                  | BA                                       | tablet formulations                           | 24                                       | -                                        | HS                                               |
| 1218.33                                  | BA                                       | tablet strenghts                              | 12                                       | -                                        | HS                                               |
| 1218.34                                  | BA                                       | food                                          | 32                                       | -                                        | HS                                               |
| 1218.45                                  | PK/PD                                    | 1x5mg vs 2x2.5mg                              | 16                                       | -                                        | HS                                               |
| Phase I studies in patients with T2DM    | Phase I studies in patients with T2DM    | Phase I studies in patients with T2DM         | Phase I studies in patients with T2DM    | Phase I studies in patients with T2DM    | Phase I studies in patients with T2DM            |
| 1218.2                                   | PK/PD                                    | 2 week multiple rising dose (MRD)             | 1-10mg: 36                               | Placebo: 12                              | T2DM                                             |
| 1218.3                                   | PK/PD                                    | 4 week MRD                                    | 2.5-10mg: 61                             | Placebo: 16                              | T2DM                                             |
| Phase I/II studies in special population | Phase I/II studies in special population | Phase I/II studies in special population      | Phase I/II studies in special population | Phase I/II studies in special population | Phase I/II studies in special population         |
| 1218.26                                  | PK/PD                                    | renal impairment                              | 5mg: 51                                  | -                                        | HS, RI, T2DM                                     |
| 1218.27                                  | PK/PD                                    | hepatic impairment                            | 5mg: 33                                  | -                                        | HS, HI                                           |
| 1218.11                                  | PK/PD                                    | SRD& 2 week MRD                               | 1-10mg: 42                               | Placebo: 14                              | HS (Japan)                                       |
| 1218.12                                  | PK/PD                                    | 4 week MRD                                    | 0.5-10mg: 55                             | Placebo: 18                              | T2DM (Japan)                                     |
| 1218.58                                  | PK                                       | SD, MD                                        | 5mg: 12                                  | -                                        | HS (China)                                       |
| Phase I drug-drug interaction trials     | Phase I drug-drug interaction trials     | Phase I drug-drug interaction trials          | Phase I drug-drug interaction trials     | Phase I drug-drug interaction trials     | Phase I drug-drug interaction trials             |
| 1218.31                                  | PK                                       | DDI-ritonavir, CO                             | 5mg: 12                                  | Rit 400mg                                | HS                                               |
| 1218.67                                  | PK                                       | DDI-rifampicin                                | 5mg: 16                                  | Rif 600mg                                | HS                                               |
| 1218.4                                   | PK                                       | DDI-metformin, CO                             | 10mg: 16                                 | Met 2550mg                               | HS                                               |
| 1218.13                                  | PK                                       | DDI-pioglitazone, CO                          | 10mg: 20                                 | Pio 45mg                                 | HS                                               |
| 1218.30                                  | PK                                       | DDI-glyburide, CO                             | 5mg: 20                                  | Glyb 1.75mg                              | HS                                               |
| 1218.9                                   | PK                                       | DDI-simvastatin                               | 10mg: 20                                 | Sim 40mg                                 | HS                                               |
| 1218.28                                  | PK/PD                                    | DDI-warfarin                                  | 5mg: 18                                  | War 10mg                                 | HS                                               |
| 1218.29                                  | PK                                       | DDI-digoxin, CO                               | 5mg: 20                                  | Digox 0.25mg                             | HS                                               |
| 1218.44                                  | PK                                       | DDI-oral contraceptive                        | 5mg: 18                                  | Microgynon                               | HS                                               |
| Phase I thorough QT study                | Phase I thorough QT study                | Phase I thorough QT study                     | Phase I thorough QT study                | Phase I thorough QT study                | Phase I thorough QT study                        |
| 1218.32                                  | PK/PD                                    | QT-interval                                   | 5mg- 100mg: 44                           | Moxifloxacin 400mg                       | HS                                               |
| Phase II studies                         | Phase II studies                         | Phase II studies                              | Phase II studies                         | Phase II studies                         | Phase II studies                                 |
| 1218.5                                   | Eff/Safety                               | 3 lina doses vs PBO vs met                    | 0.5- 5mg:170                             | PBO: 67 Met 2000mg: 65                   | T2DM                                             |
| 1218.6                                   | Eff/Safety                               | lina vs PBO vs glim                           | 1mg-10mg:                                | PBO: 71                                  | T2DM                                             |

Jentadueto

CHMP assessment report

<div style=\"page-break-after: always\"></div>

|                                                                    |                   |                                                                 | 197                                 | Glim 1-3mg: 65                |                         |
|--------------------------------------------------------------------|-------------------|-----------------------------------------------------------------|-------------------------------------|-------------------------------|-------------------------|
| 1218.37                                                            | Eff/Safety        | lina vs sita vs PBO                                             | 5mg: 40                             | Sita 100mg: 41 PBO: 40        | T2DM                    |
| Phase III studies                                                  | Phase III studies |                                                                 |                                     |                               |                         |
| Pivotal double-                                                    | 1218.15           | Lina + Pio vs. Pio                                              | 389 (100.0)                         | 130 (33.4)                    | 259 (66.6)              |
| blind placebo-                                                     | 1218.16           | Lina vs. PBO                                                    | 503 (100.0)                         | 167 (33.2)                    | 336 (66.8)              |
| controlled                                                         | 1218.17           | Lina + Met vs. Met                                              | 701 (100.0)                         | 177 (25.2)                    | 524 (74.8)              |
| efficacy studies, 24 weeks (EFF-                                   | 1218.18           | Lina + Met + SU vs. Met + SU                                    | 1058 (100.0)                        | 265 (25.0)                    | 793 (75.0)              |
| 1)                                                                 |                   |                                                                 |                                     |                               |                         |
| Double-blind active- controlled efficacy study, 52 weeks (EFF-     | 1218.20           | Lina+ Met vs. glimepiride+Met                                   | 1560 (100.0)                        | 0 (0.0)                       | 779 (49.9)              |
| Additional double-blind placebo-                                   | 1218.35           | Lina + SU vs. SU                                                | 245 (100.0)                         | 84 (34.3)                     | 161 (65.7)              |
| controlled efficacy studies, 18 weeks                              | 1218.50           | Lina vs. PBO (in metformin- intolerant patients)                | 227 (100.0)                         | 76 (33.5)                     | 151 (66.5)              |
| Double-blind efficacy studies with more than one linagliptin       | 1218.5 1218.6     | Lina vs. PBO vs. Met* Lina vs. PBO vs. SU* Lina vs. PBO vs. Vog | 302 (100.0) 333 (100.0) 561 (100.0) | 67 (22.2) 71 (21.3) 80 (14.3) | 55 (18.2) f 66 (19.8) g |
| dose level (EFF-10) Open-label long-term extension study, 78 weeks | 1218.23 c         | Lina + various antidiabetic medications                         | (100.0)                             | 0 (0.0)                       | 159 (28.3) h            |
| (EFF- 11)                                                          | 1218.40 d         |                                                                 | 2122                                |                               | 2122 (100.0) e          |
| Overall total                                                      |                   |                                                                 | 5879 (100.0)                        | 1117 (19.0)                   | 3872 (65.9)             |

PK: pharmacokinetics, PD: pharmacodynamics; BA: bioavalability; SRD: single rising dose; SD: single dose; MRD: multiple rising dose; MD: multiple dose; HS: healthy subjects; RI: renal impairment; HI: hepatic impairment; CO: cross-over,  Lina  =  linagliptin,  Pio  =  pioglitazone,  PBO  =  placebo,  Met  =  metformin,  SU  =  sulfonylurea,  Vog  = voglibose a Metformin open-label arm for sensitivity analyses

b Glimepiride open-label arm for sensitivity analyses

- c Patients initially randomised to placebo were randomised to linagliptin 5 mg or 10 mg after 12 weeks of treatment; patients initially randomised to active comparator (voglibose) were randomised to linagliptin 5 mg or 10 mg after 26 weeks of treatment. Therefore, the total number of patients in study 1218.23 is smaller than the sum of patients in the individual treatment groups.
- d Extension of the pivotal placebo-controlled studies (1218.15, 1218.16, 1218.17, 1218.18). Thus, the total number of patients who participated in study 1218.40 is not included in the overall total.
- e A total of 1533 patients in study 1218.40 had received linagliptin already in the pivotal placebo-controlled studies and they are therefore not included in the overall total.
- f Since various linagliptin dose levels were tested, overall 170 patients received linagliptin (any dose)
- g Since various linagliptin dose levels were tested, overall 197 patients received linagliptin (any dose)
- h Since both 5 mg and 10 mg linagliptin doses were tested, overall 319 patients received linagliptin

<div style=\"page-break-after: always\"></div>

Table 14. Linagliptin/metformin clinical development program

| study number                        | Objectives Study                                                                                                                                                                                       | Number of subjects                                                   | Test and referenc products; dosage regimen                                                                        | type of study                       |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| Phase 1 Studies: Healthy Subjects   | Phase 1 Studies: Healthy Subjects                                                                                                                                                                      | Phase 1 Studies: Healthy Subjects                                    | Phase 1 Studies: Healthy Subjects                                                                                 | Phase 1 Studies: Healthy Subjects   |
| 1288.1                              | To investigate bioequivalence of Lina/Met vs. Lina + Met                                                                                                                                               | 96 (95 completed)                                                    | -Lina 2.5 mg/Met 1000 mg vs -Lina 2.5 mg+ Met 1000 mg                                                             | BE                                  |
| 1288.2                              | To investigate bioequivalence of Lina/Met vs. Lina + Met                                                                                                                                               | 95 (94 completed)                                                    | -Lina 2.5 mg/Met 500 mg vs -Lina 2.5 mg+Met 500 mg                                                                | BE                                  |
| 1288.3                              | To investigate bioequivalence of Lina/Met vs. Lina + Met                                                                                                                                               | 95 (94 completed)                                                    | -Lina 2.5 mg/Met 850 mg vs -Lina 2.5 mg+Met 850 mg                                                                | BE                                  |
| 1288.4                              | To investigate the effect of food on PK of Lina/Met                                                                                                                                                    | 32                                                                   | Lina 2.5 mg/Met 1000 mg with and without food                                                                     | BE                                  |
| 1218.4                              | To investigate the relative bioavailability of linagliptin and metformin when administered together compared with the bioavailability of linagliptin and metformin when administered alone             | 16                                                                   | -Metformin tablet 850 mg (3 doses) vs-Metformin tablet 850 mg (3 doses) + Linagliptin tablet 10 mg (steady state) | PK                                  |
| 1218.45                             | To compare 2.5 mg linagliptin twice daily (bid) and 5 mg linagliptin once daily (qd)                                                                                                                   | 16                                                                   | 2.5 mg linagliptin bid vs 5 mg linagliptin qd                                                                     | PK/PD                               |
| 1218.47                             | To investigate relative bioavailability of Lina/Met vs. Lina + Met                                                                                                                                     | 20                                                                   | -Lina 2.5 mg/Met 1000 mg vs-Lina 2.5mg+Met 1000 mg                                                                | BA                                  |
| 1218.57                             | To investigate bioequivalence of European and US Glucophage® reference product                                                                                                                         | 56                                                                   | EU Glucophage US Glucophage 500mg and 1000mg                                                                      | BE                                  |
| Phase 2 Studies: Patients with T2DM | Phase 2 Studies: Patients with T2DM                                                                                                                                                                    | Phase 2 Studies: Patients with T2DM                                  | Phase 2 Studies: Patients with T2DM                                                                               | Phase 2 Studies: Patients with T2DM |
| 1218.6                              | To investigate efficacy and safety of 3 linagliptin doses in comparison with placebo; to explore the efficacy of glimepiride in comparison with placebo for sensitivity analysis                       | Total: 333 -Lina 1mg: 65 -Lina 5 mg: 66 -Lina 10 mg: 66 -Placebo: 71 | Linagliptin tablets 1mg, 5 mg, 10 mg Placebo tablet, glimepiride tablets                                          | Efficacy and Safety                 |
| 1218.62                             | To investigate the influence of different dosage regimens (twice daily versus once daily versus placebo) on the efficacy and safety of linagliptin administered orally as add-on therapy to metformin. | Total: 491 -Lina 2.5 mg bid: 223 -Lina 5 mg qd: 224 Placebo 44       | -Linagliptin 2.5 mg bid, -Linagliptin 5 mg qd, - Placebo                                                          | Efficacy and Safety                 |
| Phase 3 Studies: Patients with T2DM | Phase 3 Studies: Patients with T2DM                                                                                                                                                                    | Phase 3 Studies: Patients with T2DM                                  | Phase 3 Studies: Patients with T2DM                                                                               | Phase 3 Studies: Patients with T2DM |
| 1218.17                             | To evaluate efficacy and safety of 5 mg linagliptin in comparison with placebo as add-on therapy to metformin                                                                                          | Total: 701 Lina: 524 Placebo: 177                                    | -Linagliptin tablet 5mg -Placebo tablet                                                                           | Efficacy and Safety                 |
| 1218.18                             | To evaluate efficacy and safety of 5 mg linagliptin in comparison with                                                                                                                                 | Total: 1058 Lina: 793 Placebo:                                       | -Linagliptin tablet 5mg -Placebo tablet                                                                           | Efficacy and Safety                 |

Jentadueto

<div style=\"page-break-after: always\"></div>

| placebo as add-on therapy to metformin in combination with a sulphonylurea (SU) drug                                                    | 265                                                                                                         |                  |                                                                                                                                                                             |                  |                  |
|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------------|
| To evaluate efficacy and safety of 5 mg linagliptin in comparison with glimepiride as add-on therapy to metformin                       | Total: 1551 Lina: 776 Glim*: 775                                                                            |                  | -linagliptin tablet -Glimepiride tablet mg                                                                                                                                  |                  |                  |
| To investigate efficacy and safety of twice daily dosing of Lina + Met combination therapy compared to Lina or Met monotherapy          | Total: 791 Lina 2.5 g + Met 500 mg: 143 Lina 2.5 mg + Met 1000 mg: 143 Pbo: 72 Lina 5 mg 142 Met 500 mg 144 |                  | -Lina 2.5 mg + Met mg bid -Lina 2.5 mg + Met mg bid -Pbo -Lina 5 mg qd -Met 500 mg bid -Met 1000 mg bid -Lina 2.5 + Met 1000 bid (open-label for poorlycontrolled patients) |                  |                  |
| Ongoing                                                                                                                                 |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| Met                                                                                                                                     | 1000                                                                                                        |                  |                                                                                                                                                                             |                  |                  |
| mg Extension Studies                                                                                                                    | 147                                                                                                         |                  |                                                                                                                                                                             |                  |                  |
| an SU drug;                                                                                                                             |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| to assess efficacy                                                                                                                      |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         | 2.5 mg                                                                                                      |                  |                                                                                                                                                                             |                  |                  |
| + Met over 54 Lina                                                                                                                      |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| who +Met                                                                                                                                |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| 1218. 46 mg:                                                                                                                            |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| medication) Lina                                                                                                                        |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| + Met                                                                                                                                   | 2.5                                                                                                         |                  |                                                                                                                                                                             |                  |                  |
| mg:                                                                                                                                     |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         | 171                                                                                                         |                  |                                                                                                                                                                             |                  |                  |
| Met                                                                                                                                     |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         | 1000                                                                                                        |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         |                                                                                                             | 1000             | 1000                                                                                                                                                                        | 1000             | 1000             |
|                                                                                                                                         |                                                                                                             | mg               | mg                                                                                                                                                                          | mg               | mg               |
|                                                                                                                                         |                                                                                                             | 500 225          | 500 225                                                                                                                                                                     | 500 225          | 500 225          |
|                                                                                                                                         | mg:171                                                                                                      |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         |                                                                                                             | 2122             | 2122                                                                                                                                                                        | 2122             | 2122             |
|                                                                                                                                         |                                                                                                             | Long term Safety | Long term Safety                                                                                                                                                            | Long term Safety | Long term Safety |
| or in in 2122                                                                                                                           | of Lina 5mg:                                                                                                |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         | 5 Total:                                                                                                    |                  |                                                                                                                                                                             |                  |                  |
| mg linagliptin during long-term treatment as monotherapy combination with metformin, pioglitazone, or metformin addition to Furthermore |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
| in a descriptive exploratory way To evaluate the efficacy and safety of Lina weeks in patients completed Study (without rescue          | Total: 567                                                                                                  |                  | -Lina 2.5 mg +Met mg bid -Lina 2.5 mg + Met mg bid -Met 1000 mg bid                                                                                                         |                  |                  |
| Primarily to                                                                                                                            |                                                                                                             |                  |                                                                                                                                                                             |                  |                  |
|                                                                                                                                         | evaluate safety                                                                                             |                  | -Linagliptin tablet                                                                                                                                                         |                  |                  |

## 2.4.2. Pharmacokinetics

Although  this  application  concerns  a  fixed  dose  combination  (FDC)  tablet,  most  clinical  studies supporting the application were conducted with separate tablets of linagliptin 2.5 mg and metformin (Glucophage  1000  mg,  500  mg  and  850  mg  tablets).  Therefore  the  Applicant  performed  three bioequivalence studies (1288.1, 1288.2 and 1288.3) to justify the extrapolation of the results of the studies  conducted  with  the  mono  components  to  the  FDC  tablets.  Furthermore,  the  applicant conducted  one  bioequivalence  study  with  the  European  and  US  metformin  reference  products.  In addition, study 1218.45 was conducted to characterize the pharmacokinetics and pharmacodynamics of  2.5  mg  linagliptin  twice  daily,  in  order  to  support  BID  dosing  of  linagliptin  in  combination  with metformin.

Plasma and urine concentrations of linagliptin and its metabolite CD 1790 were measured using specific and highly sensitive HPLC-MS/MS methods. Plasma concentrations of metformin were measured using validated  liquid  chromatography  tandem  mass  spectrometry  (LC-MS/MS)  bioanalytical  methods. Analytical methods for linagliptin and metformin were well described and validated.

<div style=\"page-break-after: always\"></div>

For  the  statistical  analysis  of  bioequivalence  studies  two  different  methods  were  used.  The  initial analysis included all subjects who had been dispensed study medication, the treated set. The second analysis was a sensitivity analysis using a per protocol set for evaluation of Bioequivalence (PPS-BE set),  the  PPS-BE  set  complies  with  the  current  Guideline  on  the  the  investigation  of  bioequivalence (CPMP/EWP/QWP/1401/98 Rev1). In this document he ratio of the geometric means of T/R of the PPSBE set are presented.

## Absorption

## Bioavailability

## Linagliptin

After oral administration of a 5 mg  dose,  linagliptin  is  rapidly  absorbed,  with  peak  plasma concentrations  occurring  1.5  to  2.5  hours  post  dose  (median  tmax),  suggesting  pre-dominant absorption  in  the  upper  intestine.  Linagliptin  has  an  oral  systemic  bioavailability  of  30%  and  a moderate permeability. Additionally, linagliptin is a highly soluble drug. Therefore, linagliptin can be considered a Class 3 drug substance according to the Biopharmaceutical Classification System (BCS). In vitro data in Caco-2 cells indicated that linagliptin is a substrate for P-gp. After once-daily dosing, steady-state plasma concentrations of 5 mg linagliptin are reached by the third dose. Plasma AUC of linagliptin  increased  approximately  33%  following  5  mg  doses  at  steady-state  compared  to  the  first dose

## Metformin

f  a  metformin  500  -850  mg  tablet  given  under  fasting  conditions  is %. The  absolute  bioavailability  o approximately 50% to 60

## Linagliptin/metformin

e similar to the properties of the single linagliptin and single in combination. In study 1218.47 the relative oral bioavailability of a pilot scale fixed dose combination (FDC) tablet of linagliptin  2.5  mg/metformin  1000  mg,  was  compared  with  single  linagliptin  2.5  mg  and  metformin 1000 mg tablets administered together to 20 healthy male and female subjects.  The pharmacokinetic properties of these pilot scale tablets wer metformin tablets given

## nce Bioequivale

## Linagliptin

in the trial, one subject y excluded from the Bioequivalence of 2.5 mg linagliptin twice daily  (bid)  and  5  mg  linagliptin  once  daily  (qd)  has  been established in study 1218.45. Sixteen healthy men and women were entered discontinued due to an AE and was completel PK analysis.

of E The primary endpoint in this study was AUC0-24,ss for linagliptin. The secondary endpoints were the PK parameters  Cmax,ss ,  C pre ,  N,  AUC 0-12,ss ,  AE t1-t2,ss ,  fe t1-t2,ss ,  t max,ss ,  CL/F, ss ,  and  the  PD  parameters DPP-4  inhibition  Eavg0-24,ss , Eavg0-12,ss, E24,ss , E12,ss ,  Emax,ss ,  and min,ss .  Safety  was  monitored descriptively.

ion  (gCV)  of 14.2% (2.5 mg twice daily) and 18.0% (5 mg once daily). Median tmax,ss  was  comparable  for  both dosage regimens and the morning dose and the evening dose of the twice daily regimen. The extent of exposure over the 24-h interval at steady-state (AUC0-24,ss) was comparable between the 5  mg  once  daily  and  2.5  mg  twice  daily  regimens  (132  vs.  124  nmol·h/L).  The  AUC 0-24,ss values generally  showed  a  low  interindividual  variability  with  geometric  coefficients  of  variat

<div style=\"page-break-after: always\"></div>

The  adjusted  gMean  T/R  ratio  of  AUC 0-24,ss was  93.89%  with  a  90%  CI  of  89.49-98.51%.  DPP-4 inhibition was comparable for both dosage regimens over the whole 24-h interval at steady-state. The average DPP-4 inhibition was 85.3% for the 5 mg once daily regimen and 85.8% for the 2.5 mg twice daily regimen. The plasma concentration-time profiles of this study are presented in the figure below.

Figure 1. Arithmetic mean drug plasma concentration-time profiles of BI 1356 after multiple oral administration of 5 mg BI 1356 qd (R) and 2.5 mg BI 1356 bid (T) over 7 days (day 7) (linear scale) study 1218.45

BI Trial No.: 1218.0045

<!-- image -->

## Metformin

Clinical study 1218.46 was conducted with a metformin tablet from the US market. To allow bridging of the  results  of  this  study,  the  Applicant  conducted  bioequivalence  study  1218.57,  with  metformin tablets from the European and the US market.

In this bioequivalence study, two different metformin tablets of two different strengths administered to 56 (28 for each study part) healthy male and female subjects in an open, randomised, single dose, two-period crossover trial under fasting conditions design.

<div style=\"page-break-after: always\"></div>

Table 15. Metformin pharmacokinetic parameters (geometric mean and geometric CV(%); tmax median, range) Study 1218.57

| Treatment                    | AUC 0-z ng·h/ml                                                                                                                                                                                                                                                                 | AUC 0- ∞ ng·h/ml                                                                                                                                                                                                                                                                | C max ng/ml                                                                                                                                                                                                                                                                     | t max hr                                                                                                                                                                                                                                                                        |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| METFORMIN 1000mg             | METFORMIN 1000mg                                                                                                                                                                                                                                                                | METFORMIN 1000mg                                                                                                                                                                                                                                                                | METFORMIN 1000mg                                                                                                                                                                                                                                                                | METFORMIN 1000mg                                                                                                                                                                                                                                                                |
| EUmetformin (test) (N=28)    | 9380± 1960                                                                                                                                                                                                                                                                      | 9550 ± 1960                                                                                                                                                                                                                                                                     | 1610 ± 440                                                                                                                                                                                                                                                                      | 2.5 (0.5-3.5)                                                                                                                                                                                                                                                                   |
| US metformin (ref) (N=28)    | 9610 ± 1990                                                                                                                                                                                                                                                                     | 9810 ± 1940                                                                                                                                                                                                                                                                     | 1630 ± 385                                                                                                                                                                                                                                                                      | 2.5 (1.0-4.0)                                                                                                                                                                                                                                                                   |
| Ratio (90% CI)               | 97.64 (91.8- 103.8)                                                                                                                                                                                                                                                             | 97.21 (91.5- 103.3)                                                                                                                                                                                                                                                             | 98.4 (90.8- 106.6)                                                                                                                                                                                                                                                              | -                                                                                                                                                                                                                                                                               |
| CV (%)                       | 13.6                                                                                                                                                                                                                                                                            | 13.3                                                                                                                                                                                                                                                                            | 17.7                                                                                                                                                                                                                                                                            | -                                                                                                                                                                                                                                                                               |
| METFORMIN 500mg              | METFORMIN 500mg                                                                                                                                                                                                                                                                 | METFORMIN 500mg                                                                                                                                                                                                                                                                 | METFORMIN 500mg                                                                                                                                                                                                                                                                 | METFORMIN 500mg                                                                                                                                                                                                                                                                 |
| EUmetformin (test) (N=27)    | 5810± 1310                                                                                                                                                                                                                                                                      | 5920 ±1310                                                                                                                                                                                                                                                                      | 993 ±266                                                                                                                                                                                                                                                                        | 2.5 (1.0-4.0)                                                                                                                                                                                                                                                                   |
| US metformin (ref) (N=28)    | 5740 ± 1530                                                                                                                                                                                                                                                                     | 5870 ±1540                                                                                                                                                                                                                                                                      | 980 ±287                                                                                                                                                                                                                                                                        | 2.5 (1.5-4.0)                                                                                                                                                                                                                                                                   |
| Ratio (90% CI)               | 102.5 (95.5-109.9)                                                                                                                                                                                                                                                              | 102.37 (95.8-109.4)                                                                                                                                                                                                                                                             | 102.2 (92.1- 113.6)                                                                                                                                                                                                                                                             | -                                                                                                                                                                                                                                                                               |
| CV (%)                       | 15.2                                                                                                                                                                                                                                                                            | 14.3                                                                                                                                                                                                                                                                            | 22.9                                                                                                                                                                                                                                                                            | -                                                                                                                                                                                                                                                                               |
| AUC 0-z AUC 0- ∞ C max t max | area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentrationabove the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration | area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentrationabove the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration | area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentrationabove the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration | area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentrationabove the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration |

## Linagliptin/metformin

The  applicant  conducted  three  bioequivalence  studies  1288.1,1288.2  and  1288.3  with  the  three different linagliptin/metformin FDC tablet strengths. These three bioequivalence studies have a similar design (open-label, randomised, single dose, two-way crossover, trials in healthy volunteers).

A single dose of the test product (linagliptin/metformin FDC tablet) or reference products (linagliptin tablet  plus  metformin  tablet)  were  administered  after  an  overnight  fast  of  at  least  10  h,  in  each treatment period separated by a washout phase of at least 35 days. The blood samples were collected in each period as per the following times: pre-dose and at 20 minutes, 40 minutes, 1 , 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48 and 72 hours post dose in each of two periods.

The  primary  endpoints  were  AUC0-72 and  Cmax  for  linagliptin  and  AUC 0-tz ,  AUC0-∞ and  Cmax  for metformin. Secondary endpoints were AUC0-∞ and AUC0-tz for linagliptin and %AUCtz-, AUCt1-t2 ,  t max , λ z , t 1/2, MRTpo, CL/F, Vz/F for both analytes. Safety was monitored descriptively.

The results of studies 1288.1, 1288.2 and 1288.3 are presented in the tables below.

<div style=\"page-break-after: always\"></div>

Table 16. Linagliptin/metformin 2.5 mg/1000 mg FDC tablet vs linagliptin2.5mg tablet + metformin 1000 mg tablet: Linagliptin and Metformin pharmacokinetic parameters (Arithmic means and SD ; tmax median, range) Study 1288.1

| Treatment                             | AUC 0-72 nmol·h/L                                                                                                                                                                                                                                                                                                                            | AUC 0- ∞ nmol·h/L   | C max nmol/l                                                                                                                                                                                                                                                                                                                                 | t max hr                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| LINAGLIPTIN                           | LINAGLIPTIN                                                                                                                                                                                                                                                                                                                                  | LINAGLIPTIN         | LINAGLIPTIN                                                                                                                                                                                                                                                                                                                                  | LINAGLIPTIN                                                                                                                                                                                                                                                                                                                                  |
| FDC (Test) (N= 96)                    | 163 ±45.9                                                                                                                                                                                                                                                                                                                                    | 251 ±76.5           | 5.20 ±1.25                                                                                                                                                                                                                                                                                                                                   | 3.0 (0.7-8.0)                                                                                                                                                                                                                                                                                                                                |
| LINA+MET (Ref) (N=93)                 | 192 ±39.0                                                                                                                                                                                                                                                                                                                                    | 235 ±64.8           | 5.03 ±1.20                                                                                                                                                                                                                                                                                                                                   | 3.0 (1.0-6.0)                                                                                                                                                                                                                                                                                                                                |
| Ratio (90% CI)                        | 106.4 (102.7-110.2)                                                                                                                                                                                                                                                                                                                          | 105.2 (101.2-109.3) | 103.4 (100.3-106.7)                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                              |
| CV (%)                                | 14.5                                                                                                                                                                                                                                                                                                                                         | 16.1                | 12.7                                                                                                                                                                                                                                                                                                                                         | -                                                                                                                                                                                                                                                                                                                                            |
|                                       | AUC 0-z Ng·h/ml                                                                                                                                                                                                                                                                                                                              | AUC 0- ∞ ng·h/ml    | C max ng/ml                                                                                                                                                                                                                                                                                                                                  | t max hr                                                                                                                                                                                                                                                                                                                                     |
| METFORMIN                             | METFORMIN                                                                                                                                                                                                                                                                                                                                    | METFORMIN           | METFORMIN                                                                                                                                                                                                                                                                                                                                    | METFORMIN                                                                                                                                                                                                                                                                                                                                    |
| FDC (Test) (N= 96)                    | 11300 ±2930                                                                                                                                                                                                                                                                                                                                  | 11500 ±2910         | 1740 ±462                                                                                                                                                                                                                                                                                                                                    | 2.51 (0.7-4.0)                                                                                                                                                                                                                                                                                                                               |
| LINA+MET (Ref) (N=93)                 | 10800±2830                                                                                                                                                                                                                                                                                                                                   | 11000 ±2830         | 1670 ±478                                                                                                                                                                                                                                                                                                                                    | 3.0 (1.0-4.0)                                                                                                                                                                                                                                                                                                                                |
| Ratio (90% CI)                        | 103.6 (100.03-107.4)                                                                                                                                                                                                                                                                                                                         | 103.4 (99.9-107.1)  | 104.3 (99.8 108.9)                                                                                                                                                                                                                                                                                                                           | -                                                                                                                                                                                                                                                                                                                                            |
| CV (%)                                | 14.6                                                                                                                                                                                                                                                                                                                                         | 14.3                | 17.9                                                                                                                                                                                                                                                                                                                                         | -                                                                                                                                                                                                                                                                                                                                            |
| AUC 0-72 AUC 0-z AUC 0- ∞ C max t max | area under the plasma concentration-time curve from time zero to 72 hours area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentration above the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum | concentration       | area under the plasma concentration-time curve from time zero to 72 hours area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentration above the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum | area under the plasma concentration-time curve from time zero to 72 hours area under the plasma concentration-time curve from time zero to last timepoint with a plasma concentration above the quantification limit area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum |

<div style=\"page-break-after: always\"></div>

Table 17. Linagliptin/metformin  2.5  mg/500  mg  FDC  tablet  vs  linagliptin2.5mg  tablet  + metformin 500 mg tablet: Linagliptin and Metformin pharmacokinetic parameters (Arithmic means and SD; tmax median, range) Study 1288.2

| Treatment                  | AUC 0-72 nmol·h/L   | AUC 0- ∞ nmol·h/L   | C max nmol/l       | t max hr      |
|----------------------------|---------------------|---------------------|--------------------|---------------|
| LINAGLIPTIN                | LINAGLIPTIN         | LINAGLIPTIN         | LINAGLIPTIN        | LINAGLIPTIN   |
| FDC (Test) (N=94)          | 188 ± 50.6          | 292 ± 130           | 5.53 ± 1.51        | 3.0(0.67-8.0) |
| LINA+MET (Ref) (N=95)      | 188 ± 50.5          | 294 ± 91.7          | 5.64 ± 1.56        | 3.0 (1.0-8.0) |
| Ratio (90% CI)             | 100.0 (96.7- 103.4) | 99.3 (95.6- 103.1)  | 98.2 (94.5 102.1)  | -             |
| CV (%)                     | 13.9                | 15.5                | 16.0               | -             |
|                            | AUC 0-z ng·h/ml     | AUC 0- ∞ ng·h/ml    | C max ng/ml        | t max hr      |
| METFORMIN                  | METFORMIN           | METFORMIN           | METFORMIN          | METFORMIN     |
| FDC (Test) (N= 94)         | 7530 ± 1840         | 7630 ± 1830         | 1170 ± 315         | 2.0 (0.7-4.0) |
| LINA+MET (Ref) (N=95)      | 7590 ± 1910         | 7700 ± 1880         | 1200 ± 329         | 3.0 (0.7-4.0) |
| Ratio treated set (90% CI) | 99.4 (96.5- 102.3)  | 99.1 (96.4- 102.0)  | 97.9 (94.4- 101.5) | -             |
| Ratio PSS-BE set (90%CI)   | 99.3 (96.4- 102.3)  | 99.1 (96.4- 101.9)  | 97.9 (94.4- 101.5) | -             |
| CV (%)                     | 12.3                | 11.6                | 14.9               | -             |

Table 18. Linagliptin/metformin 2.5 mg/850 mg FDC tablet vs linagliptin2.5mg tablet + metformin 850 mg tablet: Linagliptin and Metformin pharmacokinetic parameters (Arithmic means and SD; tmax median, range) Study 1288.3

| Treatment             | AUC 0-72 nmol·h/L   | AUC 0- ∞ nmol·h/L   | C max nmol/l        | t max hr       |
|-----------------------|---------------------|---------------------|---------------------|----------------|
| LINAGLIPTIN           | LINAGLIPTIN         | LINAGLIPTIN         | LINAGLIPTIN         | LINAGLIPTIN    |
| FDC (Test) (N=95)     | 165 ±42.6           | 253 ±75.3           | 5.38 ±1.31          | 3.00 (1.0-6.0) |
| LINA+MET (Ref) (N=94) | 160 ±42.9           | 224 ±72.2           | 5.10 ±1.19          | 3.00 (1.0-6.0) |
| Ratio (90% CI)        | 104.5 (100.6-108.5) | 105.7 (101.1-110.5) | 106.2 (102.9-109.7) | -              |
| CV (%)                | 15.4                | 18.2                | 13.0                | -              |
|                       | AUC 0-z ng·h/ml     | AUC 0- ∞ ng·h/ml    | C max ng/ml         | t max hr       |
| METFORMIN             | METFORMIN           | METFORMIN           | METFORMIN           | METFORMIN      |
| FDC (Test) (N=95)     | 11400 ± 2840        | 11700 ± 2860        | 1710 ± 458          | 3.00 (0.7-6.0) |
| LINA+MET (Ref) (N=93) | 11400 ± 3030        | 11700 ± 3020        | 1730 ± 501          | 3.00 (0.7-4.0) |
| Ratio (90% CI)        | 101.0 (98.1-103.9)  | 101.3 (98.4- 104.3) | 100.1 (96.5-104.0)  |                |
| CV (%)                | 11.9                | 11.8                | 15.4                | -              |

<div style=\"page-break-after: always\"></div>

## Influence of food

## Linagliptin

Intake of food prolonged the time to reach maximum plasma concentrations by 2 hours and lowered the Cmax by 15%. No influence on the AUC0-72 was observed. The other pharmacokinetic parameters of linagliptin were comparable under fasted and fed conditions. Food has no clinical relevant influence on the pharmacokinetics of the linagliptin and linagliptin itself can be administered with and without food.

## Metformin

Food decreases the extent of and slightly delays the absorption of metformin, a 40% lower Cmax and a 25%  lower  AUC  is  observed  when  given  with  food;  the  clinical  relevance  of  these  decreases  is unknown. Metformin can be administered with and without food.

## Linagliptin/metformin

The  Applicant  conducted  study  1288.4  to  investigate  the  effect  of  food  on  the  PK  of  linagliptin/ metformin FDC tablet. A single dose of a FDC tablet with linagliptin 2.5 mg and metformin 1000 mg was administered to 32 healthy volunteers after an overnight fast (Reference) and after a high fat, high caloric meal (Test) with a wash out period of at least 35 days. The AUC0-72 and Cmax for linagliptin and AUC0-∞ and Cmax for metformin were evaluated as primary endpoints. The results of the study are summarised in table below.

Table 19. Linagliptin and Metformin pharmacokinetic parameters (Arithmic means and SD; tmax median, range) Study 1288.4

| Treatment            | AUC 0-72 nmol·h/L   | AUC 0- ∞ nmol·h/L   | C max nmol/l      | t max hr       |
|----------------------|---------------------|---------------------|-------------------|----------------|
| LINAGLIPTIN          | LINAGLIPTIN         | LINAGLIPTIN         | LINAGLIPTIN       | LINAGLIPTIN    |
| Fed (Test) (N=32)    | 165 ±35.6           | 249 ±67.4           | 4.64 ±0.9         | 3.0 (1.0-12.0) |
| Fasting (Ref) (N=32) | 167 ±36.1           | 257 ±76.0           | 5.1 ± 1.0         | 3.50 (1.0-8.0) |
| Ratio (90% CI)       | 98.7 (94.5-103.0)   | 97.6 (93.4-102.0)   | 91.4 (86.2-96.9)  | -              |
| CV (%)               | 10.1                | 10.4                | 13.9              | -              |
|                      | AUC 0-z ng·h/ml     | AUC 0- ∞ ng·h/ml    | C max ng/ml       | t max hr       |
| METFORMIN            | METFORMIN           | METFORMIN           | METFORMIN         | METFORMIN      |
| Fed (Test) (N=32)    | 11600 ±2670         | 11800 ± 2670        | 1510 ±282         | 4.00 (1.0-6.0) |
| Fasting (Ref) (N=32) | 12300± 2540         | 12100±2500          | 1850 ±366         | 2.00 (0.7-4.0) |
| Ratio (90% CI)       | 95.2 (88.5-102.3)   | 96.0 (89.2- 103.2)  | 81.9 (76.8- 87.3) | -              |
| CV (%)               | 17.3                | 17.3                | 15.2              | -              |

Administration of 2.5 mg linagliptin and 1000 mg metformin as FDC tablet after food intake had no relevant  effect  on  the  relative  bioavailability  of  linagliptin  with  regard  to  AUC 0-72 and  Cmax.  The exposure to metformin was similar under fed and fasted conditions with regard to AUC0-∞ and AUC0-tz, while Cmax was reduced. This reduction is smaller than reported in the literature for metformin... Food is not expected to have a relevant influence on the efficacy of the linagliptin and metformin FDC tablet.

<div style=\"page-break-after: always\"></div>

## Distribution

## Linagliptin

Plasma  protein  binding  of  linagliptin  in  human  plasma  is  concentration-dependent,  decreasing  from 99% at 1 nM to 83% at 20 nM. Consequently the protein unbound fraction of linagliptin in plasma increases  with  increasing  total  plasma  concentrations.  This  is  probably  reflecting  the  saturation  of binding to DPP-4 with increasing concentrations of linagliptin. As a result, linagliptin shows non-linear distribution kinetics both after oral and intravenous administration. After single oral administration of 5 mg linagliptin the apparent volume of distribution, Vz/F was approximately 12700 L.

## Metformin

Metformin protein binding in plasma is negligible, metformin partitions into erythrocytes.

## Linagliptin/metformin

No  additional  studies  have  been  conducted  for  the  linagliptin/metformin  FDC  which  is  considered acceptable.

## Elimination

## Excretion

## Linagliptin

Plasma  concentrations  of  linagliptin  decline  in  a  triphasic  manner  with  a  long  terminal  half-life (terminal half-life  for  linagliptin  more  than  100  hours),  that  is  mostly  related  to  the  saturable,  tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of linagliptin. The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of 5 mg linagliptin,  is  approximately  12  hours.  Plasma  AUC  of  linagliptin  increased  in  a  less  than  doseproportional manner.

Following administration of an oral [ 14 C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing. Renal clearance at steady state was approximately 70 mL/min.

## Metformin

Metformin is excreted unchanged in the urine, with a plasma elimination half-life of approximately 6.5 hours .

## Linagliptin/metformin

No  additional  studies  have  been  conducted  for  the  linagliptin/metformin  FDC  which  is  considered acceptable.

<div style=\"page-break-after: always\"></div>

## Metabolism

## Linagliptin

Most  of  the  parent  compound  was  excreted  unchanged  in  urine  and  faeces  with  76%  (61%  out  of 81%) of excreted radioactivity after intravenous dosing and with 90% (78% out of 87%) of excreted radioactivity after oral dosing. In vitro studies indicated that linagliptin is metabolised by CYP3A4 to form  its  major  metabolite  CD1790.  All  metabolites  contributed  to  less  than  10  %  of  the  excreted radioactivity.  A  total  of  the  seven  metabolites  were  identified,  only  two  were  formed  at  quantifiable amount,  namely  oxidation  in  the  quinazoline  moiety  and  CD1790.  In  plasma  16.9%  of  sample radioactivity in pooled samples after oral administration was identified as CD1790.

## Metformin

Metformin does not undergo hepatic metabolism (no metabolites have been identified in humans).

## Linagliptin/metformin

No  additional  studies  have  been  conducted  for  the  FDC  linagliptin/metformin  which  is  considered acceptable.

## Special populations

## Pharmacokinetics in target population

## Linagliptin

The PK of linagliptin after single and multiple rising oral doses of 1 mg to 10 mg and 2.5 mg to 10 mg linagliptin  were  evaluated in  T2DM patients using a non-compartmental approach in studies 1218.2, 1218.3 (Caucasian patients), in study 1218.12 (Japanese patients), in study 1218.26 (T2DM patients with normal and impaired renal function,), and in study 1218.55 (Black patients). The PK of patients with T2DM were also evaluated by a Pop-PK analysis using rich sampling data from trials 1218.2 and 1218.3  as  well  as  sparse  sampling  data  from  the  phase  IIb  studies  1218.5  and  1218.6.  The pharmacokinetics of linagliptin  was  generally  similar  in  healthy  subjects  and  in  patients  with  type  2 diabetes.

## Metformin

No additional studies have been conducted for metformin which is considered acceptable.

## Linagliptin/metformin

No  additional  studies  in  special  populations  have  been  conducted  for  the  linagliptin/metformin  FDC tablets. This is considered acceptable by the CHMP.

## Renal impairment

## Linagliptin

The influence of renal impairment is only moderate for the parent compound as well as for the main metabolite. The increase in exposure in severe renal impairment is less than 2 -fold and the exposure in  T2DM  patients  with  severe  renal  impairment  is  comparable  with  'healthy'  impaired  patients.  No dose adjustment is considered necessary in these patients.

<div style=\"page-break-after: always\"></div>

## Metformin

In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the  renal  clearance  is  decreased  in  proportion  to  the  decrease  in  creatinine  clearance.  Metformin  is therefore  contraindicated  in  patients  with  a  creatinine  clearance  &lt;  60  ml/min  and  the  creatinine clearance should be determined before initiating treatment and regularly thereafter.

## Linagliptin/meftormin

Jentadueto  should  not  be  used  in  patients  with  moderate  or  severe  renal  impairment  (creatinine clearance &lt; 60 ml/min) due to the metformin component. As metformin hydrochloride is excreted by the  kidney,  serum  creatinine  levels  should  be  determined  before  initiating  treatment  and  regularly thereafter.

## Hepatic impairment

## Linagliptin

In  patients  with  mild  to  moderate  and  severe  hepatic  insufficiency  (according  to  the  Child-Pugh classification),  mean  AUC  and  C max of  linagliptin  were  similar  to  healthy  matched  controls  following administration  of  multiple  5  mg  doses  of  linagliptin.  The  exposure  to  the  main  metabolite  is significantly reduced, however the elimination of linagliptin by metabolism is small (less than 13%). Although  the  pharmacokinetic  studies  indicated  that  the  exposure  to  linagliptin  is  not  affected  by hepatic impairment, clinical experience with linagliptin in patients with hepatic insufficiently is lacking.

## Metformin

Metformin is contraindicated in patients with hepatic insufficiency. Impaired hepatic function has been associated with some cases of lactic acidosis.

## Linagliptin/metformin

Jentadueto is not recommended in patients with hepatic insufficiency due to both components and this is reflected in the SmPC.

## Gender and race

## Linagliptin

Gender had no clinically relevant effect on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. The difference in exposure was not more than 9% higher in female than in male subjects. No dosage adjustment is necessary based on gender.

Race had no obvious effect on the plasma concentrations of linagliptin based on a composite analysis of available pharmacokinetic data, including patients of Caucasian, Hispanic, African, and Asian origin . In  addition  the  pharmacokinetic  characteristics  of  linagliptin  were  found  to  be  similar  in  dedicated phase  I  studies  in  Japanese,  Chinese  and  Caucasian  healthy  volunteers.  No  dosage  adjustment  is necessary based on race.

## Metformin

Although  dedicated  studies  on  the  influence  of  gender  or  race  are  not  available,  there  are  no indications that the pharmacokinetics and clinical efficacy of metformin are substantially influenced by these factors.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

No additional studies have been conducted for the linagliptin/metformin FDC tablets. This is considered acceptable by the CHMP.

## Weight

## Linagliptin

The influence of weight on the pharmacokinetics of linagliptin was less than 20% and therefore not clinically relevant effect. No dosage adjustment is necessary based on BMI.

## Metformin

No additional studies have been conducted with metformin. This is considered acceptable by the CHMP.

## Linagliptin/metformin

No additional studies have been conducted for the linagliptin/metformin FDC tablets. This is considered acceptable by the CHMP.

## Elderly population

## Linagliptin

No dosage adjustment is required based on age, as age did not have a clinically relevant impact on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data.  Elderly  subjects  (65  to  80)  had  comparable  plasma  concentrations  of  linagliptin  compared  to younger subjects.

## Metformin

Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary.

## Linagliptin/metformin

As  metformin  is  excreted  by  the  kidney,  Jentadueto  should  be  used  with  caution  as  age  increases. Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in the elderly. Clinical  experience with patients &gt; 80 years of age is limited and caution should be exercised when treating this population.

## Paediatric population

## Linagliptin

Studies  characterizing  the  pharmacokinetics  of  linagliptin  in  paediatric  patients  have  not  yet  been performed .

## Metformin

Metformin  is  indicated  in  children  from  10  years  of  age  and  adolescents,  and  may  be  used  as monotherapy or in combination with insulin. The usual starting dose is 500 mg or 850 mg metformin hydrochloride  once  daily,  given  during  meals  or  after  meals.  The  diagnosis  of  T2DM  should  be confirmed before treatment with metformin hydrochloride is initiated.

<div style=\"page-break-after: always\"></div>

No  effect  of  metformin  hydrochloride  on  growth  and  puberty  has  been  detected  during  controlled clinical  studies  of  one-year  duration  but  no  long-term  data  on  these  specific  points  are  available. Therefore,  a  careful  follow-up  of  the  effect  of  metformin  hydrochloride  on  these  parameters  in metformin hydrochloride-treated children, especially pre-pubescent children, is recommended. Only 15 subjects aged between 10 and 12 years were included in the controlled clinical studies conducted in children and adolescents. Although efficacy and safety of metformin hydrochloride in these children did not differ from efficacy and safety in older children and adolescents, particular caution is recommended when prescribing to children aged between 10 and 12 years.

After  single  doses  of  metformin  hydrochloride  500  mg,  paediatric  patients  have  shown  similar phamacokinetic profile to that observed in healthy adults. The data on the use of multiple doses of metformin  are  restricted  to  one  study.  After  repeated  doses  of  500  mg  twice  daily  for  7  days  in paediatric patients the peak plasma concentration (Cmax) and systemic exposure (AUC0-t) were reduced by  approximately  33%  and  40%,  respectively  compared  to  diabetic  adults  who  received  repeated doses  of  500  mg  twice  daily  for  14  days.  As  the  dose  is  individually  titrated  based  on  glycaemic control, this is of limited clinical relevance.

## Linagliptin/metformin

No paediatric studies have been conducted for the linagliptin/metformin FDC tablets.

## Pharmacokinetic interaction studies

## Linagliptin

In  vitro data  indicate  that  linagliptin  is  a  substrate  for  CYP3A4  and  P-gp,  OATP8-,  OCT2-,  OAT4-, OCTN1- and OCTN2.

No relevant inhibition of CYPs or transporter proteins at clinically plausible concentrations of linagliptin or its major metabolite CD 1790 was found. Linagliptin is a competitive inhibitor of MAO-B and a weak inhibitor of CYP3A4/3A5 but clinical relevance of the MAO-B and CYP3A4/3A5 inhibition is considered unlikely. Furthermore, no hints on enzyme induction (CYP 1A2, 2B6 and 3A4) were found in human hepatocytes.

Based on the in vitro data, the effects of ritonavir (a strong CYP3A4 and P-gp inhibitor) and the effects of rifampicin (a strong CYP3A and P-gp inducer) on linagliptin pharmacokinetics as well as the effects of linagliptin on the pharmacokinetics of digoxin (a sensitive P-gp substrate) and simvastatin (sensitive CYP3A4  substrate)  were  investigated.  Co-administration  with  ritonavir  led  to  a  two  fold  increase  in exposure (AUC) and multiple co-administration of linagliptin with rifampicin resulted in an about 40% decreased  linagliptin  steady-state  AUC  presumably  by  increasing/decreasing  the  bioavailability  of linagliptin by inhibition/induction of P-glycoprotein. Linagliptin did not have a clinically relevant effect on the pharmacokinetics of simvastatin or digoxine.

In  addition  to in  vitro data based  studies  also  common  co-medications  of  T2DM  patients  were investigated. This included DDI studies with several antidiabetic agents. Linagliptin's pharmacokinetics were  not  affected  to  a  clinical  relevant  degree  by  co-administration  of  glyburide,  metformin  and pioglitazone  and  linagliptin  did  not  have  a  clinically  relevant  effect  on  the  pharmacokinetics  of glyburide , metformin and pioglitazone.

Co-administration with warfarin (CYP2C9 substrate) and a combination product of ethinylestradiol and levonorgestrel  was  also  evaluated.  Linagliptin  did  not  have  a  clinically  relevant  effect  on  the pharmacokinetics of warfarin and oral contraceptives.

<div style=\"page-break-after: always\"></div>

## Metformin

Drug interactions of metformin were reported for glyburide, furosemide, nifedipine, and are likely for cationic  drugs  that  are  eliminated  by  renal  tubular  secretion  (e.g.  amiloride,  cimetidine,  digoxin, morphine,  procainamide,  quinidine,  quinine,  ranitidine,  triamterene,  trimethoprim,  or  vancomycin). Certain drugs tend to produce hyperglycaemia and may cause loss of glycaemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium-channel-blocking drugs, and isoniazid.  In  healthy  volunteers,  the  pharmacokinetics of metformin and propranolol, and metformin and ibuprofen were not affected when co-administered in single-dose interaction studies. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs  such  as  salicylates,  sulfonamides,  chloramphenicol,  and  probenecid,  as  compared  to  the sulfonylureas, which are extensively bound to serum proteins.

## Linagliptin/metformin

In  study  1218.4,  the  bioavailability  of  linagliptin  and  of  metformin  after  concomitant  multiple  oral administration of 10 mg linagliptin tablets and 3 x 850 mg metformin in comparison to linagliptin and metformin given alone was investigated.

Table 20. Linagliptin and Metformin pharmacokinetic parameters (geometric means and CV; tmax median, range) Study 1218.4

| Treatment                        | AUC GLYPH<31>,ss nmol·h/L   | C max nmol/l         | t max hr         | t 1/2,ss hr   |
|----------------------------------|-----------------------------|----------------------|------------------|---------------|
| LINAGLIPTIN                      |                             |                      |                  |               |
| Without metformin (ref) (N=32)   | 111 (29.9)                  | 9.29 (49.8)          | 1.00 (0.50-2.03) | 35.5 (45.4)   |
| With metformin (test) (N=32)     | 133 (23.2)                  | 9.60 (31.9)          | 1.50 (0.50-4.03) | 42.6 (15.6)   |
| Ratio (90% CI)                   | 120.0 (107.3-134.1)         | 103.44 (86.39-123.9) | -                | -             |
| CV (%)                           | 16.8                        | 27.4                 | -                | -             |
|                                  | AUC GLYPH<31>,ss nmol·h/L   | C max nmol/l         | t max hr         | t 1/2,ss hr   |
| METFORMIN                        |                             |                      |                  |               |
| Without Linagliptin (ref) (N=32) | 8000 (26.9)                 | 1930 (23.6)          | 1.00 (0.75-2.00) | 15.6 (49.4)   |
| With Linagliptin (test) (N=32)   | 8210 (32.6)                 | 1720 (25.0)          | 1.50 (0.75-2.00) | 13.2 (52.5)   |
| Ratio (90% CI)                   | 100.8 (89.2-113.9)          | 88.6 (78.2-100.4)    | -                | -             |
| CV (%)                           | 18.0                        | 18.5                 | -                | -             |

Co-administration of multiple TID doses of 850 mg metformin with 10 mg linagliptin once daily resulted in a 20% increase of linagliptin steady-state AUC, but did not affect linagliptin C max . These results are in  line  with  the  population  pharmacokinetic  analysis  where  an  equal  19.8%  increase  in  linagliptin exposure  in  combination  with  metformin  was  found.  The  increase  is  considered  not  clinically meaningful.  Linagliptin  co-administration  had  no  clinical  meaningful  effect  on  metformin  exposure. Steady-state AUC and Cmax of metformin were unchanged during linagliptin co-administration.

The interaction potential of linagliptin and metformin has been sufficiently characterised for both drugs individually. Linagliptin does not have a clinically relevant effect on the pharmacokinetics of metformin or vice versa.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## Mechanism of action

## Linagliptin

The mechanism of action of linagliptin is DPP-4 inhibition. Nutrient intake stimulates the secretion of the  gastrointestinal  incretin  hormones,  glucagon-like  peptide-1  (GLP-1)  and  glucose-dependent insulinotropic  polypeptide  (GIP),  both  of  which  exert  glucose-dependent  insulinotropic  effects  and assist pancreatic insulin and glucagon in maintaining glucose homeostasis.  GLP-1 lowers blood glucose levels  by  augmenting  the  glucose-stimulated  insulin  release.  Moreover,  GLP-1  inhibits  glucagon secretion, slows gastric emptying, and induces satiety. The plasma half-life of GLP-1 is limited to a few minutes because of rapid proteolytic degradation by the enzyme DPP-4. Inhibition of DPP-4 prolongs the  half-life  of  active  GLP-1  and  thereby  increases  plasma  insulin  levels  and  lowers  plasma  glucose levels. Since GLP-1 activity ceases when the glucose concentration falls below 55 mg/dL, prolongation of the half-life of GLP-1 by DPP-4 inhibitors bears little risk of hypoglycaemia.

## Metformin

The principal metabolic effects of metformin consist of a decrease of hepatic glucose production/output and  improvement  of  insulin-mediated  glucose  utilisation  (i.e.  increased  insulin  sensitivity),  thereby targeting  two  of  the  primary  metabolic  defects  contributing  to  both  fasting  and  postprandial hyperglycaemia in patients with T2DM.

This implies that with metformin treatment, insulin secretion is not directly affected, although fasting insulin  levels  decrease  as  a  result  of  improved  insulin  sensitivity.  Through  these  mechanisms, metformin  therapy  typically  leads  to  substantial  reductions  in  glycosylated  HbA1c,  but  it  does  not promote weight gain or increase the risk of hypoglycaemia.

## Primary and Secondary pharmacology

## Linagliptin

Inhibition of DPP-4 was considered the most relevant biomarker for the effectiveness of linagliptin. A median  DPP-4  inhibition  of  80%  at  trough  was  assumed  as  a  threshold  based  on  published  data. Plasma  glucose  and  active  GLP-1  were  other  markers  for  effectiveness.  Exploratory  biomarkers included  glucagon,  C-peptide,  insulin,  fructosamine,  1,5-Anhydroglucitol  and  glycated  haemoglobin (HbA1c).

## DPP-4 inhibition

Linagliptin treatment resulted in a rapid, potent and long-lasting inhibition of plasma DPP-4 in clinical studies.  Already  after  a  single  dose  of  linagliptin,  DPP-4  was  effectively  inhibited  as  shown  by maximum DPP-4 inhibitions of 72% and 88.5% for 2.5 and 5 mg, and &gt;95% for doses ≥ 25 mg. At steady-state, plasma DPP-4 activity was inhibited over 24 h by &gt;80% in most patients receiving 5 mg or  10  mg  linagliptin  once  daily  but  not  in  patients  receiving  2.5  mg  linagliptin  or  lower  doses.  A consistent DPP-4 inhibition more than 80% at the end of the dosing interval (i.e. trough) with 5 mg linagliptin q.d. was also seen in Japanese T2DM patients, as well as in Caucasian and Japanese healthy adult subjects.

<div style=\"page-break-after: always\"></div>

## Plasma Glucose and GLP-1

The  effects  of  linagliptin  on  incretin  and  glucose  concentrations  in  T2DM  patients  were  investigated during meal (MTT) and oral glucose tolerance tests (OGTT). Treatment with 5 mg linagliptin over 28 days  resulted  in a statistically significant  increase  of  active  glucagon  like  peptide  1  (GLP-1) concentrations  of  18.1  pmol*h  /L  (p&lt;0.0001)  after  a  MTT  compared  to  placebo  and  a  statistically significant  reduction  of  weighted  mean  daily  glucose  and  postprandial  plasma  glucose  AUEC 0-3h of -19.9  mg/dL  (p&lt;0.0001)  and -106.5  mg*h/dL  (p&lt;0.0001),  respectively.  Linagliptin  dosing  for  28 days  also  resulted  in  a  relevant  decrease  in  fasting  plasma  glucose  concentrations  of -10.8  mg/dL compared to placebo.

## Short term biomarkers

As  expected  from  the  mechanism  of  action,  multiple  administration  of  linagliptin  resulted  in  a significant increase in ß-cell indices based  on  fasting  and  postprandial  insulin  and  C-peptide concentrations.

Treatment with 5 mg linagliptin caused an increase in insulin secretion, as evidenced by: a placeboadjusted  insulin  secretion  change  (HOMA-%B)  from  baseline  of  24.2;  and  a  statistically  significant placebo  corrected  change  from  baseline  in  insulin  secretion  rate  (ISR)  to  glucose  ratio  of  28.7 pM/(mg/dL·h)(p=0.0004) after 28 days of treatment. Also peak glucagon concentrations after 4 week linagliptin treatment were reduced by -16.8 pg/mL (95% CI: -28.7, -4.9; p=0.0064) compared to placebo.

## Intermediate term biomarkers

Fructosamine and 1,5-Anhydroglucitol were measured during linagliptin development as intermediate term  markers  of  glucose  control,  reflecting  glucose  control  over  a  period  of  two  to  three  weeks. Fructosamine is formed by the reaction of the carbonyl group of glucose with an amino group of a protein,  whereas 1,5-Anhydroglucitol is a naturally occurring monosaccharide contained in nearly all foods, which is found in a relatively constant amount in the blood and tissues. 1,5-Anhydroglucitol is filtered in the kidney, but nearly completely re-absorbed by a glucose transporter. Thus glucose and 1,5-Anhydroglucitol  compete  for  reabsorption  during  periods  of  high  glucose  concentrations  (&gt;180 mg/dL) and consequently 1,5-Anhydroglucitol blood concentrations decrease during times of hyperglycaemia above 180 mg/dL).

The observed effect on glucose control also translated in an effect on intermediate term markers of glucose control, fructosamine and 1,5-Anhydroglucitol. As fructosamine was generally more variable in linagliptin trials, 1,5-Anhydroglucitol is assumed to be a better marker for intermediate glucose control.

Treatment  with  5  mg  linagliptin  over  4  weeks  resulted  in  a  statistically  significant  increase  of  1,5Anhydroglucitol  concentrations  of  1.8 μ g/mL  (p&lt;0.0001)  compared  to  placebo  (1.0 μ g/mL  vs.  -0.8 μ g/mL)  and  thus  indicate  that  glucose  excursions  during  linagliptin  treatment  are  substantially reduced. The concentration of 10 μ g/mL at week 4 also indicates that nearly no glucose excursions above 180 mg/dL occurred, as this was found to be the reference value in optimally controlled patients with T2DM.

<div style=\"page-break-after: always\"></div>

## Long term biomarkers

HbA1c  was  measured  in  3  early  trials  with  4  week  treatment  duration.  Despite  the  short  term treatment  period,  which  does  not  allow  HbA1c  to  reach  a  new  equilibrium  to  display  maximum treatment effects, dosing of linagliptin generally resulted in statistically significant decreases in HbA1c of up to -0.48% compared to placebo. The observed effects were similar in Caucasian and Japanese T2DM patients. HbA1c was the primary efficacy parameter used in the studies of &gt;4 weeks duration and thus also for the pivotal studies. In these studies consistent clinically relevant reductions in HbA1c compared to placebo.

A thorough QT study was performed to demonstrate that linagliptin does not lead to QT prolongation compared  to  placebo  (study  1218.32).  The  primary  analysis  demonstrated  that,  compared  with placebo, the mean changes in the QTcI interval over 1 to 4 hours were -1.1 ms for the 5 mg dose and -2.5  ms  for  the  100  mg  dose  of  linagliptin.  The  upper  bound  of  the  two-sided  90%  confidence intervals was 0.5 ms for 5 mg linagliptin and -0.9 ms for 100 mg linagliptin. This was well below the predefined non-inferiority margin of 10 ms, indicating there was no clinically relevant increase in the QTcI interval following administration of 5 mg and 100 mg linagliptin compared with placebo. Similar results  were  obtained  for  the  secondary  endpoints.  Assay  sensitivity  was  demonstrated  by  the comparison of the mean QTcI interval changes from baseline over 1 to 4 hours between moxifloxacin (single administration of 400 mg) and placebo.

## Metformin

## Effects on Hepatic Glucose Production and Glycogenolysis

The predominant glucose-lowering mechanism of action of metformin is to reduce excessive rates of hepatic  glucose  production.  Metformin  inhibits  gluconeogenesis  by  increasing  hepatic  sensitivity  to insulin  and  decreasing  the  hepatic  extraction  of  certain  gluconeogenic  substrates  (e.g.  lactate). Metformin reduces gluconeogenesis by 0.6 mg/kg per minute, in effect leading to a 75% reduction in hepatic glucose output. It is believed that this effect is achieved through metformin induced activation of adenosine monophosphate-activated protein kinase, an energy regulating enzyme expressed in the liver. Hepatic glycogenolysis is also decreased by metformin.

## Effects on Peripheral Insulin Sensitivity

The extrahepatic actions of metformin include improved glucose transport and utilisation by skeletal muscle due to improvements in non-oxidative glucose disposal and glycogen synthesis. These actions result  in  an  enhanced  insulin-stimulated  glucose  uptake  in  the  skeletal  muscle.  This  involves  an increase  in  the  movement  of  insulin-sensitive  glucose  transporter  molecules  to  the  cell  membrane. Additional  pharmacologic  actions  of  metformin  include  increased  glucose  oxidation  and  storage  in glycogen and fat, and inhibition of fatty acid oxidation. Taken together, metformin acts as an insulin sensitizer without exerting any direct effect on pancreatic β -cell insulin secretion.

## Effects on the Rate of Intestinal Glucose Absorption

The  rate  of  intestinal  glucose  absorption  is  also  reduced  with  metformin,  further  contributing  to  its blood glucose-lowering effects.

<div style=\"page-break-after: always\"></div>

## Effects on the GLP-1

In a small study in obese non-diabetic male patients it was shown that a 14-day high-dose treatment (i.e.  2.550  mg/day)  with  metformin  was  associated  with  a  significant  increase  in  circulating  GLP-1 plasma levels after an oral glucose load [R10-5241, Module 2.7.5]. As subjects were studied during euglycaemic  hyperinsulinaemic  clamp  conditions,  the  results  of  this  study  indicate  that  metformin determines a relevant elevation of oral glucose-stimulated GLP-1, which is not dependent on variations in circulating insulin or glucose. The mechanism for the observed increase in oral glucose stimulated GLP-1  levels  determined  by  metformin  treatment  could  have  been  principally  due  to  either  a stimulation of secretion or an inhibition of peptide inactivation, and was matter of debate over the last decade. The results of this study were confirmed by a recent study in healthy non-diabetic subjects, in whom a  2-day  treatment  with  1.000  mg  metformin/day  increased  postprandial  total  GLP-1  plasma concentrations (4-h weighted mean) by about ~1.8-fold relative to placebo. It was also shown by the authors that metformin did not inhibit plasma DPP-4 activity either in vitro or in vivo . Based on these data  it  was  concluded  that  metformin  is  not  a  DPP-4  inhibitor  but  rather  enhances  precursor  GCG expression  in  the  large  intestine,  thereby  increasing  total  GLP-1  plasma  concentrations,  possibly  by enhancing GLP-1 secretion from enteroendocrine L-cells.

## Other Pharmacologic and Metabolic Effects

In addition to metformin's ability to lower blood glucose concentrations, it has been shown to exert beneficial effects on dyslipidemia, hypofibrinolysis, and obesity in patients with T2DM. Metformin has been  reported  to  produce  10%  to  20%  reductions  in  plasma  TG  levels  in  nonhypertriglyceridemic patients  and  up  to  50%  TG  reductions  in  hypertriglyceridemic  patients  due  to  decreased  hepatic synthesis of very low density lipoprotein cholesterol. Total cholesterol (TC) levels have been reported to decrease a mean of 10%, with increases in HDL-C levels of up to 17% and decreases in LDL-C levels of up to 25%. Free fatty acid (FFA) levels have also been reported to decrease with metformin therapy.

In  contrast  to  patients  receiving  sulfonylurea  therapy  for  diabetes,  those  who  receive  metformin generally maintain or loose body weight, with loss of adipose tissue accounting for most of the weight loss.  Metformin  therapy  is  associated  with  a  5%  net  difference  in  weight  reduction  compared  with sulfonylurea therapy.

## Effects on Plasma Glucose and HbA1c Levels

A meta-analysis of randomized controlled trials evaluated metformin's efficacy in achieving glycaemic control,  as  well  as  its  effects  on  body  weight.  In  10  placebo-controlled  studies  (with  treatment durations  ranging  between  1  to  36  months),  metformin  monotherapy  reduced  fasting blood  glucose (FBG) concentrations by 2.0 mM compared with placebo (95% CI, -2.4 to -1.7) and HbA1c values by 0.9 percentage points (95% CI, -1.1 to -0.7). In 9 studies comparing metformin and a sulfonylurea, both agents lowered blood glucose concentrations and HbA1c values equally.

## Linagliptin/metformin

Linagliptin  in  combination  with  metformin  represents  a  pharmacologically  meaningful  therapeutic combination  approach,  because  different  pathophysiological  features  of  T2DM  (e.g.  impaired  ß-cell function,  increased  hepatic  glucose  output/gluconeogenesis,  and  peripheral  insulin  resistance)  are addressed by the complementary modes of action of both moieties.

This principle pharmacological consideration is supported by consistent clinical evidence demonstrating that novel GLP-1 based therapies display additive glucose/HbA1c lowering effects in combination with metformin. This was shown to apply to both pharmacological approaches, i.e. the strategy of activating the GLP-1 receptors by exenatide or liraglutide, and by the strategy of preventing the inactivation of endogenous GLP-1 by inhibiting DPP-4.

<div style=\"page-break-after: always\"></div>

Regarding  the  primary  PD  variable  DPP-4  inhibition  it  was  shown  by  a  7-day  repeat-dose  study  in healthy adult subjects that the linagliptin 5 mg q.d. and 2.5 mg b.i.d. treatment regimens resulted in a comparable PD response as shown by a median DPP-4 inhibition of about 80% at trough. Moreover DPP-4 inhibition was comparable for both dosage regimens over the entire 24-h (i.e. 24-h for q.d. and 2 x 12-h for b.i.d. regimen) dosing interval at steady-state. The mean average DPP-4 inhibition was 85.3% and 85.8% for the 5 mg q.d. and the 2.5 mg b.i.d. regimens, respectively (study 1218.45).

These findings were confirmed for HbA1c in study 1218.62. This study was a randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg b.i.d. versus 5 mg q.d. over 12 weeks as add-on therapy to a b.i.d. dose regimen of metformin in patients with T2DM and insufficient glycaemic control. According to the pre-specified criterion in the protocol, non-inferiority of linagliptin 2.5 mg b.i.d. treatment was established versus linagliptin 5 mg q.d treatment. The adjusted mean treatment difference in HbA1c from baseline to Week 12 with linagliptin 2.5 mg b.i.d. compared to linagliptin 5 mg q.d. was 0.06% (95% CI -0.07, 0.19).

## 2.4.4. Discussion on clinical pharmacology

The  pharmacokinetics  and  pharmacodynamics  of  linagliptin  were  studied  in  29  Phase  I/II  trials, involving healthy subjects, patients with T2DM, and special populations (renal or hepatic impairment, Japanese subjects). DPP-4 inhibition was considered the primary pharmacodynamic parameter, with an inhibition of 80% or more over 24 hours related to maximum effects in incretin response and glucose reduction.

Extrapolation of the pharmacokinetic and pharmacodynamic data of the linagliptin 5 mg tablet to the 2.5 mg is justified by study 1218.45, in which it was shown that a dosage regimen of linagliptin 2.5 mg twice daily can be considered bioequivalent with linagliptin 5 mg once daily, based on the exposure data  over  24  hours  AUC 0-24  hours. In  this  study  DPP-4  inhibition  &gt;80%  over  24h  was  achieved  with multiple  dosing  of  2.5  mg  linagliptin.  In  healthy  individuals,  linagliptin  2.5  mg  twice  daily  was bioequivalent to linagliptin 5 mg once daily.

The  applicant  conducted  three  bioequivalence  studies.  Based  on  these  studies  the  to  be  registered linagliptin 2.5 mg/metformin  1000  mg,  linagliptin 2.5 mg/metformin  850  mg,  linagliptin 2.5 mg/metformin 500 mg FDC tablets can be considered bioequivalent with the single dose formulation with linagliptin 2.5 mg tablet and metformin 1000 mg, 500 mg and 850 mg respectively.

Results on secondary parameters such as active GLP-1, glucose, insulin and glucagon were consistent with the primary parameter. In general, linagliptin plasma concentrations correlated well with DPP-4 activity/inhibition.  Although  age  has  been  investigated  as  covariate,  the  number  of  elderly  subjects &gt;75 in all clinical studies was small, and pharmacodynamics has not been studied in elderly patients. In a thorough QT study, single doses of 5 mg or 100 mg linagliptin did not prolong QT interval of the ECG.

## 2.4.5. Conclusions on clinical pharmacology

Bioequivalence of linagliptin 2.5 mg twice daily with linagliptin 5 mg once daily has been appropriately demonstrated. In addition it has been demonstrated that the linagliptin 2.5 mg/metformin 1000 mg, linagliptin  2.5  mg/metformin  850  mg  and  linagliptin  2.5  mg/metformin  500  mg  FDC  tablets  are bioequivalent with the linagliptin 2.5 mg tablet given concomitantly with metformin 1000 mg, 850 mg and 500 mg respectively.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies

## Linagliptin

The  optimum  daily  linagliptin  dose  of  5  mg  was  determined  in  the  linagliptin  mono  development programme and was primarily based on HbA1c reduction and DPP-4 inhibition in the 2 dose-finding trials 1218.5 and 1218.6. Tolerability was excellent on all dose levels tested in these 2 trials (0.5 mg, 1 mg, 2.5 mg, 5 mg, and 10 mg), and no dose-dependent increase in adverse events was observed. A median DPP-4 inhibition of at least 80% was only reached with the 5 mg and 10 mg linagliptin doses, but  not  with  lower  doses.  The  10  mg  dose  did  not  result  in  a  substantially  greater  median  DPP-4 inhibition or HbA1c reduction than the 5 mg dose, and hence, the 5 mg dose was used in phase III. In the entire phase III program, linagliptin 5 mg once daily was shown to provide consistent and clinically meaningful improvements in glycaemic control, as assessed by HbA1c, FPG, or postprandial glucose levels.  Together  with  the  favourable  safety  profile  observed,  the  risk-benefit  ratio  of  linagliptin  is considered optimal for a daily dose of 5 mg linagliptin.

Because the pharmacokinetics of metformin require an at least twice daily dosing, for the development of  the  FDC  the  once  daily  dosing  of  5  mg  linagliptin  was  split  into  2  daily  doses  of  2.5  mg.  In  trial 1218.45,  a  phase  I-study  comparing  once  daily  and  twice  daily  dosing  in  healthy  subjects,  the  2 linagliptin  dosing  regimens  were  shown  to  be  bioequivalent  in  regard  to  AUC  at  steady  state.  The average DPP-4 inhibition was 85.3% for the 5 mg once daily regimen and 85.8% for the 2.5 mg twice daily  regimen.  The  clinical  equivalence  of  both  posologies  was  demonstrated  in  a  large,  placebocontrolled,  12-week  trial  1218.62  that  investigated  linagliptin  2.5  mg  bid  +  metformin  versus linagliptin 5 mg qd + metformin.

## Metformin

Metformin in immediate release formulation is approved as tablet for oral administration in the dose strengths of 500 mg, 850 mg, and 1000 mg. In case of tolerability issues, the metformin dose should be  reduced.  is  the  Applicant  therefore  proposed  to  provide  FDC  tablets  with  linagliptin  and  all  3 metformin  dose  strengths  to  offer  patients  maximal  flexibility  in  attaining  their  individual  daily metformin dose.

For the key trials in this submission (1218.17, 1218.20, 1218.62, and 1218.18) the protocols specified that  the  daily  metformin  dose  should  be  1500  mg  or  above.  The  actual  unit  dose  strength  and  the actual  posology  was  at  the  investigator's  discretion  and  depending  on  the  patient's  need  and tolerability of metformin. The majority of patients in the 4 studies received a daily dose of 1500 mg to 2000  mg  metformin  at  baseline;  a  considerable  proportion  of  patients  took  less  than  1500 mg metformin  per  day  (range  6.3%  to  8.6%).  In  trial  1218.46,  two  treatment  groups  with  metformin mono therapy of 500 mg bid and 1000 mg bid were evaluated.

<div style=\"page-break-after: always\"></div>

## Linagliptin/metformin

The applicant proposed 3 FDC dose strengths, namely linagliptin 2.5 mg/metformin 500 mg, linagliptin 2.5  mg  /metformin  850  mg,  and  linagliptin  2.5  mg/metformin  1000  mg.  To  substantiate  the effectiveness  of  these  3  dose  strengths,  the  placebo-controlled  trials  (1218.17,  1218.62,  1218.46, 1218.18) were analysed by metformin dose and posology. Emphasis was placed on the posologies of 500 mg bid, 850 mg bid and 1000 mg bid. However, except in study 1218.46, in which all patients took  either  metformin  500  mg  bid  or  1000  mg  bid,  the  proportions  of  patients  who  received  other doses  or  other  posologies  were  between  42.1%  (1218.62)  and  58.9%  (1218.17).  For  each  of  the studies  (1218.17,  1218.18,  1218.20,  1218.62),  the  analyses  that  comprised  all  'other'  metformin doses demonstrated that the linagliptin treatment effect was similar to the efficacy observed for the planned FDC combinations.

Independent  of  metformin  dose,  the  addition  of  linagliptin  either  once  daily  or  twice  daily  led  to  a substantial and clinically meaningful reduction in HbA1c. The magnitude of the combination treatment effect was largely consistent across the different metformin doses with adjusted mean changes from baseline  of  -0.51%  to  -0.70%  after  24  weeks  of  treatment.  Only  for  the  850  mg  group  in  study 1218.62  no  difference  between  metformin  850  mg  and  linagliptin  +  metformin  850  mg  could  be established. This was likely a consequence of the small number of patients in this analysis (metformin 850 mg n=9; linagliptin 5 mg qd + metformin 850 mg n=55, linagliptin 2.5 mg bid + metformin 850 mg,  n=57).  In  addition,  study  1218.46  showed  that  the  combination  of  linagliptin  2.5  mg  bid  + metformin 500 mg bid was at least as effective in reducing HbA1c as metformin 1000 mg bid (-1.22% vs. -1.07%), adjusted mean difference -0.14%, p=0.1903. Thus, the linagliptin 2.5 mg/metformin 500 mg FDC could be considered a useful alternative to metformin monotherapy for patients intolerant to the recommended daily metformin dose.

For  all  placebo-controlled  trials,  ANCOVA  analyses  demonstrated  that  there  was  no  treatment-bymetformin dose effect for the reduction of HbA1c (treatment-by-dose p-values 0.2172 to 0.9846). In the active-controlled study 1218.20, the adjusted mean changes (SE) from baseline in HbA1c after 104 weeks of treatment were -0.10% (0.08) for linagliptin + metformin 850 mg bid and -0.12% (0.06) for linagliptin + metformin 1000 mg bid; the treatment-by-dose interaction p-value was 0.8056. Thus, it can be concluded that each of the proposed posologies of linagliptin + metformin combinations are efficacious in the reduction of HbA1c. A summary of the results by metformin dose is shown below.

<div style=\"page-break-after: always\"></div>

Table 21. Change from baseline in HbA1c in placebo-controlled trials with linagliptin+metformin combinations analysed by daily metformin doses 500 mg, 850 mg and 1000 mg - FAS (LOCF)

|                                  | Change from baseline   | Difference between treatments   | Difference between treatments   | Difference between treatments   |
|----------------------------------|------------------------|---------------------------------|---------------------------------|---------------------------------|
| Study Treatment groups           | Adjusted a mean (SE)   | Adjusted a mean (SE)            | 95% CI                          | p-value                         |
| 1218.17                          |                        | 24 weeks treatment              | 24 weeks treatment              | 24 weeks treatment              |
| 850 mg Metformin                 |                        |                                 |                                 |                                 |
| Metformin                        | 0.13 (0.14)            |                                 |                                 |                                 |
| L5 mg qd+Met vs Met              | -0.56 (0.07)           | -0.70 (0.15)                    | (-1.00, -0.39)                  | <0.0001                         |
| 1000 mg Metformin                |                        |                                 |                                 |                                 |
| Metformin                        | 0.31 (0.16)            |                                 |                                 |                                 |
| L5 mg qd+Met vs Met              | -0.36 (0.10)           | -0.67 (0.19)                    | (-1.05, -0.29)                  | 0.0005                          |
| 1218.62                          |                        | 12 weeks treatment              |                                 |                                 |
| 850 mg Metformin                 |                        |                                 |                                 |                                 |
| Metformin                        | -0.13 (0.23)           |                                 |                                 |                                 |
| L5 mg qd+Met vs Met              | -0.50 (0.09)           | -0.37 (0.24)                    | (-0.85, 0.11)                   | 0.1283                          |
| L2.5 mg bid+Met vs Met           | -0.51 (0.09)           | -0.38 (0.24)                    | (-0.86, 0.10)                   | 0.1191                          |
| L2.5 mg bid+Met vs L5 mg qd+Met  |                        | 0.01 (0.13)                     | (-0.26, 0.24)                   | 0.9502                          |
| 1000 mg Metformin                |                        |                                 |                                 |                                 |
| Metformin                        | 0.19 (0.19)            |                                 |                                 |                                 |
| L5 mg qd+Met vs Met              | -0.50 (0.09)           | -0.69 (0.21)                    | (-1.10, -0.28)                  | 0.0009                          |
| L2.5 mg bid+Met vs Met           | -0.48 (0.09)           | -0.67 (0.21)                    | (-1.08, -0.26)                  | 0.0013                          |
| L2.5 mg bid+Met vs L5mg qd + Met |                        | 0.02 (0.12)                     | (-0.22, 0.26)                   | 0.8855                          |
| 1218.46                          |                        | 24 weeeks treatment             |                                 |                                 |
| 500 mg Metformin                 |                        |                                 |                                 |                                 |
| Met bid                          | -0.64 (0.08)           |                                 |                                 |                                 |
| L2.5 mg bid+Met bid vs. Met bid  | -1.22 (0.08)           | -0.58 (0.11)                    | (-0.79, -0.36)                  | <0.0001                         |
| 1000 mg Metformin                |                        |                                 |                                 |                                 |
| Met bid                          | -1.07 (0.08)           |                                 |                                 |                                 |
| L2.5 mg bid+Met bid vs Met bid   | -1.59 (0.08)           | -0.51 (0.11)                    | (-0.73, -0.30)                  | <0.0001                         |
| 1218.18                          |                        | 24 weeks treatment              |                                 |                                 |
| 850 mg Metformin+SU              |                        |                                 |                                 |                                 |
| Met+SU                           | -0.17 (0.12)           |                                 |                                 |                                 |
| L5 mg qd+Met+SU vs Met+SU        | -0.79 (0.07)           | -0.63 (0.14)                    | (-0.90, -0.36)                  | <0.0001                         |
| 1000 mg Metformin+SU             |                        |                                 |                                 |                                 |
| Met+SU                           | -0.05 (0.10)           |                                 |                                 |                                 |
| L5 mg qd+Met+SU vs Met+SU        | -0.65 (0.06)           | -0.60 (0.12)                    | (-0.83, -0.37)                  | <0.0001                         |

<div style=\"page-break-after: always\"></div>

For the 850 mg group in study 1218.62 no difference between metformin 850 mg and linagliptin + metformin 850 mg could be established. The CHMP is in agreement with the Applicant that this was likely  a  consequence  of  the  small  number  of  patients  in  this  analysis.  In  addition,  study  1218.46 showed that the combination of linagliptin 2.5 mg bid + metformin 500 mg bid was at least as effective in reducing HbA1c as metformin 1000 mg bid (-1.22% vs. -1.07%). However, the proposed strength 2.5 mg/500 mg was not considered acceptable by the CHMP. The minimal metformin dose assessed in the clinical studies was 1500 mg per day, which is in line with clinical practice. This is also in line with the results from the UKPDS. In this study, the efficacy of metformin in reducing T2DM complications was demonstrated, but the great majority of the patients were treated with metformin doses &gt;1700 mg per day. Although there might be a minority of patients who cannot tolerate metformin at doses higher than 1000 mg, it is unlikely that the linagliptin 2.5 mg/metformin 500 mg FDC tablet offers a meaningful benefit compared to the administration of the separate components. In addition, the low dose FDC tablet could promote initial combination therapy which is not approved and not covered by current diabetes treatment guidelines.

## 2.5.2. Main studies

## Linagliptin

Four pivotal efficacy studies were submitted to support the registration of linagliptin 5 mg (Trajenta) (1218.15,  1218.16,  1218.17  and  1218.18).  These  studies  were  randomized,  multinational,  doubleblind,  placebo-controlled,  24  week  efficacy studies.  Randomisation  was  stratified  by  HbA1c  (&lt;8.5% versus ≥ 8.5%) and by the number of previous antidiabetic treatments as described below.

## Methods

## Study Participants

## Main inclusion criteria

-  Adult  male  and  non-pregnant  female  patients  with  T2DM  either  on  previous  or  no  previous antidiabetic agent and pre-defined HbA1c values at screening and randomisation, (depending on previous AHA, for details see individual studies)
-  Age ≥ 18 to ≤ 80 years of age,
-  BMI ≤ 40 kg/m 2, .

## Main exclusion criteria

-  Treatment with insulin, GLP-1 analogues/agonists, or anti-obesity drugs within past 3 months;
-  diabetic ketoacidosis within past 6 months;
-  heart failure NHYHA class III or IV; CV event within the past 6 months,
-  impaired hepatic function (ALT, AST, ALP above 3 ULN),
-  FPG &gt; 240 mg/dl(&gt; 13.3 mmol/L),
-  limitation in the degree of renal impairment in studies 1218.17 and 1218.18,
-  current  treatment  with  systemic  steroids  or  change  in  dosage  of  thyroid  hormones  within  6 weeks.

<div style=\"page-break-after: always\"></div>

## Objectives

The  primary  objective  was  testing  the  superiority  hypothesis  of  linagliptin  versus  placebo  (as monotherapy or add-on) or the non-inferiority of linagliptin versus active control in decreasing HbA1c.

## Outcomes/endpoints

The  primary  efficacy  endpoint  in  all  the  studies  was  HbA1c  change  from  baseline  to  the  last  ontreatment visit.

Secondary  glycaemic  endpoints  included:  FPG,  proportion  of  patients  reaching  HbA1c  &lt;  7.0%  or &lt;6.5 % or HbA1c reduction of at least 0.5%. Some studies included a meal tolerance test (MTT, in studies 1218.16, 1218.17).

Other relevant endpoints included: use of rescue therapy, change from baseline in body weight after 24 weeks treatment (presented in safety part), change from baseline in waist circumference after 24 weeks of treatment (presented in safety part) and change from baseline in lipid parameters after 24 weeks of treatment (presented in safety section).

## Randomisation

Randomisation was stratified by the HbA1c value at the beginning of the placebo run-in period (&lt;8.5% versus ≥ 8.5%). Randomisation was also stratified by the number of oral antidiabetic drugs at the time of enrolment in most of the trials, except for study 1218.18.

## Blinding (masking)

Access  to  the  randomisation  code  was  restricted  to  dedicated  randomisation  personnel.  Neither  the patient nor the investigator was aware of the identity of a patient's treatment.

## Statistical methods

The primary statistical analysis in all pivotal studies analyzed the change from baseline in HbA1c after 24 weeks of treatment using an ANCOVA model with 'treatment' as well as 'prior use of antidiabetic agents' as categorical covariates and 'baseline HbA1c' as continuous covariate. The primary analysis was conducted at the 2-sided 5% level of significance and based on the FAS data set. Missing data were imputed using LOFC (with observations obtained under rescue medication not being replaced) and additional sensitivity analyses were performed.

Statistical methods employed are generally considered appropriate.

Below are described aspects that were study specific:

## Study 1218.15

This was a study in patients with T2DM to evaluate the efficacy and safety of linagliptin 5 mg as initial combination  with  pioglitazone 30  mg  in  comparison  with  placebo  as  initial  combination  with pioglitazone 30 mg.

Patients  were  treated  in  43  centers  in  Europe  and  Asia:  Japan  (24.9%),  Spain  (23.1%),  Hungary (21.9%), Romania (18.8%), Greece (6.4%), Austria (4.4%), Portugal (0.5%).

The study period was from 15 April 2008 to 19 June 2009.

<div style=\"page-break-after: always\"></div>

## Methods

## Design

This was a multinational, randomized, double-blind, placebo-controlled, parallel group study, consisting of an open-label, 2-week placebo run-in, followed by a 24-week double-blind treatment period and a 1-week follow-up after termination of study medication.

## Study participants

Patients with T2DM, either drug-naive or pre-treated with any antidiabetic agent as monotherapy or combination therapy were recruited in this study.

HbA1c at screening was 7.5% to 11.0% in treatment naïve patients and 7.0% to 9.5% in pretreated patients. HbA1c at start of run-in: between 7.5% and 11.0%.

## Treatments

Patients eligible after the run-in period were randomised in a 2:1 ratio to 24 weeks of treatment with either 5 mg linagliptin or placebo as initial combination with 30 mg pioglitazone (linagliptin+pioglitazone and placebo+pioglitazone respectively).

## Results

## Participant flow

A total of 707 patients were enrolled and 389 were randomized (see table below). The most common reason for not being randomized was the HbA1c results before randomisation (42.5 %).

Table 22. Disposition of randomised patients -Screened set

|                                               | Pbo+pio N (%)   | Lina+pio N (%)   | Total N (%)   |
|-----------------------------------------------|-----------------|------------------|---------------|
| Enrolled                                      |                 |                  | 707           |
| Randomised                                    | 130             | 259              | 389           |
| Treatedl                                      | 130 (100.0)     | 259 (100.0)      | 389 (100.0)   |
| Not prematurely discontinued trial medication | 111 (85.4)      | 244 (94.2)       | 355 (91.3)    |
| Prematurely discontinued trial medication     | 19 (14.6)       | 15 (5.8)         | 34 (8.7)      |
| Adverseevent                                  | 6 (4.6)         | 4 (1.5)          | 10 (2.6)      |
| Study disease worsening                       | 1 (0.8)         | 1 (0.4)          | 2 (0.5)       |
| Other disease worsening                       | 2 (1.5)         | 0 (0.0)          | 2 (0.5)       |
| Other AE                                      | 3 (2.3)         | 3 (1.2)          | 6 (1.5)       |
| Lack of efficacy 2                            | 1 (0.8)         | 1 (0.4)          | 2 (0.5)       |
| Non-compliance to protocol                    | 2 (1.5)         | 3 (1.2)          | 5 (1.3)       |
| Lost to follow-up                             | 3 (2.3)         | 2 (0.8)          | 5 (1.3)       |
| Refused to continue trial medication          | 4 (3.1)         | 4 (1.5)          | 8 (2.1)       |
| Other reason                                  | 3 (2.3)         | 1 (0.4)          | 4 (1.0)       |

<div style=\"page-break-after: always\"></div>

## Conduct of the study

There were three global and two local protocol amendments to the original clinical trial protocol. These amendments were considered not influencing the study results.

No interim analysis was planned or performed for this study.

## Baseline data

At study start, main demographic characteristics were as follows [mean (range)]:

-  Age: 57.5 y (25-79), 25.4 % of patients were ≥ 65,
-  BMI: 29.0 kg/m 2  (16.8- 39.7), 42.2 % had a BMI ≥ 30,
-  Diabetes duration: 25.5 % had duration of diabetes up to 1 year, 42.4% &gt;5 years.

A  total  of  31.8%  of  the  patients  had  taken  one  antidiabetic  agent  and  18.4%  had  taken ≥ 2 antidiabetic  agents.  Pre-treated  patients  were  mainly  on  metformin  monotherapy  (22.1%)  or  SU monotherapy (7.9%) or the combination of both (9.5%).

Overall, 60.9% of patients were male, 74.6% were Caucasian and 24.9% Asian.

## Numbers analyzed

In both groups, over 97.0% of patients were included in the primary FAS analysis and over 95% in the PPS analysis (see table below).

Table 23. Number of patients by analysis set -Randomized set

|                 | Pbo+pio N (%)   | Lina+pio N (%)   | Total N (%)   |
|-----------------|-----------------|------------------|---------------|
| Randomisedset   | 130 (100.0)     | 259 (100.0)      | 389 (100.0)   |
| Treated set     | 130 (100.0)     | 259 (100.0)      | 389 (100.0)   |
| FAS             | 128 (98.5)      | 252 (97.3)       | 380 (97.7)    |
| FAS-completers* | 106 (82.8)      | 236 (93.7)       | 342 (90.0)    |
| PPS             | 123 (96.1)      | 246 (97.6)       | 369 (97.1)    |

## Outcomes and estimation

## Primary endpoint

Treatment with 5 mg once daily linagliptin + pioglitazone was superior to treatment with placebo + pioglitazone in lowering HbA1c with a statistically significant difference of -0.51%.

The unadjusted mean change from baseline in HbA1c showed similar results.

<div style=\"page-break-after: always\"></div>

Table 24. Adjusted means for the change in HbA1c (%) from baseline at Week 24 - FAS (LOCF )

|                                                           | Pbo+pio      | Lina+pio      |
|-----------------------------------------------------------|--------------|---------------|
| Number of patients                                        | 128          | 252           |
| Number of patients with baseline and on-treatment results | 128          | 252           |
| Baseline                                                  |              |               |
| Mean (SE)                                                 | 8.58 (0.08)  | 8.60 (0.05)   |
| Changefrombaseline                                        |              |               |
| Mean (SE)                                                 | -0.75 (0.11) | -1.25 (0.07)  |
| Adjusted' mean (SE)                                       | -0.56 (0.09) | -1.06 (0.06)  |
| Comparison vs. pbo+pio (difference lina+pio - pbo+pio)    |              |               |
| Adjusted' mean (SE)                                       |              | -0.51 (0.10)  |
| 95%Confidenceinterval                                     |              | (-0.71,-0.30) |
| p-value                                                   |              | <0.0001       |

Model includes continuous baseline HbAie, number of prior antidiabetic drugs, and treatment

SE = Standard error

In both treatment groups, HbA1c levels decreased until week 18 and remained stable thereafter.

The secondary analysis PPS supports the results of the primary analysis, although the placebo adjusted treatment effect was smaller: -0.48 [-0.69; -0.28, 95 % CI] for HbA1c (mean difference).

The FAS-completers showed an even smaller placebo adjusted treatment effect: -0.35 [-0.56; -0.14, 95 % CI] for HbA1c (mean difference).

Adjusted mean HbA1c changes from baseline were similar between Asian and European populations (0.96 % vs. -1.09%, respectively), whereas placebo-adjusted changes were not (-0.91% vs. -0.37%, respectively).

## Secondary endpoints:

The addition of 5 mg qd linagliptin to pioglitazone was superior to placebo in addition to pioglitazone in lowering  FPG resulting  in  a  treatment  difference  of  -14.2  mg/dL  (3.5  mmol/L).  The  results  were confirmed by the secondary FAS-completer analysis.

A larger proportion of patients in the linagliptin + pioglitazone group achieved HbA1c levels &lt;7% or &lt;6.5% or an HbA1c reduction of at least 0.5%.

<div style=\"page-break-after: always\"></div>

Table 25. Number of patients with categorical HbA1c change from baseline at Week 24 -FAS (LOCF)

|                                          | Pbo+pio   | Pbo+pio   | Pbo+pio   | Lina+pio   | Lina+pio   | Lina+pio   |
|------------------------------------------|-----------|-----------|-----------|------------|------------|------------|
|                                          | n         | (%)       | N2        | n          | (%)        | N2         |
| Response criterion                       |           |           |           |            |            |            |
| HbA1c<7.0%                               | 39        | (30.5)    | 128       | 108        | (42.9)     | 252        |
| Among patients with baseline HbAic≥7.0%  | 39        | (30.5)    | 128       | 108        | (42.9)     | 252        |
| HbA1c<6.5%                               | 18        | (14.1)    | 128       | 44         | (17.5)     | 252        |
| Among patients with baseline HbAic ≥7.0% | 18        | (14.1)    | 128       | 44         | (17.5)     | 252        |
| Among patients with baseline HbAic ≥6.5% | 18        | (14.1)    | 128       | 44         | (17.5)     | 252        |
| HbAic reduction from baseline ≥0.5%      | 65        | (50.8)    | 128       | 189        | (75.0)     | 252        |

The proportion of patients requiring rescue therapy was 7.9% in the linagliptin + pioglitazone group and  14.1%  in  the  placebo  +  pioglitazone  group.  The  odds  ratio  obtained  from  the  accompanying logistic regression was 0.446 (p&lt;0.05). In addition, linagliptin + pioglitazone patients required rescue therapy later than placebo + pioglitazone patients.

## Other endpoints

By week 24, both treatment groups had an increase in mean weight, with an adjusted mean change from baseline that was greater in the linagliptin + pioglitazone group (2.3 kg) than in the placebo + pioglitazone group (1.2 kg). This translated to a statistically significant treatment difference in mean change from baseline of 1.10 kg (p&lt;0.05).

## Discussion of the study results

Overall, superiority of linagliptin + pioglitazone over placebo + pioglitazone was demonstrated in the present study by the primary endpoint change in HbA1c from baseline after 24 weeks of treatment. However,  the  placebo  adjusted  effect  of  linagliptin  (-0.51%)  was  rather  modest  and  of  borderline clinical relevance. The PPS analysis showed an even smaller effect (-0.48%). Clinically relevant effects on HbA1c were also not reached in patients on combination therapy prior to study.

Due  to  differences  in  placebo  response,  the  placebo-adjusted  treatment  effect  was  larger  in  Asian patients (-0.91%) than in European patients (-0.37%). The treatment effect observed in the European population is not considered clinically relevant.

Linagliptin  aggravated  the  pioglitazone-induced  weight  gain  by  a  yet  unknown  mechanism,  which  is clearly undesirable.

Overall,  the  placebo-adjusted  glucose-lowering  effect  of  linagliptin  in  this  study  was  modest  and  of borderline  clinical  relevance.  European  patients,  the  relevant  population  for  this  application,  did  not have a relevant placebo-adjusted improvement in glycaemic control. Considering these efficacy results and  the  observed  weight  gain,  the  combination  therapy  of  linagliptin  +  pioglitazone  appears unfavourable.

<div style=\"page-break-after: always\"></div>

## Study 1218.16

This  was  a  study  in  patients  with  T2DM  to  evaluate  the  efficacy  and  safety  of  linagliptin  5  mg  as monotherapy in comparison to placebo. Patients were treated in 66 centers in in Asia 50.1 % (with the highest proportion of 26.8 % in India and of 14.3 % in Malaysia) and Europe 49.9% (with the highest proportion of 17.7% in Ukraine and of 12.3% Slovakia). The study period was 15 February 2008 to 06 May 2009.

## Methods

## Design

This was a multinational, randomized, double-blind, placebo-controlled, parallel group study, consisting of an open-label, 2-week placebo run-in, followed by a 24-week double-blind treatment period and a 1-week follow-up after termination of study medication.

## Study participants

Patients  with  T2DM,  either  drug-naive  or  pre-treated  with  not  more  than  one  antidiabetic  agent (except for PPAR γ agonist) with a stable dose for 10 weeks prior study were included in this study.

HbA1c at screening was 7.0% to 10.0% in treatment naïve patients and 6.5% to 9.0% in pretreated patients. HbA1c at start of run-in was between 7.0% and 10.0%.

There were no limitations in the degree of renal impairment in this study.

## Treatments

Patients eligible at start of the run-in period were randomised in a 2:1 ratio to either 5 mg linagliptin or placebo.

## Outcomes/endpoints

The primary and secondary endpoints are described above in the general method section above.

In addition, PK/PD of linagliptin (plasma concentrations at trough after 12 and 24 weeks of treatment) was also an endpoint.

To support the analysis of renal function during the trial, estimated Glomerular Filtration Rate (eGFR) was  categorised  according  to  the  Modification  of  Diet  in  Renal  Disease (MDRD)  staging,  and  the frequency of patients with shifts in renal impairment stage was investigated. In addition, renal function was  categorised  based  on  the  estimated  creatinine  clearance  (eCcr)  values  calculated  using  the Cockcroft-Gault formula. The stages of renal function are specified in the table below.

Table 26. Staging of renal function based on eGFR values (MDRD) and eCcr values (Cockcroft-Gault)

|   Stage | eGFR[mL/min]   | eCcr [mL/min]   | Description               |
|---------|----------------|-----------------|---------------------------|
|       1 | ≥90            | >80             | Normalrenalfunction       |
|       2 | 60 to89        | 50 to80         | Mild renal impairment     |
|       3 | 30to59         | 30to<50         | Moderate renal impairment |
|       4 | <30            | <30             | Severe renal impairment   |

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

A  total  of  935  patients  were  enrolled  and  503  were  randomized.  The  most  common  reason  for  not being randomized was the HbA1c at screening and before randomisation (38.2%).

The discontinuation rates were higher in the placebo group (9%) compared with the linagliptin group (5.4%) without a striking difference in any specific cause.

Table 27. Disposition of randomised patients -Screened set

|                                               | Placebo N (%)   | Linagliptin N (%)   | Total N (%)   |
|-----------------------------------------------|-----------------|---------------------|---------------|
| Enrolled                                      |                 |                     | 935           |
| Randomised                                    | 167             | 336                 | 503           |
| Treatedl                                      | 167 (100.0)     | 336 (100.0)         | 503 (100.0)   |
| Not prematurely discontinued trial medication | 152 (91.0)      | 318 (94.6)          | 470 (93.4)    |
| Prematurely discontinued trialmedication      | 15 (9.0)        | 18 (5.4)            | 33 (6.6)      |
| Adverseevent                                  | 4 (2.4)         | 5 (1.5)             | 6 (1.8)       |
| Other disease worsening                       | 0 (0.0)         | 1 (0.3)             | 1 (0.2)       |
| Other AE                                      | 4 (2.4)         | 4 (1.2)             | 8 (1.6)       |
| Lack of efficacy 2                            | 2 (1.2)         | 0 (0.0)             | 2 (0.4)       |
| Lost to follow-up                             | 1 (0.6)         | 2 (0.6)             | 3 (0.6)       |
| Refused to continue trial medication          | 4 (2.4)         | 6 (1.8)             | 10 (2.0)      |
| Other reason                                  | 4 (2.4)         | 5 (1.5)             | 9 (1.8)       |

## Conduct of the study

There were three global and two local protocol amendments to the original clinical trial protocol. These amendments were not considered as influencing the study results.

No interim analysis was planned or performed for this study.

## Baseline data

At study start, the main demographic characteristics were as follows [mean (range)]:

-  Age: 55.7 y (24-79), 20.9 % of patients were ≥ 65 y,
-  BMI: 29.5 kg/m 2  (16.0- 41.2), 40.0 % had a BMI ≥ 30,
-  Diabetes duration: 36.1% had duration of diabetes up to 1 year, 25.2% &gt;5 years.

A total of 56.5% of the patients had not previously taken an antidiabetic agent, 43.5% had taken one antidiabetic  agent.  Pre-treated  patients  were  mainly  on  metformin  monotherapy  (32.3%)  or  SU monotherapy (10.9%).

Overall, 48.3% of patients were male, 53.7% were Caucasian and 46.1% Asian.

43.1% of patients had an eGFR of ≥ 90 mL/min, 3.6% had an eGFR 30 to &lt;60 mL/min.

There were no relevant differences in the mean baseline characteristics between the treatment groups.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

In both groups, over 97.0% of patients were included in the primary FAS analysis, over 93% in the PPS analysis and over 90&amp; in the FAS-completers analysis.

Table 28. Number of patients by analysis set

|                | Placebo N (%)   | Linagliptin N (%)   | Total N (%)   |
|----------------|-----------------|---------------------|---------------|
| Randomised set | 167 (100.0)     | 336 (100.0)         | 503 (100.0)   |
| Treated set    | 167 (100.0)     | 336 (100.0)         | 503 (100.0)   |
| FAS            | 163 (97.6)      | 333 (99.1)          | 496 (98.6)    |
| FAS-completers | 148 (90.8)      | 312 (93.7)          | 460 (92.7)    |
| PPS            | 152 (93.3)      | 314 (94.3)          | 466 (94.0)    |
| MTT-set        | 29 (17.8)       | 73 (21.9)           | 102 (20.6)    |

## Outcomes and estimations

## Primary endpoint

Treatment with 5 mg qd linagliptin was superior to treatment with placebo in lowering HbA1c with a statistically significant difference of -0.69% (p&lt;0.0001). The unadjusted mean change from baseline in HbA1c showed similar results.

Table 29. Adjusted means for the change in HbA1c (%) from baseline at Week 24 - FAS (LOCF)

|                                                           | Placebo     | Linagliptin   |
|-----------------------------------------------------------|-------------|---------------|
| Number of patients                                        | 163         | 333           |
| Number ofpatientswithbaseline and on-treatmentresults     | 163         | 333           |
| Baseline                                                  |             |               |
| Mean (SE)                                                 | 8.00 (0.07) | 8.00 (0.05)   |
| Change from baseline                                      |             |               |
| Mean (SE)                                                 | 0.22 (0.08) | -0.46 (0.05)  |
| Adjusted' mean (SE)                                       | 0.25 (0.07) | -0.44 (0.05)  |
| Comparison vs. placebo (difference linagliptin - placebo) |             |               |
| Adjusted' mean (SE)                                       |             | -0.69 (0.08)  |
| 95%Confidenceinterval                                     |             | -0.85,-0.53   |
| p-value                                                   |             | <0.0001       |

In  the  linagliptin  group,  HbA1c  levels  decreased  until  week  12  and  remained  relatively  stable thereafter. In the placebo group, HbA1c levels increased slightly over time.

The  secondary  analysis  PPS  supports  the  results  of  the  primary  analysis,  the  placebo  adjusted treatment effect was: -0.69 [-0.86; -0.53, 95 % CI] for HbA1c (mean difference). The FAS-completers showed a smaller placebo adjusted treatment effect: -0.56 [-0.73; -39, 95 % CI] for HbA1c.

Whereas  the  mean  absolute  change  from  baseline  in  HbA1c  was  similar  for  Asian  and  Caucasian patients  (-0.45%  vs.  -0.42%,  respectively)  the  placebo-adjusted  change  was  not  (-0.91%  vs.  0.52%).

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

The  treatment  of  5  mg  QD  linagliptin  was  superior  to  placebo  in  lowering  FPG  resulting  in  a  mean treatment difference of -23.3 (3.6) mg/dL at week 24. The results were confirmed by the secondary FAS-completer analysis.

A larger proportion of patients in the linagliptin compared to the placebo group achieved HbA1c levels &lt; 7% or &lt; 6.5% or HbA1c reduction ≥ 0.5%.

Table 30. Number of patients with categorical HbA1c change from baseline at Week 24 -FAS (LOCF)

|                                           | Placebo   | Placebo   | Placebo   | Linagliptin   | Linagliptin   | Linagliptin   |
|-------------------------------------------|-----------|-----------|-----------|---------------|---------------|---------------|
|                                           | n         | (%)       | N2        | n             | (%)           | N2            |
| Response criterion                        |           |           |           |               |               |               |
| HbA1c <7.0%                               | 25        | (15.3)    | 163       | 94            | (28.2)        | 333           |
| Among patients with baseline HbAic ≥7.0%  | 17        | (11.6)    | 25        | 77            | (25.2)        | 94            |
| HbA1c<6.5%                                | 8         | (4.9)     | 163       | 36            | (10.8)        | 333           |
| Among patients with baseline HbAic ≥7.0%  | 6         | (12.8)    | 8         | 26            | (20.1)        | 36            |
| Among patients with baseline HbAic ≥6.5%  | 8         | (4.9)     | 8         | 35            | (10.6)        | 36            |
| HbA1c reduction from baseline HbA1c ≥0.5% | 31        | (19.0)    | 163       | 157           | (47.1)        | 333           |

Of the MTT parameters, difference in the adjusted mean change from baseline in total glucose AUC at 24 weeks between the two treatment groups was -3.26 mmol h/L with a statistically significant p-value of 0.0026, further supporting the results of the primary and secondary endpoints.

The proportion of patients requiring rescue therapy was 20.9 % in the placebo group versus 10.2% in the linagliptin group. Based on the regression result, the odds of requiring rescue therapy was about 3 times lower for patients treated with linagliptin compared to those taking placebo (odds ratio = 0.316, p &lt; 0.05).

## Other endpoints

In  patients  receiving  linagliptin,  the  median  DPP-4  inhibition  at  trough  was  greater  than  80%  with 84.18% at week 12 and 82.81% at week 24 and thus constant over time.

No meaningful change in the body weight was observed in either group. The difference in the adjusted means of change from baseline to 24 weeks in body weight between treatment groups was 0.28 kg.

## Pharmacokinetic results

Analysis of linagliptin plasma concentrations at trough was performed on the data with original results (OR). The geometric mean (gMean) plasma concentrations of linagliptin at trough remained constant over time.

Mean  linagliptin  trough  levels  over  time  were  comparable  between  patients  with  normal,  mildly  or moderately impaired renal function.

<div style=\"page-break-after: always\"></div>

Table 31. Geometric mean trough plasma concentrations of linagliptin - FAS (OR)

|                         | Visit 5   | Visit 5        | Visit 7   | Visit 7        |
|-------------------------|-----------|----------------|-----------|----------------|
|                         | N         | gMean [nmol/L] | N         | gMean [nmol/L] |
| MDRD                    |           |                |           |                |
| no renal impairment     | 123       | 6.55           | 114       | 6.23           |
| mild renal impairment   | 142       | 6.30           | 114       | 6.82           |
| moderaterenalimpairment | 14        | 6.30           | 11        | 6.32           |
| eCcr                    |           |                |           |                |
| no renal impairment     | 200       | 6.33           | 176       | 6.34           |
| mild renal impairment   | 73        | 6.77           | 59        | 6.99           |
| moderaterenalimpairment | 6         | 5.15           | 4         | 7.31           |

## Discussion of the study results

In  the  present  study  linagliptin  at  dose  of  5  mg  QD  provided  statistically  significant  and  clinically relevant  improvement  in  glycaemic  control  in  patients  with  T2DM  not  sufficiently  controlled  on monotherapy (PPAR γ agonists excluded) and in treatment naïve patients. Due to differences in placebo response,  the  placebo-adjusted  treatment  effect  was  larger  in  Asian  patients  (-0.91%)  than  in Caucasian patients (-0.52%). The results on HbA1c were supported by the results on the secondary endpoints.

The data of pharmacokinetic properties in patients with mild to moderate degrees of renal insufficiency confirm that dose adjustment in these patients is not necessary.

## Study 1218.17

This was a study in patients with type 2 diabetes to evaluate the efficacy and safety of linagliptin 5 mg as add-on therapy to metformin in comparison to placebo. Patients were treated in Asia, Europe, North America, South America and New Zealand. The study period was 31 January 2008 to 18 May 2009.

## Methods

## Design

This was a multinational, randomized, double-blind, placebo-controlled, parallel group study, consisting of an open-label, 2-week placebo run-in, followed by a 24-week double-blind treatment period and a 1-week follow-up after termination of study medication.

## Study participants

Patients  with  T2DM,  pre-treated  with  either  metformin  alone  or  metformin  in  combination  with  one other antidiabetic agent (except pioglitazone, rosiglitazone, insulin) unchanged for at least 10 weeks prior to study were included. A dose of ≥ 1500 mg/day metformin was required for inclusion into the trial.  Minimal required dose of metformin was 1500 mg per day unless the investigator documented patients to be on their maximum tolerated dose.

HbA1c at screening was 7.0% to 10.0% in patients pre-treated on metformin alone and 6.5% to 9.0% in patients pre-treated on metformin in combination with one other antidiabetic agent.

HbA1c at start of run-in was between 7.0% and 10.0%.

<div style=\"page-break-after: always\"></div>

## Treatments

Patients eligible after the run-in period were randomised in 3:1 to either 5 mg linagliptin or placebo.

## Outcome/endpoints

The primary and secondary endpoints are already covered in the general methods section above.

In addition further endpoints were:

-  MTT:  change  from  baseline  for  2-h  post-prandial  glucose  (2hPPG),  glucose  AUC,  insulin  AUC,  Cpeptide AUC, and insulin AUC to glucose AUC ratio.

## Results

## Participant flow

A total of 1268 patients were enrolled and 701 were randomized. The most common reason for not being randomized was not meeting the HbA1c criteria (36.0%).

The highest percentage of randomized study participants were from Asia (39.5%), 26.1% were from Europe, 18.7% from North America and 15.7% from South America.

The premature discontinuation rates were 7.9% in the placebo group and 7.5% in the linagliptin group. The  main  reason  for  premature  discontinuation  was  in  both  groups,  refused  to  continue  trial medication.

Table 32. Disposition of randomised patients -Screened set

|                                               | Placebo N(%)   | Placebo N(%)   | Linagliptin N(%)   | Linagliptin N(%)   |   Total N (%) | Total N (%)   |
|-----------------------------------------------|----------------|----------------|--------------------|--------------------|---------------|---------------|
| Enrolled                                      |                |                |                    |                    |          1268 |               |
| Startedwash-out                               |                |                |                    |                    |           297 |               |
| Startedplaceborun-in                          |                |                |                    |                    |           808 |               |
| Not randomised                                |                |                |                    |                    |           567 |               |
| Randomised                                    | 177            |                | 524                |                    |           701 |               |
| Not treated                                   | 0              |                | 1                  |                    |             1 |               |
| Treated*                                      | 177            | (100.0)        | 523                | (100.0)            |           700 | (100.0)       |
| Not prematurely discontinued trial medication | 163            | 92.1)          | 484                | 92.5)              |           647 | 92.4)         |
| Prematurelydiscontinuedtrialmedication        | 14             | 7.9)           | 39                 | 7.5)               |            53 | 7.6)          |
| Adverse events                                | 3              | 1.7)           | 9                  | 1.7)               |            12 | 1.7)          |
| AEstudydis.worse                              | 1              | 0.6)           | 1                  | 0.2)               |             2 | 0.3)          |
| AE other dis. worse                           | 0              | 0.0)           | 3                  | 0.6)               |             3 | 0.4)          |
| AE other                                      | 2              | 1.1)           | 5                  | 1.0)               |             7 | 1.0)          |
| Lack of efficacy #                            | 0              | 0.0)           | 1                  | 0.2)               |             1 | 0.1)          |
| Non compl._protocol                           | 3              | 1.7)           | 2                  | 0.4)               |             5 | 0.7)          |
| Lost tofollow-up                              | 2              | 1.1)           | 6                  | 1.1)               |             8 | 1.1)          |
| Refused cont.medic.                           | 4              | 2.3)           | 13                 | 2.5)               |            17 | 2.4)          |
| Other                                         | 2              | 1.1)           | 8                  | 1. 5)              |            10 | 1 . 4)        |

## Conduct of the study

There were three global and two local protocol amendments to the original clinical trial protocol. These amendments are not considered as influencing the study results.

No interim analysis was planned or performed for this study.

<div style=\"page-break-after: always\"></div>

## Baseline data

At study start, the main demographic characteristics were as follows [mean (range)]:

-  Age: 56.5 y (21-79), 22.0% of patients were ≥ 65 y,
-  BMI: 29.9 kg/m 2  (19.1-52.3), 43.9 % had a BMI ≥ 30,
-  Diabetes duration: 34.0% had duration of diabetes &gt; 1 to 5 years, 54.9% &gt;5 years.

Overall,  54.1%  of  patients  were  male,  76.1%  were  Caucasian  and  20.9%  were  Asian.  In  both treatment groups, around 20% of the patients were of Hispanic/Latino origin.

Pre-treated patients were mainly on metformin monotherapy (68.6%) or on combination of metformin plus sulfonylurea (26.9%).

59.1% of patients had an eGFR of ≥ 90 mL/min, 37.6% had an eGFR 60 to &lt; 90 mL/min and 3.3% had an eGFR 30 to &lt;60 mL/min.

There were no relevant differences in baseline efficacy variables.

The  study  population  adequately  represents  the  intended  target  population  of  patients  with  T2DM, patients on metformin alone or in combination with one other oral antidiabetic agent with insufficient glycaemic  control.  The  age  group  65  to  74  years  (19.8%  in  the  placebo  group  and  18.7%  in  the linagliptin group) was rather small to reflect the real proportion of T2DM and the group of ≥ 75 years (3.4% placebo and 2.9% linagliptin) was not sufficiently considered.

## Numbers analysed

In both treatment groups, more than 97% of patients were included in the primary FAS analysis and more than 89% in the secondary FAS-completers and PPS analysis. Treatment compliance was 97.7% in the placebo and 96.8% and thus similar between both treatment groups

Table 33. Number of patients by analysis set

|                |                         | Placebo N (%)   | Placebo N (%)   | Linagliptin N (%)   | Linagliptin N (%)   | Total N (%)   | Total N (%)   |
|----------------|-------------------------|-----------------|-----------------|---------------------|---------------------|---------------|---------------|
| Randomised set | Randomised set          | 177 (100.0)     | 177 (100.0)     | 524 (100.0)         | 524 (100.0)         | 701 (100.0)   | 701 (100.0)   |
| Treated set    | N (% of randomised set) | 177 (100.0)     |                 | 523                 | (99.8)              | 700           | (99.9)        |
| FAS            | N (% of randomised set) | 175             | (98.9)          | 513                 | (97.9)              | 688           | (98.1)        |
| FAS-completers | N (% ofFAS)             | 156             | (89.1)          | 468                 | (91.2)              | 624           | (90.7)        |
| PPS            | N (% ofFAS)             | 156             | (89.1)          | 460                 | (89.7)              | 616           | (89.5)        |
| MTT-set        | N (% of FAS)            | 26              | (14.9)          | 85                  | (16.6)              | 111           | (16.1)        |

## Outcomes and estimations

## Primary endpoint

The add-on of 5 mg QD linagliptin to metformin was superior to add-on of placebo to metformin in lowering HbA1c with an adjusted mean treatment difference of -0.64% (p&lt; 0.0001). The unadjusted mean change from baseline in HbA1c showed similar results.

<div style=\"page-break-after: always\"></div>

Table 34. Adjusted means for the change in HbA1c (%) from baseline at Week 24 - FAS (LOCF)

|                                                      | Placebo     | Linagliptin   |
|------------------------------------------------------|-------------|---------------|
| Numberofpatientswithbaseline andon-treatmentresults  | 175         | 513           |
| Baseline                                             |             |               |
| Mean (SE)                                            | 8.02 (0.07) | 8.09 (0.04)   |
| Changefrom baseline                                  |             |               |
| Mean (SE)                                            | 0.10 (0.08) | -0.56 (0.04)  |
| Adjusted* mean (SE)                                  | 0.15 (0.06) | -0.49 (0.04)  |
| Comparison vs. Placebo (diff. Linagliptin - Placebo) |             |               |
| Adjusted* mean (SE)                                  |             | -0.64 (0.07)  |
| 95% confidenceinterval                               |             | (-0.78,-0.50) |
| p-value                                              |             | <0.0001       |

* Model includes continuous baseline HbAlc, prior use of antidiabetic agents, and treatment

SE=Standarderror

In  the  linagliptin  group,  HbA1c  levels  decreased  until  week  12  and  remained  relatively  stable thereafter. In the placebo group, HbA1c levels increased minimally over time.

The  secondary  analysis  PPS  supports  the  results  of  the  primary  analysis,  the  placebo  adjusted treatment effect was: -0.68 [-0.84; -0.53, 95 % CI] p&lt;.0001 for HbA1c (mean diference). The FAScompleters  showed  a  smaller  placebo  adjusted  treatment  effect:  -0.57  [-0.72;  -42,  95  %  CI]  for HbA1c.

Whereas  the  adjusted  mean  HbA1c  change  from  baseline  was  slightly  smaller  for  Asian  than  for European  patients  (-0.49%  vs.  -0.57%,  respectively),  contrasting  results  were  obtained  for  the placebo-adjusted changes (-0.73% vs. -0.51%).

## Secondary endpoints

The add-on of 5 mg QD linagliptin to metformin was superior to add-on of placebo to metformin in lowering FPG with an adjusted mean treatment difference of -21.1 mg/dL (3.1 mmol/L).

More  patients  on  linagliptin  compared  to  placebo  achieved  HbA1c  values  of  &lt;7%  or  &lt;6.5%  or  an HbA1c reduction of ≥ 0.5%.

<div style=\"page-break-after: always\"></div>

Table 35. Number of patients with categorical HbA1c change from baseline at Week 24 -FAS (LOCF)

|                                     | Placebo   | Placebo   | Placebo   | Linagliptin   | Linagliptin   | Linagliptin   |
|-------------------------------------|-----------|-----------|-----------|---------------|---------------|---------------|
|                                     |           | (%)       | N2        |               | (%)           | N2            |
| Response criterion                  |           |           |           |               |               |               |
| HbA1c<7.0%                          | 20        | (11.4)    | 175       | 145           | (28.3)        | 513           |
| AmongpatientswithbaselineHbAlc≥7.o% | 15        | (9.2)     | 163       | 127           | (26.2)        | 485           |
| HbA1c<6.5%                          | 6         | (3.4)     | 175       | 55            | (10.7)        | 513           |
| AmongpatientswithbaselineHbAlc≥7.o% | 4         | (2.5)     | 163       | 47            | (9.7)         | 485           |
| AmongpatientswithbaselineHbAlc≥6.5% | 4         | (2.3)     | 171       | 53            | (10.4)        | 511           |
| HbAicreductionfrombaseline≥0.5%     | 38        | (21.7)    | 175       | 255           | (49.7)        | 513           |

In the MTT subpopulation the treatment difference in adjusted mean change from baseline at week 24 was -67.13 mg/dL (p&lt;0.05) for 2hPPG and -5.35 mmol h/L (p&lt;0.05) for glucose AUC in favour of linagliptin.

The proportion of patients requiring the use of rescue medication was 18.9% in the placebo group and 7.8% in  the  linagliptin  group  (odds  ratio  0.276,  p  &lt;  0.05).  In  addition  linagliptin  patients  required rescue therapy later than placebo patients.

## Other endpoints

The treatment difference in the adjusted means of change from baseline to 24 weeks in body weight was estimated to be 0.04 kg.

## Discussion of the study results

The  results  of  this  study  showed  statistically  significant  and  clinically  relevant  (albeit  moderate) superior efficacy of linagliptin 5 mg as add-on in comparison to placebo add-on in patients with T2DM with  insufficient  glycaemic  control  on  metformin.  Results  of  primary  and  secondary  analyses  were consistent.

Due  to  differences  in  placebo  response,  the  placebo-adjusted  treatment  effect  was  larger  in  Asian patients (-0.73%) than in European patients (-0.51%).

## Study 1218.18

This was a study in patients with T2DM to evaluate the efficacy and safety of linagliptin 5 mg as addon  to  metformin  in  combination  with  a  SU  in  comparison  to  placebo.  Patients  were  treated  in  the following countries: Argentina, Belgium, Canada, China, Germany, Korea, Philippines, Russia, Taiwan, Turkey, and the United Kingdom. The study period was from 25 February 2008 to 21 May 2009.

## Methods

## Design

This was a multinational, randomized, double-blind, placebo-controlled, parallel group study, consisting of an open-label, 2-week placebo run-in, followed by a 24-week double-blind treatment period and a 1-week follow-up after termination of study medication.

<div style=\"page-break-after: always\"></div>

## Study participants

Patients with T2DM, pre-treated only with a stable daily dose of ≥ 1500 mg per day (or documented maximally tolerated dose) of metformin and a maximally tolerated dose of a SU both unchanged for at least 10 weeks prior to study were included.

HbA1c at screening and after the placebo run-in period had to be between 7.0% and 10.0%.

## Treatments

Patients eligible  after  the  run-in  period  were  randomised  in  a  3:1  ratio  to  either  5  mg  linagliptin  or placebo.

## Results

## Participant flow

A total of 1598 patients were enrolled and 1058 were randomized. The most common reason for not being randomized was not fulfilling HbA1c criteria (26 %).

The  highest  percentage  of  randomized  study  participants  were  from  Asia  (50.6%),  whereas  only 18.7% were from Europe and the lowest percentage from North America (8.7%).

The discontinuation rates were 8.0% in the placebo group and 7.3% in the linagliptin group. The main reasons for premature discontinuation were refused to continue trial medication (3%) in the placebo group and adverse events (2.9%) in the linagliptin group.

Table 36. Disposition of randomised patients

|                                               | Placebo N(%)   | Placebo N(%)   | Linagliptin N(%)   | Linagliptin N(%)   |   Total N(%) | Total N(%)   |
|-----------------------------------------------|----------------|----------------|--------------------|--------------------|--------------|--------------|
| Enrolled                                      |                |                |                    |                    |         1598 |              |
| Startedplaceborun-in                          |                |                |                    |                    |         1136 |              |
| Not randomised                                |                |                |                    |                    |          540 |              |
| Randomised                                    | 265            |                | 793                |                    |         1058 |              |
| Not treated                                   | 2              |                | 1                  |                    |            3 |              |
| Treated *                                     | 263            | (100.0)        | 792                | (100.0)            |         1055 | (100.0)      |
| Not prematurely discontinued trial medication | 242            | 92.0)          | 734                | 92.7)              |          976 | 92.5)        |
| Prematurely discontinued trial medication     | 21             | 8.0)           | 58                 | 7.3)               |           79 | 7.5)         |
| Adverseevents                                 | 5              | 1.9)           | 23                 | 2.9)               |           28 | 2.7)         |
| AEstudydis.worse                              | 1              | 0.4)           | 3                  | 0.4)               |            4 | 0.4)         |
| AE other dis.worse                            | 1              | ( 0.4)         | 4                  | 0.5)               |            5 | 0.5)         |
| AE other                                      | 3              | 1.1)           | 16                 | 2.0)               |           19 | 1.8)         |
| Lack of efficacy #                            | 4              | 1.5)           | 2                  | 0.3)               |            6 | 0.6)         |
| Non compl.protocol                            | 4              | 1.5)           | 19                 | 2.4)               |           23 | 2.2)         |
| Lost to'follow-up                             | 0              | ( 0.0)         | 0                  | 0.0)               |            0 | 0.0)         |
| Refused cont.medic.                           | 8              | 3.0)           | 14                 | 1.8)               |           22 | 2.1)         |
| Other                                         | 0              | ( 0.0)         | 0                  | 0.0)               |            0 | 0.0)         |

## Conduct of the study

There were three global and six local protocol amendments to the original clinical trial protocol. These amendments performed during the study are not considered as influencing the study results.

<div style=\"page-break-after: always\"></div>

No interim analysis was planned or performed for this study.

## Baseline data

At study start, the main demographic characteristics were as follows [mean (range)]:

-  Age: 58.1 y (23-79), 27.3% of patients were ≥ 65 y,
-  BMI:  28.33 kg/m 2  (15.75-39.97), 32% had a BMI ≥ 30,
-  Diabetes duration: 23.9% had duration of diabetes &gt; 1 to 5 years, 73.3% &gt;5 years.

Overall,  47.2%  of  patients  were  male,  46.6%  were  Caucasian  and  51.7%  were  Asian.  In  both treatment groups, around 22% of the patients were of Hispanic/Latino origin.

57.0% had an eGFR ≥ 90 and 5% an eGFR 30 to &lt;60 mL/min.

There  were  no  relevant  differences  in  mean  values  of  baseline  characteristics  including  efficacy variables.

The study population adequately represents the intended target population of patients with T2DM with an insufficient glycaemic control despite a background therapy of metformin and a SU. However, the very elderly subgroup of T2DM of ≥ 75 years (3.0% placebo and 4.8% linagliptin) was not sufficiently considered.

## Numbers analysed

In both groups, over 98% of patients were included in the primary FAS analysis, over 93% in the PPS analysis and over 90% in the FAS-completers analysis (see table below). Treatment compliance was 96.5% in the placebo and 97.8% in the linagliptin group.

Table 37. Number of patients by analysis set

|                | Placebo N (%)   | Linagliptin N (%)   | Total N (%)   |
|----------------|-----------------|---------------------|---------------|
| Randomised     | 265 (100.0)     | 793 (100.0)         | 1058 (100.0)  |
| Treated        | 263 (99.2)      | 792 (99.9)          | 1055 (99.7)   |
| FAS            | 262 (98.9)      | 778 (98.1)          | 1040 (98.3)   |
| FAS-completers | 236 (90.1)      | 725 (93.2)          | 961 (92.4)    |
| PPS            | 246 (93.9)      | 733 (94.2)          | 979 (94.1)    |

## Outcomes and estimations

## Primary endpoint

The  add-on  of  5  mg  QD  linagliptin  to  metformin  and  a  SU  was  superior  to  add-on  of  placebo  in lowering HbA1c resulting in mean adjusted mean treatment difference of -0.62%.

<div style=\"page-break-after: always\"></div>

Table 38. Adjusted means for the change in HbA1c (%) from baseline at Week 24 - FAS (LOCF)

|                                                           | Placebo      | Linagliptin   |
|-----------------------------------------------------------|--------------|---------------|
| Number of patients                                        | 262 (100.0)  | 778 (100.0)   |
| Number ofpatientswithbaseline and on-treatment results    | 262 (100.0)  | 778 (100.0)   |
| Baseline                                                  |              |               |
| Mean (SE)                                                 | 8.14 (0.05)  | 8.15 (0.03)   |
| Change from baseline                                      |              |               |
| Mean (SE)                                                 | -0.10 (0.05) | -0.72 (0.03)  |
| Adjusted mean (SE)                                        | -0.10 (0.05) | -0.72 (0.03)  |
| Comparison vs. placebo (difference linagliptin - placebo) |              |               |
| Adjusted mean (SE)                                        |              | -0.62 (0.06)  |
| 95%Confidenceinterval                                     |              | (-0.73,-0.50) |
| p-value                                                   |              | <0.0001       |

SE =Standard error

The  secondary  PPS  analysis  supports  the  results  of  the  primary  analysis,  the  placebo  adjusted treatment effect was: -0.61 [-0.73; -0.49, 95 % CI] p&lt;.0001) for HbA1c (mean difference).

The  FAS-completers  showed  a  smaller  placebo  adjusted  treatment  effect  [95%CI]:  -0.54  [-0.66;  0.42] p&lt;.0001 for HbA1c.

HbA1c results were similar in patients on metformin doses ≥ 1500 mg and &lt;1500 mg.

Whereas the adjusted mean HbA1c change from baseline was similar for Asian and European patients (-0.69%  vs.  -0.63%,  respectively),  placebo-adjusted  changes  were  not  (-0.69%  vs.  -0.47%, respectively).

No significant effect of the baseline metformin dose was observed on HbA1c in this trial.

## Secondary endpoints:

The add-on of 5 mg QD linagliptin to metformin and a SU was superior to the add-on of placebo in lowering FPG resulting with an adjusted mean treatment difference of -12.7 mg/dL (2.8 mmol/L). The results were confirmed by the secondary FAS-completer analysis.

A larger proportion of patients in the linagliptin compared to the placebo group achieved HbA1c levels &lt; 7% or &lt; 6.5% or HbA1c reduction ≥ 0.5% (see table below).

<div style=\"page-break-after: always\"></div>

Table 39. Number of patients with categorical HbA1c change from baseline at Week 24 -(NCF) - FAS

|                                          | Placebo   | Placebo   | Placebo   | Linagliptin   | Linagliptin   | Linagliptin   |
|------------------------------------------|-----------|-----------|-----------|---------------|---------------|---------------|
|                                          | n         | (%)       | N2        | n             | (%)           | N2            |
| Response criterion                       |           |           |           |               |               |               |
| HbA1c<7.0%                               | 24        | (9.2)     | 262       | 243           | (31.2)        | 778           |
| Among patients with baseline HbAic ≥7.0% | 20        | (8.1)     | 247       | 217           | (29.2)        | 742           |
| HbA1c<6.5%                               | 11        | (4.2)     | 262       | 102           | (13.1)        | 778           |
| Among patients with baseline HbAic ≥7.0% | 8         | (3.2)     | 247       | 85            | (11.5)        | 742           |
| Among patients with baseline HbAic ≥6.5% | 11        | (4.2)     | 262       | 102           | (13.1)        | 777           |
| HbAic reduction from baseline ≥0.5%      | 79        | (30.2)    | 262       | 453           | (58.2)        | 778           |

The number of patients requiring rescue therapy was 34 (13.0%) in the placebo group and 42 (5.4%) in the linagliptin group (odds ratio: 0.361, p&lt;0.0001). The median time to start of rescue therapy was shorter (119 days) for patients under placebo than for patients under linagliptin treatment (132 days).

## Other endpoints

No meaningful change in body weight was noted in both treatment groups.

## Discussion of the study results

In  the  present  study,  linagliptin  add-on  at  a  dose  of  5  mg  q.d.  provided  statistically  significant  and clinically  relevant  (albeit  modest)  improvement  in  glycaemic  control  compared  to  placebo  add-on  in patients  with  T2DM not sufficiently  controlled  on  metformin  and  a  sulfonylurea.  The  superiority  was reflected  in  all  glycaemic  parameters  evaluated  and  the  proportion  of  patients  requiring  rescue therapy.

Due to differences  in  placebo  response,  the  placebo-adjusted  treatment  effect,  again,  was  larger  in Asian patients (-0.69%) than in European patients (-0.47%).

## Metformin

Antidiabetic  therapy  with  metformin  is  associated  with  dose-related  reductions  in  HbA 1c and  FPG. According to literature data, treatment with metformin 500 to 2000 mg per day decreases HbA1c levels by 0.4% to 2.0% and decreases FPG levels by 5.4 to 68.4 mg/dL.

No additional clinical  efficacy  studies  have  been  conducted  for  metformin as  monotherapy  However, efficacy  data  for  metformin  monotherapy  are  available  from  the  placebo-controlled  trials  for  the combination therapy with linagliptin and metformin, where metformin was taken either as background therapy as in studies 1218.17 and 1218.62 or as study medication as in study 1218.46 (metformin 500 mg  bid  or  1000  mg  bid).  Placebo-controlled  efficacy  data  for  metformin  monotherapy  from  study 1218.46  are  shown  in  the  table  below.  After  24  weeks  of  treatment,  both  metformin  doses  led  to reductions in HbA1c and FPG that were consistent with literature data.

<div style=\"page-break-after: always\"></div>

Table 40. Change from baseline  in  HbA1c  [%]  and  FPG  [mg/dL]  for  metformin  groups  in study 1218.46 - FAS (LOCF)

|                         | Numbe          |                     | Change from baseline             | Change from baseline             | Difference to placebo            | Difference to placebo            | Difference to placebo            |
|-------------------------|----------------|---------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Study/ treatmen t group | r of patient s | Baseline, mean (SD) | Mean (SD)                        | Adjusted mean (SE)               | Adjusted mean (SE)               | 95% CI                           | p- value                         |
| 1218.46 / a             |                |                     | Endpoint assessed after 24 weeks | Endpoint assessed after 24 weeks | Endpoint assessed after 24 weeks | Endpoint assessed after 24 weeks | Endpoint assessed after 24 weeks |
| HbA 1c                  |                |                     |                                  |                                  |                                  |                                  |                                  |
| Placebo                 | 65             | 8.67 (0.95)         | 0.13 (1.17)                      | 0.13 (0.11)                      |                                  |                                  |                                  |
| Met500                  | 141            | 8.66 (0.90)         | -0.63 (1.05)                     | -0.64 (0.08)                     | -0.77 (0.14)                     | (-1.04, -0.50)                   | <0.000 1                         |
| Met 1000                | 138            | 8.52 (0.87)         | -1.02 (1.01)                     | -1.07 (0.08)                     | -1.20 (0.14)                     | (-1.47, -0.93)                   | <0.000 1                         |
| FPG                     |                |                     |                                  |                                  |                                  |                                  |                                  |
| Placebo                 | 61             | 203.3 (51.5)        | 6.0 (55.8)                       | 10.2 (5.26)                      |                                  |                                  |                                  |
| Met500                  | 136            | 190.6 (46.6)        | -13.4 (52.5)                     | -15.8 (3.52)                     | -26.0 (6.34)                     | (-38.4, -13.5)                   | <0.000 1                         |
| Met 1000                | 132            | 190.6 (52.2)        | -30.2 (42.9)                     | -32.2 (3.58)                     | -42.3 (6.37)                     | (-54.8, -29.8)                   | <0.000 1                         |

## Linagliptin/metformin

## Study 1218.46

## Methods

## Design, randomisation, blinding and treatment

This  was  a  phase  3  multinational,  randomised,  double-blind,  placebo-controlled,  parallel  group, factorial  design  study  to  compare  the  efficacy  and  safety  of  twice  daily  administration  of  the  free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg, with the individual components of metformin (500 mg or 1000 mg, twice daily) and linagliptin (5 mg, once daily) over 24 weeks in drug naïve (47.5%) or previously treated (4 weeks washout and 2 weeks placebo  run-in)  T2DM  patients  with  insufficient  glycaemic  control.  The  study  period  was  from  5 December 2008 to 26 May 2010.

Patients  who  met  the  trial  eligibility  criteria  at  the  end  of  the  2-week  placebo  run-in  period  were randomly assigned to one of the treatment groups in a 1 (placebo):2:2:2:2:2 ratio. Randomisation was stratified by baseline A1C and number of prior oral antidiabetic drug (OADs).

All  subjects  were  randomly  assigned  to  double  blind  study  drug  utilizing  a  double-dummy  design  to ensure adequate blinding.

Subjects  with  baseline  HbA1C  of ≥ 11% were enrolled  into  an  open-label  arm.  Details  of  the  study design are given in the figure below.

Patients who regularly completed the randomised period of this study were offered to participate in an extension trial (study 1218.52).

<div style=\"page-break-after: always\"></div>

Figure 2. Overview of the study design

<!-- image -->

## Study Participants

## Main inclusion criteria

-  Male  and  non-fertile  or  contraceptive-using  female  patients  age ≥ 18  and ≤ 80  with  T2DM, either  treatment  naïve  or  previously  treated  with  not  more  than  one  oral  antidiabetic  drug. Antidiabetic therapy had to be unchanged for 10 weeks prior to the date of informed consent.
-  HbA1C  at  screening  for  patients  undergoing  washout  of  previous  antidiabetic  medication: HbA1C ≥ 7.0 to ≤ 10.5%, for patients not undergoing washout: A1C ≥ 7.5 to &lt;11.0%
-  HbA1C at start of run-in: ≥ 7.5 to &lt;11.0%
-  Body mass index (BMI) ≤ 40 kg/m 2

## Main exclusion criteria

-  MI, stroke, or TIA within 6 months prior to the date of informed consent
-  Impaired hepatic function, defined as serum levels of either alanine transaminase (ALT/SGPT), aspartate transaminase (AST/SGOT), or alkaline phosphatase (ALP) above 3x the upper limit of normal (ULN)
-  Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, insulin, or anti-obesity drugs (e.g. sibutramine, rimonabant, orlistat) within 3 months prior to the date of informed consent
-  Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent
-  Renal failure or renal impairment at screening (estimated glomerular filtration rate[eGFR] &lt;60 mL/min)
-  Gastric bypass

<div style=\"page-break-after: always\"></div>

-  Dehydration by clinical judgement of the investigator
-  Unstable or acute congestive heart failure
-  Acute or chronic metabolic acidosis (present in patient history)
-  Hereditary galactose intolerance.

## Outcomes/endpoints

## Primary endpoint :

The primary endpoint was change in HbA1C from baseline to week 24.

Secondary endpoints:

-  Change from baseline in FPG at Week 24
-  Responder rates: HbA1C&lt; 7.0% and  &lt; 6.5%
-  Reduction in HbA1C ≥ 0.5%
-  Change from baseline in 2h PPG at Week 24
-  Use of rescue medication

## Objectives, statistical methods and sample size

The trial was designed to demonstrate superiority of the 2 free combination treatments consisting of different doses of linagliptin plus metformin over the individual components with regards to change in HbA1C.

Sample size was calculated to detect a true difference (deltas) in mean change from baseline A1C for the individual treatment-comparisons as follows:

-  Linagliptin plus metformin 500 mg vs. linagliptin: -0.8%
-  Linagliptin plus metformin 1000 mg vs. linagliptin: -1.0%
-  Linagliptin plus metformin 500 mg vs. metformin 500 mg: -0.5%
-  Linagliptin plus metformin 1000 mg vs. metformin 1000 mg: -0.5%
-  Linagliptin vs. placebo: -0.5%
-  Metformin 500 mg vs. placebo: -0.8%
-  Metformin 1000 mg vs. placebo: -1.0%

for a two tailed test at α = 0.05 with a power of &gt;90%.

A standard deviation (SD) for HbA1C change from baseline of 1.1% was used for the calculation of the sample size.

## Randomised part

Primary  endpoint:  4  confirmatory  hypotheses  in  regard  to  the  HbA1C  change  from  baseline  were tested. These hypotheses were ordered hierarchically and tested sequentially at the level of α = 0.05 (2-sided).

-  superiority of linagliptin 2.5 mg bid + metformin 1000 mg bid versus metformin 1000 mg bid
-  superiority of linagliptin 2.5 mg bid + metformin 1000 mg bid versus linagliptin 5 mg qd

<div style=\"page-break-after: always\"></div>

-  superiority of linagliptin 2.5 mg bid + metformin 500 mg bid versus metformin 500 mg bid
-  superiority of linagliptin 2.5 mg bid + metformin 500 mg bid versus linagliptin 5 mg qd

with  an  analysis  of  covariance  (ANCOVA)  with  treatment  and  prior  use  of  antidiabetic  therapy  as factors and baseline HbA1C as covariate.

A  last  observation  carried  forward  (LOCF)  approach  was  used  to  replace  missing  data.  In  general, baseline values were not carried forward, but could be used for interpolation.

Additional sensitivity analyses were performed (e.g. MMRM and observed cases approach).

Safety endpoints: descriptive statistics, for hypoglycaemic events logistic regression and Kaplan-Meier analysis.

Secondary  and  other  endpoints:  ANCOVA  (exploratory),  descriptive  statistics,  for  use  of  rescue medication logistic regression and Kaplan-Meier analysis.

## Open-label arm

Primary and secondary endpoint were descriptive statistics.

The main analysis sets used were as outlined in the table below. All efficacy analyses were based on FAS and safety analysis on TS.

| Analysis set            | Definition                                                                                                                                                        |
|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Full analysis set (FAS) | All randomised patients who received at least one dose of study medication, had a baseline HbAie measurement, and had at least one on-treatment HbAie measurement |
| Per-protocol set (PPS)  | All patients in the FAS who did not have any important protocol violations that had an impact on the efficacy evaluation                                          |
| FAS-completers          | All patients in the FAS who completed a required minimum treatment duration and did not prematurely discontinue the trial                                         |
| PPS-completers          | All patients in the PPS who completed a required minimum treatment duration and did not prematurely discontinue the trial                                         |
| MTT-set                 | All patients in the FAS with a valid MTT at baseline and at least one valid on-treatment MTT                                                                      |

TS-set

All patients who received at least one dose of study medication.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Table 41. Disposition of randomised patients - Screened set

|                                               | Placebo N(%)       | Lina 5 N (%)       | Met 500 N (%)             | Met 1000 N (%)   |
|-----------------------------------------------|--------------------|--------------------|---------------------------|------------------|
| Emrolled                                      |                    |                    |                           |                  |
| Randomised                                    | 72                 | 142                | 144                       | 147              |
| Treated'                                      | 72 (100.0)         | 142 (100.0)        | 144 (100.0)               | 147 (100.0)      |
| Not prematurely discontinued trial medication | 54 (75.0)          | 121 (85.2)         | 127 (88.2)                | 126 ($5.7)       |
| Prematurely discontinued tial medication      | 18 (25.0)          | 21 (14.8)          | 17 (11.8)                 | 21 (14.3)        |
| Adverse events                                | 3 (4.2)            | 6 (4.2)            | 4 (2.8)                   | 6 (4.1)          |
| Study disease worsening                       | 1 (1.4)            | 0 (0.0)            | 0 (0.0)                   | 1 (0.7)          |
| Other disease worsening                       | 0 (0.0)            | 1 (0.7)            | 1 (0.7)                   | 0 (0.0)          |
| Other AEs                                     | 2 (2.8)            | 5 (3.5)            | 3 (2.1)                   | 5 (3.4)          |
| Lack of efficacy                              | 6 (8.3)            | 3 (2.1)            | 4 (2.8)                   | 2 (1.4)          |
| Non-compliance to the protocol                | 2 (2.8)            | 3 (2.1)            | 1 (0.7)                   | 3 (2.0)          |
| Lost to follow-up                             | 1 (1.4)            | 3 (2.1)            | 3 (2.1)                   | 4 (2.7)          |
| Refusal to continue hial medication           | 5 (6.9)            | 4 (2.8)            | 4 (2.8)                   | 5 (3.4)          |
| Other reason                                  | 1 (1.4)            | 2 (1.4)            | 1 (0.7)                   | 1 (0.7)          |
| (%) N                                         | Lina 2.5 + Met 500 | Lina 2.5 + Met 500 | Lina 2.5 + Met 1000 N (%) | Total (%) N      |
| Emrolled                                      |                    |                    |                           | 1770             |
| Randomised                                    | 143                | 143                | 143                       | 791              |
| Treated'                                      | 143 (100.0)        | 143 (100.0)        | 143 (100.0)               | 791 (100.0)      |
| Not prematurely discontinued tial medication  | 127 (88.8)         | 127 (88.8)         | 132 (92.3)                | 687 (86.9)       |
| Prematurely discontinued tial medication      | 16 (11.2)          | 16 (11.2)          | 11 (7.7)                  | 104 (13.1)       |
| Adverse events                                | 5 (3.5)            | 5 (3.5)            | 2 (1.4)                   | 26 (3.3)         |
| Study disease worsening                       | 0 (0.0)            | 0 (0.0)            | 0 (0.0)                   | 2 (0.3)          |
| Other disease worsening                       | 0 (0.0)            | 0 (0.0)            | 0 (0.0)                   | 2 (0.3)          |
| Other AEs                                     | 5 (3.5)            | 5 (3.5)            | 2 (1.4)                   | 22 (2.8)         |
| Lack of efficacy                              | 1 (0.7)            | 1 (0.7)            | 2 (1.4)                   | 18 (2.3)         |
| Non-compliance to the protocol                | 3 (2.1)            | 3 (2.1)            | 2 (1.4)                   | 14 (1.8)         |
| Lost to follow-up                             | 4 (2.8)            | 4 (2.8)            | 0 (0.0)                   | 15 (1.9)         |
| Refusal to continue trial medication          | 2(1.4)             | 2(1.4)             | 3 (2.1)                   | 23 (2.9)         |
| Other reason                                  | 1 (0.7)            | 1 (0.7)            | 2 (1.4)                   | 8 (1.0)          |

Note: if combined with metfonmin 500 mg or 1000 mg, linagliptin was administered as 2.5 mg b.i.d.

Includes patients who discontinued due to hyperglycaemia

## Conduct of the study

In total, 54 patients (6.8%) ranging from 2 patients (1.4%) in the Met 500 mg group to 17 patients (11.6%) in the Met 1000 mg group, were reported with protocol violations (PVs) related to efficacy (no PVs related to safety) that led to exclusion from the Per-Protocol-Set (PPS). The PVs were related to entrance  criteria  not  met,  trial  medication  and  randomisation,  concomitant  medication,  and  missing data. In the open label arm 21 patients (31.8%) reported PVs.

According to the clinical stuyd report, there were a few protocol amendments mainly related to the level of HbA1C at inclusion.

<div style=\"page-break-after: always\"></div>

During the course of the study, concerns were expressed about the overall quality of the source data documentation and study conduct at one German site. As a result from these concerns, the site was closed prematurely in the course of the extension study 1218.52. It was decided to include the data of these patients in the study analysis of 1218.46, as the audit findings were unlikely to affect the overall validity of the study data. There were no acute safety concerns for the patients.

## Study 1218.62

This  study  was  performed  on  request  of  the  CHMP.  It  was  a  randomised,  double-blind,  placebocontrolled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type  2  diabetes  mellitus  and  insufficient  glycaemic  control  HbA1c ≥ 7.0-≤ 10.0%)  on  metformin  (at least 1500 mg/day, bid or maximum tolerated dose if lower than this). Patients had to be between 18 and  80  years  of  age  and  had  to  have  a  BMI  up  to  45  kg/m 2 .  Metformin  was  administered  as background  therapy  in  an  unchanged  total  daily  dosage  throughout  the  trial  (including  wash-out, placebo run-in, 12-week randomised treatment, and follow-up phases).

The primary endpoint was the change from baseline in HbA1c. The primary analysis was performed on the full analyses set (FAS), with a last observation carried forward (LOCF) approach used to replace missing data. Important secondary endpoints were the change from baseline in fasting plasma glucose (FPG) and the occurrence of treat-to-target response (i.e. HbA1c on treatment &lt;7.0%).

## Subject disposition

A  total  of  771  patients  were  enrolled,  491  patients  were  randomised  in  a  1:5:5  ratio  to  receive treatment with either placebo (44 patients), linagliptin 2.5 mg twice daily (223 patients) or linagliptin 5 once daily (224 patients). Of the 491 patients treated with randomised study medication, 464 patients (94.5%)  completed  the  planned  12-week  treatment  period  and  27  patients  (5.5%)  prematurely discontinued the trial medication. The rate of premature discontinuations was higher in the linagliptin 2.5 bid group (7.2%) compared to the linagliptin 5 qd and placebo treatment groups (4.5% and 2.3%, respectively). In the placebo group, one of the 44 treated patients discontinued (cause: Other). In the linagliptin 2.5 bid group, the most frequent reasons for premature discontinuation were due to adverse events  (3.6%),  refusal  to  continue  trial  medication  (1.8%),  and  non-compliance  with  the  protocol (1.3%). In the linagliptin 5 qd group, the most frequent reasons were due to non-compliance with the protocol (2.2%) and adverse events (1.3%).

## Baseline data

More  than  half  of  the  population  was  male  (total  57.0%).  Nearly  two  thirds  of  the  population  was White  (total  65.4%)  and  about  one  third  was  Asian  (total  33.8%).  The  mean  age  was  58.6  years (total) with the largest proportion of patients being 65 years of age or younger (total 69.5%). All three treatment groups had comparable distribution of patients across age groups. In total, the mean weight was  81.0  kg  and  the  mean  BMI  was  29.6  kg/m 2 .  Almost  three-quarters  of  the  patients  were  pretreated  with  metformin  monotherapy  (71.3%  total),  with  comparable  percentages  seen  across treatment groups. A total of 28.7% of patients were pre-treated with combination therapy (metformin and 1 'other' OAD) prior to study entry and underwent a washout period for the 'other' OAD.

<div style=\"page-break-after: always\"></div>

## Outcome and estimation

## HbA1c

In study 1218.62, the baseline mean HbA1c percent values were comparable between the treatment groups and the overall mean HbA1c was 7.97%. The adjusted mean treatment difference in HbA1c change from baseline to Week 12 for linagliptin 2.5 twice daily over placebo was -0.74% (95% CI 0.97, -0.52), p&lt;0.0001, Table 5 upper panel). For linagliptin 5 mg over placebo the adjusted mean difference was -0.80% (95% CI -1.02, -0.58), p&lt;0.0001). The adjusted mean treatment difference for linagliptin  2.5  mg  twice  daily  vs.  linagliptin  5  mg  once  daily  was  0.06%  (95%  CI  -0.07,  0.19), indicating  non-inferiority  as  the  upper  bound  of  the  95%  confidence  interval  was  below  the  prespecified margin of 0.35% (see figure below).

Table 42. Changes from baseline in HbA1c [%] in trials 1218.62, 1218.46 - FAS (LOCF)

|                                            | Change from baseline                                             | Difference                                                       |                                                                  |                                                                  |
|--------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Study Treatment groups                     | Adjusted a mean (SE)                                             | Adjusted a mean (SE)                                             | 95% CI                                                           | p-value                                                          |
| 1218.62                                    |                                                                  | Difference between treatments 12 weeks treatment                 | Difference between treatments 12 weeks treatment                 | Difference between treatments 12 weeks treatment                 |
| Met                                        | 0.28 (0.11)                                                      |                                                                  |                                                                  |                                                                  |
| Lina 5 mg qd + Met vs Met                  | -0.52 (0.05)                                                     | -0.80 (0.11)                                                     | (-1.02, -0.58)                                                   | <0.0001                                                          |
| Lina 2.5 mg bid + Met vs Met               | -0.46 (0.05)                                                     | -0.74 (0.11)                                                     | (-0.97, -0.52)                                                   | <0.0001                                                          |
| Lina 2.5 mg bid + Met vs Lina 5mg qd + Met |                                                                  | 0.06 (0.07)                                                      | (-0.07, 0.19)                                                    | 0.3834                                                           |
| 1218.46                                    | Difference between combination and components 24 weeks treatment | Difference between combination and components 24 weeks treatment | Difference between combination and components 24 weeks treatment | Difference between combination and components 24 weeks treatment |
| Placebo                                    | 0.13 (0.11)                                                      |                                                                  |                                                                  |                                                                  |
| Lina 2.5 mg bid + Met 500 mg bid           | -1.22 (0.08)                                                     |                                                                  |                                                                  |                                                                  |
| Met 500 mg bid                             | -0.64 (0.08)                                                     | -0.58 (0.11)b                                                    | (-0.79, -0.36)                                                   | <0.0001                                                          |
| Lina 5 mg qd                               | -0.45 (0.08)                                                     | -0.77 (0.11)c                                                    | (-0.99, -0.55)                                                   | <0.0001                                                          |
| Lina 2.5 mg bid + Met 1000 mg bid          | -1.59 (0.08)                                                     |                                                                  |                                                                  |                                                                  |
| Met 1000 mg bid                            | -1.07 (0.08)                                                     | -0.51 (0.11)d                                                    | (-0.73, -0.30)                                                   | <0.0001                                                          |
| Lina 5 mg qd                               | -0.45 (0.08)                                                     | -1.14 (0.11)e                                                    | (-1.36, -0.92)                                                   | <0.0001                                                          |

Glim = glimepiride; Met = metformin; Lina 5 mg, Lina = linagliptin 5 mg; Lina 2.5 mg = linagliptin 2.5 mg

a Model includes continuous baseline HbA1c, prior use of antidiabetic drugs, and treatment

b Difference between Lina 2.5 mg + Met 500 mg bid and Met 500 mg bid;

c Difference between Lina 2.5 mg + Met 500 mg bid and Lina 5 mg qd d Difference between Lina 2.5 mg + Met 1000 mg bid and Met 1000 mg bid

e Difference between Lina 2.5 mg + Met 1000 mg bid and Lina 5 mg qd

<div style=\"page-break-after: always\"></div>

Figure 3. Adjusted HbA1c (%) mean change from baseline over time in study 1218.62 - FAS (OC)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Study 1218.46 yielded qualitatively similar results to other studies described above (pivotal studies for the  linagliptin  MAA),  mean  baseline  HbA1c  values  were  comparable  between  the  treatment  groups, ranging from 8.52  % in patients treated with metformin 1000 mg to 8.71% in patients treated with linagliptin  2.5  mg  +  metformin  500  mg.  The  linagliptin  +  metformin  groups  were  superior  to  both metformin monotherapy groups and also to linagliptin monotherapy. The mean treatment difference in HbA1c  from  baseline  to  Week  24  was  -0.51%  for  the  free  combination  of  linagliptin  2.5    mg  + metformin 1000 mg compared to the individual component metformin 1000 mg, -1.14% for the free combination of linagliptin 2.5 mg + metformin 1000 mg compared to linagliptin 5mg, -0.58% for the free  combination  of  linagliptin  2.5    mg+  metformin  500  mg  compared  to  the  individual  component metformin 500 mg, and -0.77% for the free combination of linagliptin 2.5 mg+ metformin 500 mg compared to linagliptin  5  mg  (see  figure  below).  In  this  study,  linagliptin  was  investigated  in  initial combination with metformin. At least half of the patients was not treated with oral antidiabetic drugs before inclusion in the study. This is not in line with the requested indication for linagliptin/metformin in patients that are insufficiently controlled with metformin or metformin in combination with SU. The inclusion  of  treatment  naive  patients  resulted  in  an  overestimation  of  the  treatment  effects  of metformin in this study. Nevertheless, the treatment effects of linagliptin were similar in patients that were pretreated and those that were treatment naive. In this study, the treatment effect of linagliptin 2.5 mg twice daily was smaller in Asians compared to Whites (-0.42% vs. -0.65% in combination with metformin 500 mg;-0. 39% vs. -0.59% in combination with metformin 1000 mg).

Figure 4. Unadjusted mean HbA1c (%) and SE over time in study 1218.46 - FAS (LOCF)

<!-- image -->

Results  of  other  glycaemic  parameters,  such  as  patients  reaching  their  goal  HbA1c,  fasting  plasma glucose, were in line with HbA1c results.

<div style=\"page-break-after: always\"></div>

## Body weight

In study 1218.17 and 1218.18, the effect of combination therapy was shown to be neutral in regard to body weight. In study 1218.20, after 104 weeks of treatment, a decrease in body weight was noted in the linagliptin + metformin group as opposed to a weight gain in the glimepiride + metformin group (treatment difference of -2.7 kg (p &lt;0.0001)). In study 1218.46 and its extension study 1218.52 as well as in study 1218.62, the mean changes in body weight were between -1.1 kg and -0.01 kg across all treatment groups.

## Subgroup analyses

The 24-week trials 1218.17 and 1218.46 were pooled (n=1244). For most subgroups investigated, the treatment effect was consistent and the achieved changes from baseline in HbA1c were comparable across all subcategories. Thus, the factors age, gender, ethnicity, geographical region, baseline BMI, and  baseline  HbA1c  did  not  have  an  influence  on  the  efficacy  of  the  combination  therapy  with linagliptin + metformin. The treatment effect of linagliptin + metformin compared with metformin was almost identical in Europe (n=442) and in Asia (n=446) with HbA1c changes of -0.56% (Europe) and 0.59% (Asia), and p-values below 0.0001. Likewise, for race there was no difference between White (0.61%)  and  Asian  (-0.57%)  patients  in  the  efficacy  of  linagliptin  +  metformin  compared  with metformin (p&lt;0.0001 for both races). Treatment effects were smaller, but acceptable in patients with prior OADs and a longer time since diagnosis of diabetes. Patients with hepatic impairment were also not investigated in sufficient amount. The number of patients aged 75 years or above was very low (in the  grouping  of  1218.17  and  1218.46  only  24  patients  &gt;75  years  were  included).  It  is  difficult  to estimate the effect of linagliptin on HbA1c in elderly patients. During the evaluation, a study in elderly patients  was  submitted  (1218.63).  This  study  was  a  phase  III  multi-national,  randomised,  doubleblind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally  once daily over 24 weeks in type 2 diabetic (T2DM) patients, age ≥ 70 years, with insufficient glycaemic control (HbA1c ≥ 7.0%) despite metformin and/or sulphonylurea (SU) and/or insulin therapy. 241 patients  were  randomised  in  a  2:1  ratio  to  receive  treatment  either  with  linagliptin  5  mg  (162 patients) or placebo (79 patients). Mean age was 74.9±4.3 years. The estimated treatment difference between  linagliptin  (n=160)  and  placebo  (n=78),  calculated  as  the  adjusted  mean  change  from baseline  in  HbA1c  at  Week  24,  was  -0.64%  (95%  CI  [-0.81;  -0.48],  p&lt;0.0001),  demonstrating superiority of linagliptin over placebo in the reduction of HbA1c.

## Trials with a longer treatment duration

Long term efficacy of linagliptin in combination with metformin was investigated in the double blind extension of study 1218.46 (study 1218.52). Throughout the entire treatment duration of 78 weeks, the linagliptin 2.5 mg + metformin 1000 mg combination achieved greater reductions in mean HbA1c than  the  metformin  1000  bid  group.  In  addition,  the  proportion  of  patients  who  required  rescue medication up to Week 78 was lower in the linagliptin 2.5+ metformin1000 mg bid group (12.6%) than in the metformin 1000 mg bid group (22.9%).

<div style=\"page-break-after: always\"></div>

Figure 5. Mean  change  from  baseline  in  HbA1c  [%]  over  time  in  the  combined  studies 1218.46 and 1218.52 - FAS (OC)

<!-- image -->

Long term efficacy of linagliptin 5 mg in combination with metformin or metformin with SU was also investigated  in  study  1218.40,  the  open-label  extension  of  study  1218.17  and  1218.18.  Interim analyses were presented in the MAA for Trajenta (linagliptin). New interim analyses provided efficacy data for  linagliptin  up  to  102  weeks.  The  decrease  in  HbA1c  was  maintained  in  the  individuals  that continued the use of linagliptin  with metformin. However, 38.7% of the patients using linagliptin in combination with metformin required rescue medication, and 33.8% of the patients using linagliptin in combination  with  metformin  and  SU  required  rescue  medication.  The  relatively  large  proportion  of patients  requiring  rescue  medication  in  the  extension  trials  in  comparison  to  the  initial  trials  was  a concern.  However,  it  is  conceivable  that  this  is  explained  by  the  low  threshold  for  the  initiation  of rescue therapy, the long study duration and the fact that the extension trials also allowed entry for patients who already received rescue medication in the initial trials.

## Summary of main studies

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 1. Summary of Efficacy for trial 1218.17

| Title: A randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of linagliptin (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy   | Title: A randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of linagliptin (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy                                                                                           | Title: A randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of linagliptin (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy                                                                                           | Title: A randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of linagliptin (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy                                                                                           | Title: A randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of linagliptin (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                               | 1218.17 [U09-2533]                                                                                                                                                                                                                                                                                                                                     | 1218.17 [U09-2533]                                                                                                                                                                                                                                                                                                                                     | 1218.17 [U09-2533]                                                                                                                                                                                                                                                                                                                                     | 1218.17 [U09-2533]                                                                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                         | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                                                                                                                                                | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                                                                                                                                                | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                                                                                                                                                | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                         | Duration of main phase:                                                                                                                                                                                                                                                                                                                                | Duration of main phase:                                                                                                                                                                                                                                                                                                                                | 24-week treatment period with linagliptin 5 mg or placebo as add-on therapy to metformin                                                                                                                                                                                                                                                               | 24-week treatment period with linagliptin 5 mg or placebo as add-on therapy to metformin                                                                                                                                                                                                                                                               |
| Design                                                                                                                                                                                                                                                         | Duration of run-in phase:                                                                                                                                                                                                                                                                                                                              | Duration of run-in phase:                                                                                                                                                                                                                                                                                                                              | 6-week washout including a 2-week open- label placebo run-in (patients pre-treated with metformin and an additional OAD) or 2-week open-label placebo run-in (patients pre-treated with metformin only)                                                                                                                                                | 6-week washout including a 2-week open- label placebo run-in (patients pre-treated with metformin and an additional OAD) or 2-week open-label placebo run-in (patients pre-treated with metformin only)                                                                                                                                                |
| Design                                                                                                                                                                                                                                                         | Duration of extension phase:                                                                                                                                                                                                                                                                                                                           | Duration of extension phase:                                                                                                                                                                                                                                                                                                                           | Not applicable                                                                                                                                                                                                                                                                                                                                         | Not applicable                                                                                                                                                                                                                                                                                                                                         |
| Hypothesis                                                                                                                                                                                                                                                     | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                                                                        | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                                                                        | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                                                                        | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                                                                        |
| Treatment groups                                                                                                                                                                                                                                               | Linagliptin                                                                                                                                                                                                                                                                                                                                            | Linagliptin                                                                                                                                                                                                                                                                                                                                            | Linagliptin 5 mg tablet qd for 24 weeks as add-on to metformin, 524 patients randomised                                                                                                                                                                                                                                                                | Linagliptin 5 mg tablet qd for 24 weeks as add-on to metformin, 524 patients randomised                                                                                                                                                                                                                                                                |
| Treatment groups                                                                                                                                                                                                                                               | Placebo                                                                                                                                                                                                                                                                                                                                                | Placebo                                                                                                                                                                                                                                                                                                                                                | Placebo tablet for 24 weeks as add-on to metformin, 177 patients randomised                                                                                                                                                                                                                                                                            | Placebo tablet for 24 weeks as add-on to metformin, 177 patients randomised                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                                                                                                                                       | Confirmatory                                                                                                                                                                                                                                                                                                                                           | HbA 1c change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                                                                | HbA 1c change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                      | Secondary endpoint                                                                                                                                                                                                                                                                                                                                     | Exploratory                                                                                                                                                                                                                                                                                                                                            | FPG change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                                                                   | FPG change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                                                                   |
| Database lock                                                                                                                                                                                                                                                  | 16 July 2009                                                                                                                                                                                                                                                                                                                                           | 16 July 2009                                                                                                                                                                                                                                                                                                                                           | 16 July 2009                                                                                                                                                                                                                                                                                                                                           | 16 July 2009                                                                                                                                                                                                                                                                                                                                           |
| Results and Analysis                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                   | Results and Analysis                                                                                                                                                                                                                                                                                                                                   |
| Analysis description                                                                                                                                                                                                                                           | Primary Analysis: After 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed effects and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. | Primary Analysis: After 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed effects and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. | Primary Analysis: After 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed effects and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. | Primary Analysis: After 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed effects and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. |
| Analysis population and time point description                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline HbA 1c measurement, and had at least one on-treatment HbA 1c measurement.                                                                                                                            | Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline HbA 1c measurement, and had at least one on-treatment HbA 1c measurement.                                                                                                                            | Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline HbA 1c measurement, and had at least one on-treatment HbA 1c measurement.                                                                                                                            | Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline HbA 1c measurement, and had at least one on-treatment HbA 1c measurement.                                                                                                                            |
| Descriptive stati and estima stics te variability                                                                                                                                                                                                              | Treatment group                                                                                                                                                                                                                                                                                                                                        | Treatment group                                                                                                                                                                                                                                                                                                                                        | Placebo                                                                                                                                                                                                                                                                                                                                                | Linag liptin                                                                                                                                                                                                                                                                                                                                           |
| Descriptive stati and estima stics te variability                                                                                                                                                                                                              | Number of patients                                                                                                                                                                                                                                                                                                                                     | Number of patients                                                                                                                                                                                                                                                                                                                                     | 175                                                                                                                                                                                                                                                                                                                                                    | 513                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive stati and estima stics te variability                                                                                                                                                                                                              | e after 24 weeks [%] Adjusted mean change in HbA 1c from baselin                                                                                                                                                                                                                                                                                       | e after 24 weeks [%] Adjusted mean change in HbA 1c from baselin                                                                                                                                                                                                                                                                                       | 0.15                                                                                                                                                                                                                                                                                                                                                   | -0.49                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                 | SE                                                                                                                                         | 0.06                                                                                                                                       | 0.04                                                                                                                                       |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                             | Comparison groups                                                                                                                          | Treatment difference (linagliptin - placebo)                                                                                               |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                             | Adjusted mean                                                                                                                              | -0.64                                                                                                                                      |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                             | SE                                                                                                                                         | 0.07                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                             | P-value                                                                                                                                    | <0.0001                                                                                                                                    |
| Analysis description                            | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way. | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way. | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                            | Placebo                                                                                                                                    | Linagliptin                                                                                                                                |
| Descriptive statistics and estimate variability | Number of patients                                                                                                                         | 159                                                                                                                                        | 495                                                                                                                                        |
| Descriptive statistics and estimate variability | Adjusted mean change in FPG from baseline after 24 weeks [mg/dL]                                                                           | 10.46                                                                                                                                      | -10.68                                                                                                                                     |
| Descriptive statistics and estimate variability | SE                                                                                                                                         | 2.80                                                                                                                                       | 1.65                                                                                                                                       |
| Effect estimate per comparison                  | FPG change from baseline after 24 weeks [mg/dL]                                                                                            | Comparison groups                                                                                                                          | Treatment difference (linagliptin - placebo)                                                                                               |
| Effect estimate per comparison                  |                                                                                                                                            | Adjusted mean                                                                                                                              | -21.13                                                                                                                                     |
| Effect estimate per comparison                  |                                                                                                                                            | SE                                                                                                                                         | 3.14                                                                                                                                       |
| Effect estimate per comparison                  |                                                                                                                                            | P-value                                                                                                                                    | <0.0001                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

Table 2. Summary of Efficacy for trial 1218.18

| Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylurea   | Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylurea   | Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylurea   | Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylurea   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                       | 1218.18 [U09-2458]                                                                                                                                                                                                                                                                                     | 1218.18 [U09-2458]                                                                                                                                                                                                                                                                                     | 1218.18 [U09-2458]                                                                                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                                                                                                 | Randomised, double-blind, placebo-controlled, parallel-group comparison                                                                                                                                                                                                                                | Randomised, double-blind, placebo-controlled, parallel-group comparison                                                                                                                                                                                                                                | Randomised, double-blind, placebo-controlled, parallel-group comparison                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                         | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                         | 24-week treatment period with linagliptin 5 mg or placebo as add-on therapy to metformin in combination with a sulphonylurea (SU) 2-week open-label placebo run-in Not applicable                                                                                                                      |
| Hypothesis                                                                                                                                                                                                                                                                                             | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                        | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                        | Superiority of treatment with linagliptin over placebo in regard to the adjusted mean change in HbA 1c from baseline to Week 24                                                                                                                                                                        |
| Treatment groups                                                                                                                                                                                                                                                                                       | Linagliptin                                                                                                                                                                                                                                                                                            | Linagliptin                                                                                                                                                                                                                                                                                            | Linagliptin 5 mg tablet qd for 24 weeks as add-on to metformin and an SU, 793 patients randomised                                                                                                                                                                                                      |
| Treatment groups                                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                                                | Placebo                                                                                                                                                                                                                                                                                                | Placebo tablet for 24 weeks as add-on to metformin and an SU, 265 patients randomised                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                                                                              | Primary endpoint                                                                                                                                                                                                                                                                                       | Confirmatory                                                                                                                                                                                                                                                                                           | HbA 1c change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                |
| Endpoints and definitions                                                                                                                                                                                                                                                                              | Secondary endpoint                                                                                                                                                                                                                                                                                     | Exploratory                                                                                                                                                                                                                                                                                            | FPG change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                   |
| Database lock                                                                                                                                                                                                                                                                                          | 19 August 2009                                                                                                                                                                                                                                                                                         | 19 August 2009                                                                                                                                                                                                                                                                                         | 19 August 2009                                                                                                                                                                                                                                                                                         |

| Results and Analysis                             | Results and Analysis                                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                           | Results and Analysis                                                                                                                                                                                                                                                                                           |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                             | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' as fixed effect and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' as fixed effect and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' as fixed effect and 'baseline HbA 1c ' as covariate. The primary analysis was conducted at the 2-sided 5% level of significance. |
| Analysis popula and time po tion int description | bA 1c measurement, and had at least one on-treatment HbA 1c Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline H measurement.                                                                                   | bA 1c measurement, and had at least one on-treatment HbA 1c Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline H measurement.                                                                                   | bA 1c measurement, and had at least one on-treatment HbA 1c Full analysis set (FAS): the FAS consisted of all randomised patients who were treated with at least one dose of study medication, had a baseline H measurement.                                                                                   |
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                                                                | Pl acebo                                                                                                                                                                                                                                                                                                       | Lin n aglipti                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability  | Number of patients                                                                                                                                                                                                                                                                                             | 262                                                                                                                                                                                                                                                                                                            | 778                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability  | change in from baseline 24 weeks [%] Adjusted mean HbA 1c after                                                                                                                                                                                                                                                | -0. 10                                                                                                                                                                                                                                                                                                         | -0.72                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                                                 | SE                                                                                                                                            | 0.05                                                                                                                                          | 0.03                                                                                                                                          |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                | Comparison groups                                                                                                                             | ent difference liptin - placebo) Treatm (linag                                                                                                |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                | Adjusted mean                                                                                                                                 | -0.62                                                                                                                                         |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                | SE                                                                                                                                            | 0.06                                                                                                                                          |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                | P-value                                                                                                                                       | <0.0001                                                                                                                                       |
| Notes                                           |                                                                                                                                               |                                                                                                                                               |                                                                                                                                               |
| Analysis description                            | Secondary endpoint: the chang seline in FPG w in a similar way as the HbA 1c percent change, but in an exploratory way. e from ba as analysed | Secondary endpoint: the chang seline in FPG w in a similar way as the HbA 1c percent change, but in an exploratory way. e from ba as analysed | Secondary endpoint: the chang seline in FPG w in a similar way as the HbA 1c percent change, but in an exploratory way. e from ba as analysed |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                               | Placebo                                                                                                                                       | Linagliptin                                                                                                                                   |
| Descriptive statistics and estimate variability | Number of patients                                                                                                                            | 248                                                                                                                                           | 739                                                                                                                                           |
| Descriptive statistics and estimate variability | Adju in F sted mean change PG from baseline g/dL] after 24 weeks [m                                                                           | 8.1                                                                                                                                           | -4.6                                                                                                                                          |
| Descriptive statistics and estimate variability | SE                                                                                                                                            | 2.4                                                                                                                                           | 1.4                                                                                                                                           |
| Effect estimate per comparison                  | FPG change from aseline after 24 weeks [mg/dL] b                                                                                              | Comparison groups                                                                                                                             | Treatment difference ptin - placebo) (linagli                                                                                                 |
| Effect estimate per comparison                  |                                                                                                                                               | Adjusted mean                                                                                                                                 | -12.7                                                                                                                                         |
| Effect estimate per comparison                  |                                                                                                                                               | SE                                                                                                                                            | 2.8                                                                                                                                           |
| Effect estimate per comparison                  |                                                                                                                                               | P-value                                                                                                                                       | <0.0001                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

Table 3. Summary of Efficacy for trial 1218.46

Title: A Phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy  and  safety  of  twice  daily  administration  of  the  free  combination  of  linagliptin  2.5  mg  + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg, with the individual components of metformin (500 mg or 1000 mg, twice daily) and linagliptin (5 mg, once daily) over 24 weeks in drug naïve or previously treated (4 weeks washout and 2 weeks placebo run-in) type 2 diabetic patients with insufficient glycaemic control

| Study identifier          | 1218.46 [U10-2372]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1218.46 [U10-2372]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1218.46 [U10-2372]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Randomised, double-blind, placebo-controlled, factorial design with an additional open-label arm                                                                                                                                                                                                                                                                                                                                                                                                                 | Randomised, double-blind, placebo-controlled, factorial design with an additional open-label arm                                                                                                                                                                                                                                                                                                                                                                                                                 | Randomised, double-blind, placebo-controlled, factorial design with an additional open-label arm                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 24-week treatment period with the free dose combination of linagliptin 2.5 mg + metformin 500 mg bid and linagliptin 2.5 mg + metformin 1000 mg bid, the individual components of metformin (500 mg or 1000 mg, both bid) and linagliptin 5 mg qd 6-week washout including a 2-week open- label placebo run-in (patients pre-treated with an OAD) or 2-week open-label placebo run-in (patients not pre-treated with an OAD) optional participation in an extension trial over 54 weeks (BI trial no. 1218.52)   |
| Hypothesis                | The following 4 hypotheses were tested using a sequential testing procedure at the level of α =0.05 (2-sided): 1) Superiority of linagliptin 2.5 mg + metformin 1000 mg bid vs. metformin 1000 mg bid in terms of change in HbA 1c from baseline 2) Superiority of linagliptin 2.5 mg + metformin 1000 mg bid vs. linagliptin 5 mg qd in terms of change in HbA 1c from baseline 3) Superiority of linagliptin 2.5 mg + metformin 500 mg bid vs. metformin 500 mg bid in terms of change in HbA 1c from baseline | The following 4 hypotheses were tested using a sequential testing procedure at the level of α =0.05 (2-sided): 1) Superiority of linagliptin 2.5 mg + metformin 1000 mg bid vs. metformin 1000 mg bid in terms of change in HbA 1c from baseline 2) Superiority of linagliptin 2.5 mg + metformin 1000 mg bid vs. linagliptin 5 mg qd in terms of change in HbA 1c from baseline 3) Superiority of linagliptin 2.5 mg + metformin 500 mg bid vs. metformin 500 mg bid in terms of change in HbA 1c from baseline | The following 4 hypotheses were tested using a sequential testing procedure at the level of α =0.05 (2-sided): 1) Superiority of linagliptin 2.5 mg + metformin 1000 mg bid vs. metformin 1000 mg bid in terms of change in HbA 1c from baseline 2) Superiority of linagliptin 2.5 mg + metformin 1000 mg bid vs. linagliptin 5 mg qd in terms of change in HbA 1c from baseline 3) Superiority of linagliptin 2.5 mg + metformin 500 mg bid vs. metformin 500 mg bid in terms of change in HbA 1c from baseline |
| Treatment groups          | Lina 2.5 + Met 500 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Lina 2.5 + Met 500 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Linagliptin 2.5 mg + metformin 500 mg bid for 24 weeks, 143 patients randomised                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Treatment groups          | Lina 2.5 + Met 1000 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Lina 2.5 + Met 1000 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Linagliptin 2.5 mg + metformin 1000 mg bid for 24 weeks, 143 patients randomised                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Treatment groups          | Lina 5 qd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Lina 5 qd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Linagliptin 5 mg qd for 24 weeks, 142 patients randomised                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Treatment groups          | Met 500 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Met 500 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Metformin 500 mg bid for 24 weeks, 144 patients randomised                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Treatment groups          | Met 1000 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Met 1000 bid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Metformin 1000 mg bid for 24 weeks, 147 patients randomised                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Treatment groups          | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Matching placebo for linagliptin 2.5 mg, linagliptin 5 mg, metformin 500 mg, and metformin 1000 mg for 24 weeks, 72 patients randomised                                                                                                                                                                                                                                                                                                                                                                          |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Confirmatory                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | HbA 1c change from baseline after 24 weeks of treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|               | Secondary endpoint   | Exploratory   | FPG change from baseline after 24 weeks of treatment   |
|---------------|----------------------|---------------|--------------------------------------------------------|
| Database lock | 25 June 2010         | 25 June 2010  | 25 June 2010                                           |

| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                       |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                            | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. | Primary Analysis: after 24 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA 1c . The model included 'treatment' and 'prior use of antidiabetic agents' as fixed classification effects and 'baseline HbA 1c ' as linear covariate. The primary analysis was conducted at a 2-sided 5% level of significance. |
| Analysis population and time point description  | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 | Full analysis set (FAS): the FAS consisted of all treated patients who had a baseline HbA 1c measurement and at least one on-treatment HbA 1c measurement.                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                            | Lina 2.5 + Met 500 bid                                                                                                                                                                                                                                                                                                                                                     | Lina 2.5 + Met 1000 bid                                                                                                                                                                                                                                                                                                                                                    | Lina 5 qd                                                                                                                                                                                                                                                                                                                                                                  | Met 500 bid                                                                                                                                                                                                                                                                                                                                                                | Met 1000 bid                                                                                                                                                                                                                                                                                                                                                               | Placebo                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Number of patients                                                                                                                                                                                                                                                                                                                                                         | 137                                                                                                                                                                                                                                                                                                                                                                        | 140                                                                                                                                                                                                                                                                                                                                                                        | 135                                                                                                                                                                                                                                                                                                                                                                        | 141                                                                                                                                                                                                                                                                                                                                                                        | 138                                                                                                                                                                                                                                                                                                                                                                        | 65                                                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Adjusted mean change in HbA 1c from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                            | -1.22                                                                                                                                                                                                                                                                                                                                                                      | -1.59                                                                                                                                                                                                                                                                                                                                                                      | -0.45                                                                                                                                                                                                                                                                                                                                                                      | -0.64                                                                                                                                                                                                                                                                                                                                                                      | -1.07                                                                                                                                                                                                                                                                                                                                                                      | 0.13                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | SE                                                                                                                                                                                                                                                                                                                                                                         | 0.08                                                                                                                                                                                                                                                                                                                                                                       | 0.08                                                                                                                                                                                                                                                                                                                                                                       | 0.08                                                                                                                                                                                                                                                                                                                                                                       | 0.08                                                                                                                                                                                                                                                                                                                                                                       | 0.08                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Treatment difference Lina 2.5 + Met 1000 bid vs.                                                                                                                                                                                                                                                                                                                           | Treatment difference Lina 2.5 + Met 1000 bid vs.                                                                                                                                                                                                                                                                                                                           | Treatment difference Lina 2.5 + Met 1000 bid vs.                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | -0.51                                                                                                                                                                                                                                                                                                                                                                      | -0.51                                                                                                                                                                                                                                                                                                                                                                      | -0.51                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Treatment difference Lina 2.5 + Met 1000 bid vs. Lina 5 qd                                                                                                                                                                                                                                                                                                                 | Treatment difference Lina 2.5 + Met 1000 bid vs. Lina 5 qd                                                                                                                                                                                                                                                                                                                 | Treatment difference Lina 2.5 + Met 1000 bid vs. Lina 5 qd                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | -1.14                                                                                                                                                                                                                                                                                                                                                                      | -1.14                                                                                                                                                                                                                                                                                                                                                                      | -1.14                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Treatment difference Lina 2.5 + Met 500 bid vs. Met 500 bid                                                                                                                                                                                                                                                                                                                | Treatment difference Lina 2.5 + Met 500 bid vs. Met 500 bid                                                                                                                                                                                                                                                                                                                | Treatment difference Lina 2.5 + Met 500 bid vs. Met 500 bid                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | -0.58                                                                                                                                                                                                                                                                                                                                                                      | -0.58                                                                                                                                                                                                                                                                                                                                                                      | -0.58                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Comparison groups                                                                                                                                                                                                                                                                                                                                                          | Treatment difference Lina 2.5 + Met 500 bid vs. Lina 5 qd                                                                                                                                                                                                                                                                                                                  | Treatment difference Lina 2.5 + Met 500 bid vs. Lina 5 qd                                                                                                                                                                                                                                                                                                                  | Treatment difference Lina 2.5 + Met 500 bid vs. Lina 5 qd                                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | Adjusted mean                                                                                                                                                                                                                                                                                                                                                              | -0.77                                                                                                                                                                                                                                                                                                                                                                      | -0.77                                                                                                                                                                                                                                                                                                                                                                      | -0.77                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                         | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       | 0.11                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                                                                                                                                                                                                                                                             | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | P-value (superiority)                                                                                                                                                                                                                                                                                                                                                      | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   | Secondary endpoint: the change from baseline in FPG was analysed in a similar way as the HbA 1c percent change, but in an exploratory way.   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability | Treatment group                                                                                                                              | Lina 2.5 + Met 500 bid                                                                                                                       | Lina 2.5 + Met 1000 bid                                                                                                                      | Lina 5 qd                                                                                                                                    | Met 500 bid                                                                                                                                  | Met 1000 bid                                                                                                                                 | Placebo                                                                                                                                      |
| Descriptive statistics and estimate variability | Number of patients                                                                                                                           | 135                                                                                                                                          | 136                                                                                                                                          | 134                                                                                                                                          | 136                                                                                                                                          | 132                                                                                                                                          | 61                                                                                                                                           |
| Descriptive statistics and estimate variability | Adjusted mean change in FPG from baseline after 24 weeks [mg/dL]                                                                             | -33.2                                                                                                                                        | -49.4                                                                                                                                        | -8.6                                                                                                                                         | -15.8                                                                                                                                        | -32.2                                                                                                                                        | 10.2                                                                                                                                         |
| Descriptive statistics and estimate variability | SE                                                                                                                                           | 3.5                                                                                                                                          | 3.5                                                                                                                                          | 3.6                                                                                                                                          | 3.5                                                                                                                                          | 3.6                                                                                                                                          | 5.3                                                                                                                                          |
| Effect estimate per comparison                  | FPG change from baseline after 24 weeks [mg/dL]                                                                                              | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Treatment difference Lina 2.5 + Met 1000 bid vs.                                                                                             | Treatment difference Lina 2.5 + Met 1000 bid vs.                                                                                             | Treatment difference Lina 2.5 + Met 1000 bid vs.                                                                                             |
| Effect estimate per comparison                  | FPG change from baseline after 24 weeks [mg/dL]                                                                                              | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | Met 1000 bid -17.2                                                                                                                           | Met 1000 bid -17.2                                                                                                                           | Met 1000 bid -17.2                                                                                                                           |
| Effect estimate per comparison                  | FPG change from baseline after 24 weeks [mg/dL]                                                                                              | SE                                                                                                                                           | SE                                                                                                                                           | SE                                                                                                                                           | 5.0                                                                                                                                          | 5.0                                                                                                                                          | 5.0                                                                                                                                          |
| Effect estimate per comparison                  | FPG change from baseline after 24 weeks [mg/dL]                                                                                              | P-value                                                                                                                                      | P-value                                                                                                                                      | P-value                                                                                                                                      | 0.0006                                                                                                                                       | 0.0006                                                                                                                                       | 0.0006                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Treatment difference Lina 2.5 + Met 1000 bid vs. Lina 5 qd                                                                                   | Treatment difference Lina 2.5 + Met 1000 bid vs. Lina 5 qd                                                                                   | Treatment difference Lina 2.5 + Met 1000 bid vs. Lina 5 qd                                                                                   |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | -40.8                                                                                                                                        | -40.8                                                                                                                                        | -40.8                                                                                                                                        |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | SE                                                                                                                                           | SE                                                                                                                                           | SE                                                                                                                                           | 5.0                                                                                                                                          | 5.0                                                                                                                                          | 5.0                                                                                                                                          |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | P-value                                                                                                                                      | P-value                                                                                                                                      | P-value                                                                                                                                      | <0.0001                                                                                                                                      | <0.0001                                                                                                                                      | <0.0001                                                                                                                                      |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Treatment difference Lina 2.5 + Met 500 bid vs. Met 500 bid                                                                                  | Treatment difference Lina 2.5 + Met 500 bid vs. Met 500 bid                                                                                  | Treatment difference Lina 2.5 + Met 500 bid vs. Met 500 bid                                                                                  |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | -17.4                                                                                                                                        | -17.4                                                                                                                                        | -17.4                                                                                                                                        |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | SE                                                                                                                                           | SE                                                                                                                                           | SE                                                                                                                                           | 5.0                                                                                                                                          | 5.0                                                                                                                                          | 5.0                                                                                                                                          |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | P-value                                                                                                                                      | P-value                                                                                                                                      | P-value                                                                                                                                      | 0.0005                                                                                                                                       | 0.0005                                                                                                                                       | 0.0005                                                                                                                                       |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Comparison groups                                                                                                                            | Treatment difference Lina 2.5 + Met 500 bid vs. Lina 5 qd                                                                                    | Treatment difference Lina 2.5 + Met 500 bid vs. Lina 5 qd                                                                                    | Treatment difference Lina 2.5 + Met 500 bid vs. Lina 5 qd                                                                                    |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | Adjusted mean                                                                                                                                | -24.6                                                                                                                                        | -24.6                                                                                                                                        | -24.6                                                                                                                                        |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | SE                                                                                                                                           | SE                                                                                                                                           | SE                                                                                                                                           | 5.0                                                                                                                                          | 5.0                                                                                                                                          | 5.0                                                                                                                                          |
| Effect estimate per comparison                  | HbA 1c change from baseline after 24 weeks [%]                                                                                               | P-value                                                                                                                                      | P-value                                                                                                                                      | P-value                                                                                                                                      | <0.0001                                                                                                                                      | <0.0001                                                                                                                                      | <0.0001                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Table 43. Summary of Efficacy for trial 1218.62

Title: A randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control

| Study identifier          | 1218.62 [U11-3093]                                                                                                                                                                                                              | 1218.62 [U11-3093]                                                                                                                                                                                                              | 1218.62 [U11-3093]                                                                                                                                                                                                                                                                                                              |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                         | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                         | Randomised, double-blind, placebo-controlled, parallel group comparison                                                                                                                                                                                                                                                         |
| Design                    | Duration of main phase: Duration of run-in phase: Duration of                                                                                                                                                                   | extension phase:                                                                                                                                                                                                                | 12-week treatment period with linagliptin 2.5 mg bid, 5 mg qd, or placebo as add-on therapy to metformin 6-week washout including a 2-week open- label placebo run-in (patients pre-treated with metformin and an additional OAD) or 2-week open-label placebo run-in (patients pre-treated with metformin only) Not applicable |
| Hypothesis                | 3 hypotheses were tested in the following fixed sequence: (1) superiority of linagliptin 2.5 mg bid vs. placebo; (2) non-inferiority of linagliptin 2.5 mg bid vs. 5 mg qd; (3) superiority of linagliptin 5 mg qd vs. placebo. | 3 hypotheses were tested in the following fixed sequence: (1) superiority of linagliptin 2.5 mg bid vs. placebo; (2) non-inferiority of linagliptin 2.5 mg bid vs. 5 mg qd; (3) superiority of linagliptin 5 mg qd vs. placebo. | 3 hypotheses were tested in the following fixed sequence: (1) superiority of linagliptin 2.5 mg bid vs. placebo; (2) non-inferiority of linagliptin 2.5 mg bid vs. 5 mg qd; (3) superiority of linagliptin 5 mg qd vs. placebo.                                                                                                 |
| Treatment groups          | Linagliptin 2.5 mg                                                                                                                                                                                                              | Linagliptin 2.5 mg                                                                                                                                                                                                              | Linagliptin 2.5 mg tablet bid for 12 weeks as add-on to metformin, 223 patients randomised                                                                                                                                                                                                                                      |
| Treatment groups          | Linagliptin 5 mg                                                                                                                                                                                                                | Linagliptin 5 mg                                                                                                                                                                                                                | Linagliptin 5 mg tablet qd for 12 weeks as add-on to metformin, 224 patients randomised                                                                                                                                                                                                                                         |
| Treatment groups          | Placebo                                                                                                                                                                                                                         | Placebo                                                                                                                                                                                                                         | Placebo tablet for 12 weeks as add-on to metformin, 44 patients randomised                                                                                                                                                                                                                                                      |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                | Confirmatory                                                                                                                                                                                                                    | HbA 1c change from baseline after 12 weeks of treatment                                                                                                                                                                                                                                                                         |
| Endpoints and definitions | Secondary endpoint                                                                                                                                                                                                              | Exploratory                                                                                                                                                                                                                     | FPG change from baseline after 12 weeks of treatment                                                                                                                                                                                                                                                                            |
| Database lock             | 04 November 2010                                                                                                                                                                                                                | 04 November 2010                                                                                                                                                                                                                | 04 November 2010                                                                                                                                                                                                                                                                                                                |

## Results and Analysis

<div style=\"page-break-after: always\"></div>

| Analysis description                            | 1c fixed ine Hb ovariate. agains as (2-side on-inferi tment w tin to 5 mg qd was tested at the l 025 (1-s d of a 95% con ce interval) w non-inferiority margin of Primary Analysis: after 12 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA . he model included 'treatment', 'prior use of antidiabetic agents' as T effects and 'basel tested at α =0.05 A 1c ' as c d). The n Superiority ority of trea evel of α =0. t placebo w ith linaglip ided; i.e. the 2.5 mg bid upper boun 0.35%. fiden ith a   | 1c fixed ine Hb ovariate. agains as (2-side on-inferi tment w tin to 5 mg qd was tested at the l 025 (1-s d of a 95% con ce interval) w non-inferiority margin of Primary Analysis: after 12 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA . he model included 'treatment', 'prior use of antidiabetic agents' as T effects and 'basel tested at α =0.05 A 1c ' as c d). The n Superiority ority of trea evel of α =0. t placebo w ith linaglip ided; i.e. the 2.5 mg bid upper boun 0.35%. fiden ith a   | 1c fixed ine Hb ovariate. agains as (2-side on-inferi tment w tin to 5 mg qd was tested at the l 025 (1-s d of a 95% con ce interval) w non-inferiority margin of Primary Analysis: after 12 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA . he model included 'treatment', 'prior use of antidiabetic agents' as T effects and 'basel tested at α =0.05 A 1c ' as c d). The n Superiority ority of trea evel of α =0. t placebo w ith linaglip ided; i.e. the 2.5 mg bid upper boun 0.35%. fiden ith a   | 1c fixed ine Hb ovariate. agains as (2-side on-inferi tment w tin to 5 mg qd was tested at the l 025 (1-s d of a 95% con ce interval) w non-inferiority margin of Primary Analysis: after 12 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA . he model included 'treatment', 'prior use of antidiabetic agents' as T effects and 'basel tested at α =0.05 A 1c ' as c d). The n Superiority ority of trea evel of α =0. t placebo w ith linaglip ided; i.e. the 2.5 mg bid upper boun 0.35%. fiden ith a   | 1c fixed ine Hb ovariate. agains as (2-side on-inferi tment w tin to 5 mg qd was tested at the l 025 (1-s d of a 95% con ce interval) w non-inferiority margin of Primary Analysis: after 12 weeks of treatment an analysis of covariance (ANCOVA) was performed to compare the change from baseline in HbA . he model included 'treatment', 'prior use of antidiabetic agents' as T effects and 'basel tested at α =0.05 A 1c ' as c d). The n Superiority ority of trea evel of α =0. t placebo w ith linaglip ided; i.e. the 2.5 mg bid upper boun 0.35%. fiden ith a   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | AS): the FAS consisted o andomised p who t least one dose of study medication, had a baseline ement, and had at least one on-treatment HbA 1c surement. Full analysis set (F were treated with a HbA f all r atients 1c measur mea                                                                                                                                                                                                                                                                                                                                         | AS): the FAS consisted o andomised p who t least one dose of study medication, had a baseline ement, and had at least one on-treatment HbA 1c surement. Full analysis set (F were treated with a HbA f all r atients 1c measur mea                                                                                                                                                                                                                                                                                                                                         | AS): the FAS consisted o andomised p who t least one dose of study medication, had a baseline ement, and had at least one on-treatment HbA 1c surement. Full analysis set (F were treated with a HbA f all r atients 1c measur mea                                                                                                                                                                                                                                                                                                                                         | AS): the FAS consisted o andomised p who t least one dose of study medication, had a baseline ement, and had at least one on-treatment HbA 1c surement. Full analysis set (F were treated with a HbA f all r atients 1c measur mea                                                                                                                                                                                                                                                                                                                                         | AS): the FAS consisted o andomised p who t least one dose of study medication, had a baseline ement, and had at least one on-treatment HbA 1c surement. Full analysis set (F were treated with a HbA f all r atients 1c measur mea                                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pl acebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | pti g b Linagli 2.5 m n id                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Linagliptin 5 mg qd                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Number of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 214                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 221                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Adjusted mean change in HbA 1c from baseline after 12 weeks [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | -0.46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -0.52                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | SE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | HbA 1c change from baseline after 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | HbA 1c change from baseline after 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups ent liptin Treatm (linag                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | difference 2.5 mg bid - o) placeb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Adjusted mean                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -0.74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | SE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | SE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 0.11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | HbA 1c change from baseline after 12 weeks [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | HbA 1c change from baseline after 12 weeks [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | ent difference liptin 5 mg qd - o) Treatm (linag placeb                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Adjusted mean                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | -0.80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | SE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | HbA 1c change from baseline after 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | HbA 1c change from baseline after 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Treatment difference (linagliptin 2.5 mg bid - linagliptin 5 mg qd)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | [%]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Adjusted mean                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.06                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | S E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07 0.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.07, 0.19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

| Analysis description                            | nt: the change from baseline in FPG was analysed in a HbA 1c percent change, but in an exploratory way. The el additionally included 'fasting plasma glucose at baseline' as covariate Secondary endpoi similar way as the mod   | nt: the change from baseline in FPG was analysed in a HbA 1c percent change, but in an exploratory way. The el additionally included 'fasting plasma glucose at baseline' as covariate Secondary endpoi similar way as the mod   | nt: the change from baseline in FPG was analysed in a HbA 1c percent change, but in an exploratory way. The el additionally included 'fasting plasma glucose at baseline' as covariate Secondary endpoi similar way as the mod   | nt: the change from baseline in FPG was analysed in a HbA 1c percent change, but in an exploratory way. The el additionally included 'fasting plasma glucose at baseline' as covariate Secondary endpoi similar way as the mod   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                  | Pl acebo                                                                                                                                                                                                                         | pti g b Linagli 2.5 m n id                                                                                                                                                                                                       | Linagliptin 5 mg qd                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Number of patients                                                                                                                                                                                                               | 40                                                                                                                                                                                                                               | 203                                                                                                                                                                                                                              | 213                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | A c djusted mean hange in FPG from baseline after 12 weeks [mg/dL]                                                                                                                                                               | -3.5                                                                                                                                                                                                                             | -17.2                                                                                                                                                                                                                            | -21.3                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                | SE                                               | 4.2               | 1.9                                                                 |
|--------------------------------|--------------------------------------------------|-------------------|---------------------------------------------------------------------|
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | Comparison groups | ent difference gliptin 2.5 mg bid - bo) Treatm (lina place          |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | Adjusted mean     | -13.7                                                               |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | SE                | 4.6                                                                 |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | P-value           | 0.0029                                                              |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | Comparison groups | tment difference gliptin 5 mg qd - bo) Trea (lina place             |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | Adjusted mean     | -17.8                                                               |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | SE                | 4.6                                                                 |
| Effect estimate per comparison | FPG change from baseline after 12 weeks [mg/dL]  | P-value           | 0.0001                                                              |
| Effect estimate per comparison | G change from baseline after 12 weeks FP [mg/dL] | Comparison groups | Treatment difference (linagliptin 2.5 mg bid - linagliptin 5 mg qd) |
| Effect estimate per comparison | G change from baseline after 12 weeks FP [mg/dL] | Adjusted mean     | 4.1                                                                 |
| Effect estimate per comparison | G change from baseline after 12 weeks FP [mg/dL] | SE                | 2.6                                                                 |
| Effect estimate per comparison | G change from baseline after 12 weeks FP [mg/dL] | 95% CI            | -1.0, 9.2                                                           |

## Supportive studies

Long-term  efficacy  and  safety  were  examined  in  studies:  1218.20,  1218.23  and  1218.40.  Other supportive studies submitted with this application are studies 1218.35 and 1218.50.

## Study 1218.52

This  was  a  multinational  phase  III  randomised,  double-blind,  parallel  group,  extension  study  to 2.5 1000 mg versus monotherapy with etformin 1000 mg twice daily over 54 weeks in T2DM patients previously completing the double-blind art of study 1218.46 and not requiring rescue therapy. investigate the safety and efficacy of twice daily administration of the free combination of linagliptin mg + metformin 500 mg or of linagliptin 2.5 mg + metformin m p

There was no primary endpoint for efficacy in this study. Instead, safety and efficacy were assessed through descriptive analyses. Change in HbA1C was assessed as a secondary endpoint.

The mean HbA1C results are displayed in the below table.

## Table 44. Descriptive statistics for HbA1C (%) change from baseline over time -FAS (OC*) Patients staying on same treatment in extension

<div style=\"page-break-after: always\"></div>

|          | L2.5+M500   | L2.5+M500   | L2.5+M500   | L2.5+M1000   | L2.5+M1000   | L2.5+M1000   | M1000   | M1000   | M1000   |
|----------|-------------|-------------|-------------|--------------|--------------|--------------|---------|---------|---------|
|          | n           | Mean        | SD          | n            | Mean         | SD           | n       | Mean    | SD      |
| Baseline | 113         | 8.61        | 0.87        | 111          | 8.61         | 0.96         | 109     | 8.47    | 0.85    |
| Week 6   | 113         | -0.85       | 0.66        | 111          | -1.06        | 0.64         | 107     | -0.68   | 0.68    |
| Week 12  | 113         | -1.15       | 0.96        | 108          | -1.46        | 0.97         | 107     | -1.06   | 0.87    |
| Week 18  | 105         | -1.22       | 1.02        | 110          | -1.64        | 0.94         | 107     | -1.15   | 1.02    |
| Week 24  | 107         | -1.28       | 1.01        | 108          | -1.70        | 0.98         | 106     | -1.16   | 0.99    |
| Week30   | 100         | -1.32       | 0.91        | 106          | -1.74        | 0.97         | 105     | -1.20   | 0.99    |
| Week 42  | 90          | -1.28       | 1.00        | 96           | -1.62        | 1.04         | 94      | -1.15   | 0.99    |
| Week 54  | 46          | -1.38       | 1.16        | 59           | -1.69        | 0.99         | 50      | -1.29   | 0.97    |
| Week 66  | 13          | -1.83       | 0.91        | 18           | -1.61        | 1.13         | 16      | -1.53   | 1.16    |
| Week 78  | 1           | -1.00       |             | 4            | -1.53        | 0.87         | 4       | -0.53   | 0.54    |

*In the observed cases (OC) analysis, missing data were not replaced. Values measured after rescue medication was set to missing.

Mean HbA1C remained fairly stable in all 3 treatment groups, indicating persistence of the glucosereached the end of the study (78 weeks) in this partial initial combination setting that differs from the lowering  effect  of  metformin  monotherapy  and  the  combination  of  linagliptin  and  metformin  up  to Week 54. However, one must bear in mind that only a limited number of the included subjects have applied add-on setting.

## Study 1218.20

It  was  a  multinational,  randomised,  double-blind,  active-controlled  study  to  evaluate  efficacy  and safety of linagliptin 5 mg compared to glimepiride over two years, in T2DM patients with insufficient glycaemic  control  despite  metformin  therapy.  After  52  weeks,  lnagliptin  was  associated  with  a atment difference with a mean value of 0.26%. After 104 weeks, linagliptin was associated with a decrease in HbA1c of -0.16%, decrease in HbA1c of -0.38%, and glimepiride was associated with a decrease of -0.60% in the full analysis  set  (FAS).  According  to  the  pre-defined  non-inferiority  margin  of  0.35%  for  HbA1c,  noninferior efficacy of linagliptin vs. glimepiride could be shown in the primary FAS analysis at 52 weeks (treatment difference 0.22%). The PPS analysis showed a slightly higher tre and glimepiride was associated with a decrease of -0.36% in the full analysis set (FAS) with a mean treatment difference of 0.20%. The PPS (LOCF) analysis again showed a larger treatment difference of 0.28% in HbA1C.

18.23 Study 12 was a placebo and active-controlled study using voglibose. Voglibose is not approved in the EU and, therefore, the comparison with voglibose is not considered relevant for this application.

Study 1218.40 was an open-label extension trial without a control group in patients who completed one of the 4 pivotal placebo-controlled trials (1218.15, 1218.16, 1218.17, or 1218.18). The objective linagliptin. was primarily to evaluate safety of 5 mg linagliptin during long-term treatment as monotherapy or in combination  with  metformin,  pioglitazone,  or metformin  in  addition to  a  sulphonylurea  drug. Furthermore,  the  objective  was  to  assess  efficacy  in  a  descriptive  exploratory  way.  All  patients received 5 mg ed  linagliptin  in  the  previous  studies,  the  HbA1c  levels  achieved  during  the  24  weeks  of y  until  week  42.  Thereafter, HbA1c appeared to increase slightly but patient numbers were small. Patients were analysed according to their previous exposure to linagliptin. In the group of patients who had  receiv treatment  in  the  previous  trials  were  maintained  in  this  extension  stud

In the group of patients who had been randomised to placebo in the previous studies, the maximum effect of linagliptin on HbA1c was observed at Week 18 of this extension study (mean change from baseline:  -0.68%).  From  Week  30  to  Week  42,  no  further  reductions  in  mean  HbA1c  values  were observable. Subsequently, HbA1c levels started to slightly increase again but patient number became smaller.

<div style=\"page-break-after: always\"></div>

Study  1218.35 was  a  multinational,  18-week  study  investigating  efficacy  and  safety  of  5  mg linagliptin in combination with a SU.

Linagliptin was superior in reducing HbA1c compared to placebo with a mean treatment difference of 0.47%  (95%  CI  -0.7,  -0.24)  at  week  18  week.  However,  the  clinical  relevance  of  this  effect  is considered  questionable.  Subgroup  analysis  confirmed  that  gender  did  not  influence  the  treatment response.

Asian patients had a larger mean change from baseline in HbA1c (-0.76%) than European (-0.40%) patients.

The placebo-adjusted effect on HbA1c in European patients was -0.29%.

<div style=\"page-break-after: always\"></div>

Study 1218.50 investigated efficacy and safety of linagliptin 5 mg compared to placebo (part 1, 18 weeks) and to glimepiride (part 2, 34 weeks) in patients intolerant to metformin therapy. 93% of study population did not tolerate metformin due to gastrointestinal intolerance.

arger in Asian patients (-0.80%) than in Caucasian patients (-0.45%). At week 18 linagliptin was superior to placebo in reducing HbA1c with a mean treatment difference of 0.57%.  Secondary  results  were  consistent.  The  mean  HbA1c  change  from  baseline  was  small  and similar in Asian (-0.35%) and European (-0.37%) patients. However, the placebo-adjusted treatment mean change in HbA1c was l

The results of part 2 of the study (double-blind extension period, where placebo patients switched to glimepiride)  were  provided  with  the  linagliptin  MAA.  The  results  showed  a  fall  in  the  mean  HbA1c change from baseline in the control group (glimepiride) from Week 18 to Week 30 and thereafter the mean was fairly  constant.  The  mean  HbA1c  change  from  baseline  remained  constant  for  linagliptin from  Week  18  throughout  the  remainder  of  the  trial.  There  were  differences  in  mean  HbA1c  from baseline between linagliptin and glimepiride from Week 30 onwards, with glimepiride having a larger decrease from baseline compared with linagliptin. The treatment with glimepiride induced a decrease in HbA1c of 0.82%, whereas linagliptin was associated with a decrease of 0.44%.

## 2.5.3. Discussion on clinical efficacy

Linagliptin 5 mg has been approved in combination with metformin and metformin plus sulphonylurea. m metformin is inappropriate due to intolerance, or renal impairment. In  addition,  linagliptin  5  mg  has  been  approved  for  use  as  monotherapy  in  patients  inadequately controlled by diet and exercise alone and for who contraindicated due to practice  taking  into account  effects  on  HbA1C,  clinical  outcome  and  intolerance  of  higher  dosages  of  metformin.  The withdraw this lower strength during the evaluation. The Applicant now proposes a fixed dose combination of linagliptin 2.5 mg and metformin 500 mg, 850 mg or 1000 mg bid. The lowest proposed strength, i.e. linagliptin 2.5 mg/metformin 500 mg, contains a dose of metformin with a questionable benefit in terms of effects on HbA1C and clinical outcome. In the UKPDS study, the efficacy of metformin in reducing T2DM complications was demonstrated, but the great majority of patients was treated with metformin doses &gt;1700 mg per day. Therefore, metformin 500 mg bid is considered only a starting dose that should be increased first before linagliptin is added. The Applicant was requested by the CHMP to justify this lowest dosage strength on the basis of the clinical  data  of  Jentadueto  and  of  the  use  of  metformin  500  mg  bid  in  clinical Applicant decided to

The  clinical  development  programme  for  the  combination  therapy  comprised  several  trials.  In  total 3529  patients  with  type  2  diabetes  received  treatment  with  linagliptin  and  metformin  (linagliptin  + metformin). Overall, 2694 patients were treated for at least 24 weeks, 2081 patients for at least 52 weeks, and 1756 patients for more than 78 weeks.

The  pivotal  placebo-controlled  trial  1218.17  investigated  the  efficacy  of  linagliptin  5  mg  as  add-on therapy  to  metformin  over  24  weeks.  In  comparison  to  placebo,  linagliptin  was  associated  with  a significant  and  relevant  effect  on  HbA1c.  This  study  was  also  included  in  the  MAA  for  Trajenta (linagliptin).

4 weeks, linagliptin was associated with a decrease  in  HbA1c  of  -0.16%,  and  glimepiride  was  associated  with  a  decrease  of  -0.36%.  Noninferiority was not reached. The results of this trial are appropriately described in the SmPC. One active controlled trial was performed in which linagliptin 5 mg was compared with glimepiride (1-4 mg) in patients treated with metformin (1218.20). After 10

<div style=\"page-break-after: always\"></div>

## Studies investigating linagliptin 2.5 mg twice daily

Because the pharmacokinetics of metformin require at least a twice daily dosing, for the development of the FDC the once daily dosing of 5 mg linagliptin was split into 2 daily doses of 2.5 mg. This study was  performed  on  request  of  the  CHMP.  This  was  a  placebo-controlled  study  over  12  weeks  that showed comparable efficacy of the linagliptin 2.5 mg twice daily regimen and the linagliptin 5 mg once daily regimen when added to metformin. The difference in efficacy was negligible and well within the non-inferiority boundaries.

al for the establishment of efficacy of linagliptin 2.5 mg twice daily was study 1218.46. inagliptin-metformin combinations versus metformin in a partial first-line setting e that were treatment naive. An additional tri This study tested 2 l (47.5%  treatment-naïve  patients).  The  treatment  effect  in  the  linagliptin-metformin  combination therapy groups versus metformin was -0.58% for linagliptin 2.5 mg bid in combination with metformin 500 mg vs. metformin 500 mg.  For linagliptin 2.5 mg in combination with metformin 1000 mg vs. metformin 1000 mg, the treatment effect was -0.51%. The fact that at least half of the patients were not treated with oral antidiabetic drugs before inclusion in the study is not in line with the requested indication  for  linagliptin/metformin  in  patients  that  are  insufficiently  controlled  with  metformin  or metformin  in  combination  with  SU.  The  inclusion  of  treatment  naive  patients  resulted  in  an overestimation of the treatment effects of metformin in this study. Nevertheless, the treatment effects of linagliptin were similar in patients that were pre-treated and thos

In general, the effects of linagliptin on fasting plasma glucose and treat to target proportions showed a pattern that was similar to the effects on HbA1c.

## Combination with SU

1218.18, where linagliptin 5 mg qd or placebo were added to ongoing therapy with metformin and an SU. This study was also included in the MAA for Trajenta. The treatment effect f linagliptin 2.5 mg twice daily in combination with metformin and SU was not investigated. It is unlikely that SU influences the efficacy and/or safety g once daily in patients on metformin. Efficacy  of  linagliptin  5  mg  once  daily  in  combination  with  metformin  and  SU  over  24  weeks  was investigated in study was clinically relevant. However, the treatment effect o of  linagliptin  2.5  mg.  In  healthy  individuals,  bioequivalence between linagliptin 5 mg once daily and linagliptin 2.5 mg twice daily has been shown. In addition, the efficacy of linagliptin 2.5 mg twice daily was similar to the efficacy of linagliptin 5 m

## Long term efficacy

Data  on  long-term  efficacy  of  linagliptin  in  combination  with  metformin  and  SU  is  available  from completed study 1218.17 and A1c  was maintained in the individuals that continued the use of linagliptin with metformin. However, 38.7% of in  and  SU  required  rescue  medication. , the long study duration and the fact that the extension trials also allowed entry for patients who already received rescue medication in the initial trials. patients  who  completed  study  1218.18  and  continued  into  trial  1218.40.  The  final  results  were provided  during  the  evaluation.  HbA1c  levels  remained  reasonably  stable.  Long-term  efficacy  of linagliptin with metformin is also studied in new data from patients who continued  into  the  open-label  78-week  extension  study  1218.40.  The  decrease  in  Hb the patients using linagliptin in combination with metformin required rescue medication, and 33.8% of the  patients  using  linagliptin  in  combination  with  metform Nevertheless, it is conceivable that this is explained by the low threshold for the initiation of rescue therapy

<div style=\"page-break-after: always\"></div>

(54  weeks,  interim  analyses)  are  available  from  study  1218.52  (final results  were  provided  during  the  evaluation),  which  is  a  double-blind  metformin  monotherapyp (22.9%). Furthermore  long-term  data controlled extension trial in patients who completed the 24-week treatment period of study 1218.46 without  requiring  rescue  medication.  Throughout  the  entire  treatment  duration  of  78  weeks,  the linagliptin 2.5 mg + metformin 1000 mg combination achieved greater reductions in mean HbA1c than the metformin 1000 bid group. In addition, the proportion of patients who required rescue medication up  to  Week  78  was  lower  in  the  linagliptin  2.5+metformin  1000  bid  group  (12.6%)  than  in  the metformin 1000 bid grou

## Subgroups

results of study 1218.46 suggest the opposite: the treatment effect of linagliptin 2.5 mg twice daily The efficacy of linagliptin and metformin over metformin could also be shown in relevant subgroups of patients. Thus factors such as age, gender, race (White vs. Asian), ethnicity, geographical region, and baseline BMI did not have an influence on the treatment effect. The presence of a washout period and the  longer  duration  of  the  disease  diabetes  did  negatively  influence  the  treatment  effect  of  the linagliptin/metformin combination therapy, but efficacy was acceptable. Interestingly, previous studies suggested that the treatment effect of linagliptin  was lower in  Whites  than  in  Asians. However,  the was smaller in Asians  compared to  Whites  (-0.42%  vs.  -0.65%  in  combination  with  metformin  500 mg;-0. 39% vs. -0.59% in combination with metformin 1000 mg).

ove was very low (in the grouping of 1218.17 and 1218.46 only  24  patients  &gt;75  years  were  included).  During  the  evaluation,  a  study  in  elderly  patients  was .48],  p&lt;0.0001),  demonstrating  superiority  of  linagliptin  over  placebo  in  the The number of patients aged 75 years or ab submitted  (1218.63).  The  estimated  treatment  difference  between  linagliptin  (n=160)  and  placebo (n=78),  calculated  as  the  adjusted  mean  change  from  baseline  in  HbA1c  at  Week  24,  was  -0.64% (95%  CI  [-0.81;  -0 reduction of HbA1c.

## 2.5.4. Conclusions on the clinical efficacy

tformin resulted in a modest effect endpoint  (HbA1c)  with  statistically  significant  reductions  in  HbA1c,  fasting prandial glucose. Treatment with 5 mg linagliptin once daily in combination with me on  the  primary  efficacy plasma glucose and post

The efficacy of linagliptin 2.5 mg twice daily was similar to the efficacy of linagliptin 5 mg once daily in patients on metformin. Efficacy of the combination linagliptin 2.5 mg with metformin is acceptable.

The  fixed  dose  combination  has  also  not  been  investigated  in  combination  with  SU,  but  this  is considered not necessary as efficacy of linagliptin 2.5 mg twice daily with metformin and SU is likely to be similar to that of linagliptin 5 mg once daily with metformin and SU.

Results of long term studies with a follow up suggest that efficacy is modest, but acceptable.

A study in elderly patients revealed that linagliptin added to ongoing treatment with glucose lowering drugs was superior to placebo after 24 weeks of treatment.

Patients with hepatic impairment were not investigated in sufficient amounts and this is reflected in the SmPC.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

Generally,  the  analysis  of  safety  is  presented  separately  for  linagliptin  monotherapy,  metformin monotherapy, the combination of linagliptin + metformin, and the triple combination of linagliptin + metformin + SU. Since metformin has been in clinical use for some 50 years in the European Union, no dedicated  studies  to  assess  the  safety  of  metformin  were  conducted.  However,  information  on metformin monotherapy is included in some of the safety analysis sets (SAFs) for the linagliptin mono and combination arms.

orted by data from a pooled analysis of all placebo-controlled trials that  used  metformin  either  as  background  medication  or  as  study  treatment  (n=1971)  (SAF-C5). For  the  evaluation  of  safety  of  the  linagliptin  +  metformin  combination,  14  clinical  studies  were analysed.  The  focus  is  on  the  safety  data  of  the  pivotal  study  1218.17  (SAF-C1)  (n=700)  which compared linagliptin with placebo in patients who took metformin as background medication over 24 weeks. This safety analysis is supp Additionally, for the establishment of the side effect profile of linagliptin 5 mg + metformin, an analysis set (SEA-2, n=1905) was generated that was based on SAF-C5 but considered solely patients who took linagliptin 5 mg resulting in an exclusion of 66 patients from study 1218.6 who took linagliptin 10 mg.

glimepiride + metformin over 104 weeks. Data on long-term use of the linagliptin + metformin combination is available from the 24 week study 1218.46  with  its  double-blind  extension  trial  1218.52  to  provide  data  over  78  weeks.  This  is supplemented  by  safety  data  from  study  1218.20  that  compared  linagliptin  +  metformin  with

The safety of the triple combination therapy linagliptin + metformin + SU was evaluated based on the pivotal study 1218.18, a 24-week placebo-controlled trial of linagliptin added to background treatment of metformin + SU.

Adverse  events  of  special  interest  were  hypoglycaemia,  hypersensitivity  reactions,  renal  events (including laboratory evaluations), hepatic events (including laboratory evaluations), severe cutaneous adverse  reactions,  and  pancreatitis.  In  addition,  the  evaluation  of  cardiovascular  risk  potentially associated with the use of linagliptin received particular attention.

## Patient exposure

Overall,  median  exposures  were  similar  between  treatment  groups.  In  the  pooled  metformin dditionally, long-term safety (n=567) included patients who completed the 24 weeks of study 1218.46, did not use rescue medication, and continued in the double-blind extension (study 1218.52). The planned treatment duration of the extension trial was  54  weeks.  At  the  time  of  the  interim  analysis  about  50%  of  patients  had  been  treated  in  the extension trial for 24 weeks or more. background studies the planned study durations ranged from 12 weeks (studies 1218.6 and 1218.62) to  24  weeks (studies 1218.17 and 1218.46). In the active-controlled long-term study 1218.20, 776 patients  received  linagliptin  +  metformin  and  775  patients  received  linagliptin  +  glimepiride.  The planned  study  duration  was  104  weeks.  A  large  proportion  of  patients  in  both  treatment  groups (linagliptin  +  metformin 80.5%, glimepiride + metformin 81.3%) was exposed to randomised study medication  for  78  weeks  or  more.  The  mean  exposure  was  comparable:  627  days  (linagliptin  + metformin) and 625 days (glimepiride + metformin). A

<div style=\"page-break-after: always\"></div>

the pivotal trial (1218.17), similar proportions of patients in both treatment groups completed the foll metformi compl equent reason for premature discontinuation in oth treatment groups were admi issues, i.e. no nce with the pro st to followup, and refusal to continue with t tion (metfo gliptin In study  (metformin  92.1%,  linagliptin  +  metformin  92.5%).  The  most  frequent  reason  for  premature discontinuation was refusal to continue medication (metformin 2.3%, linagliptin + metformin 2.5%), owed  by  the  occurrence  of  adverse  events  (1.7%  in  both  treatment  groups).  In  the  pooled n  background  studies,  88.5%  (metformin)  and  92.2%  (linagliptin  +  metformin)  of  patients eted the planned treatment period. The most fr b nistrative rial medica n-complia rmin 5.5%, lina tocol, lo + metformin 3.7%).

the  active-controlled long-term set 18.2 milar ents d the trial  period  (linagliptin  +  m 75. .  glim +  m in  77 he  m equent reasons  for  premature  discontinuation adverse  events iptin  +  metform ormin 11.6 In (study 12 6% vs 0) si proportions of pati etform complete ost  fr etformin epiride .9%); t were (linagl in  7.9%  vs. glimepiride + metf %).

In the long-term safety set, 4% complete anned treatment The proportions of tions w est ag mg rm g .1%) linagliptin 2.5mg + metformin 500 mg group (23.1%). The most frequent reasons m e i . n n e p ost to nue  with  trial  medication)  ranging  from  5.6%  in  the  metformin1000 linagl mg + metform g g adverse events ranging from 5 mg +metformi 8% i n 1000 overall 80. d the pl period. premature discontinua and highest in the ere low in the lin liptin 2.5 + metfo in 1000 m group (16 for premature discontinuati follow-up,  and  refusal  to  conti on were ad inistrativ ssues (i.e on-complia ce with th rotocol, l group to 10.5% in the 4.9% in the linagliptin 2. iptin 2.5 in 500 m group to 6. roup and n the metformi n 1000 mg mg group.

e triple tion lipt etf S st edian days in both treatment groups was in accordance with this. Overall 92.0% (metformin aglipti tfor ) c th tr pe hence were similar in both treatment groups (8.0% vs. 7.3%). nuation were adverse events (metformin + SU 1.9%, 1.5%, n  +  SU  3.0%, In study 1218.18, th exposure of 170 combina of linag in with m ormin and U was inve igated. M + SU) and 92.7% (lin n + me min + SU ompleted e planned eatment riod and the proportions of premature discontinuations The most frequent reasons for premature disconti linagliptin  +  metformin  +  SU  2.9%),  non-compliance  with  study  protocol  (metformin  +  SU linagliptin  +  metformin  +  SU  2.4%),  refusal  to  continue  trial  medication  (metformi linagliptin  +  metformin  +  SU  1.8%),  and  lack  of  efficacy  (metformin  +  SU  1.5%,  linagliptin  + metformin + SU 0.3%).

## A dverse events

In  the  pivotal  trial  1218.17  (SAF-C1)  the  incidences  of  adverse  events  were  comparable  in  the metformin (57.1%) and the linagliptin + metformin group (53.9%) (see table below). The incidence of adverse events of severe intensity was slightly higher in the linagliptin + metformin group (1.1% vs. 2.1%). Conversely the adverse events considered related to study drug by the investigators were more frequent  in  the  metformin  group  (11.3%  vs.  7.3%).  The  proportions  of  patients  who  discontinued because  of  adverse  events  (2.3%  vs.  1.7%)  were  similar  in  both  treatment  groups  as  was  the incidence of serious adverse events (2.8% vs. 3.4%).

<div style=\"page-break-after: always\"></div>

to  patients  taking linagliptin 5 mg (SEA-2) - TS Table 45. Adverse  event  overall  summary  for  1218.17  (SAF-C1)  and  the  double-blind, placebo-controlled studies with metformin; comparing safety of linagliptin+metformin  with  PBO+metformin  (SAF-C5)  limited

|                                                      | -C 8.17) SAF (121 1   | -C 8.17) SAF (121 1      | -C t vs. li tin+M SAF (Me 5 naglip et)   | -C t vs. li tin+M SAF (Me 5 naglip et)   | A (Met vs. Lina SE -2 5+Met)   | A (Met vs. Lina SE -2 5+Met)   |
|------------------------------------------------------|-----------------------|--------------------------|------------------------------------------|------------------------------------------|--------------------------------|--------------------------------|
|                                                      | M N et (%)            | linag + N liptin Met (%) | M N et (%)                               | lina + N gliptin Met (%)                 | N Met (%)                      | linagliptin +Met N (%)         |
| Patients (100.0%)                                    | 177                   | 5 23                     | 5 83                                     | 1 388                                    | 583                            | 1322                           |
| Patients with AEs                                    | 1 (5 01 7.1)          | ( 282 53.9)              | ( 295 50.6)                              | 66 0 (47.6)                              | 295 (50.6)                     | 632 (47.8)                     |
| Patients with AE severe intensity s of               | 2 (1.1)               | 11 (2.1)                 | 1 0 (1.7)                                | 2 9 (2.1)                                | 1 0 (1.7)                      | 27 (2.0)                       |
| Patients with drug-related AEs investigator- defined | 20 (11.3)             | 38 (7.3)                 | 5 1 (8.7)                                | 10 1 (7.3)                               | 5 1 (8.7)                      | 95 (7.2)                       |
| Patients with AEs of terest 1 special in             | 3 (1.7)               | 2 (0.4)                  | 1 0 (1.7)                                | 1 1 (0.8)                                | n.a.                           | n.a.                           |
| Patients with AEs leading to discontinuation         | 4 (2.3)               | 9 (1.7)                  | 15 (2.6)                                 | 33 (2.4)                                 | 1 5 (2.6)                      | 3 1 (2.3)                      |
| Patients with SAEs                                   | 5 (2.8)               | 18 (3.4)                 | 1 5 (2.6)                                | 4 1 (3.0)                                | 1 5 (2.6)                      | 37 (2.8)                       |

n.a. = not applicable, was not perfo SEA rmed for -2

Es = adverse events; SAEs = serious a A dverse events

AF-C5 and SEA-2 are identical except for 66 patients excluded from SEA-2 because they had mg agliptin. S taken 10 lin

SAF-C1: Linagliptin was administer mg qd rmin w n as b nd m n. ed as 5 , metfo as give ackgrou edicatio

SAF-C5: Linagliptin was administer 5 mg g qd, g qd; metformin wa as ba apy (500 mg or 1000 mg, bid), or free combi n the 0 mg or 1000 mg, together with bid). ed as 2. or 10 m s given bid, 5 m ckground medication, monother linagliptin 2.5 mg; all natio rapy (50

ions, r ents, and events (based on investigator-report cluding pancreatitis). 1 Including hypersensitivity react cutaneous adverse reactions and enal ev hepatic ing, ex severe ed ci t re ve ilar  in n  study  1218.17. ost  frequent  adverse  ev O l  were stations (2 21 d g stin ers vs ) both cidence th tr t groups. Differences of 2% or more were observed onn issu ers er re th tin  + roup  (7.9%  vs. , s e  b Also ,  p a edural s.  5.0% esp ho m l  d (2 e  frequent  in  the  linagliptin  +  metformin  group  than  in  the  metformin  group. etabolism  and di ere  substantia fre th tin  + the metformin group (23.7% .1% ly du lowe nce of 6. so em ss w pti ormin with metformin alone (2.8% vs. 0.6%). Furthermore, investigations (8.5% disorders (2.8% %) f it b erapy lone. Co g the frequencies erse in th lipti ormin tal  trial  w e  o ag up lin o ission imilar incidence s sy an The analyses demonstrat both  treat that the in dences of he most f quent ad rse events were sim ment  groups  i fe The  m . ents  on  S C  leve infections and in 2. 0% vs. 6%) an astrointe al disord (11.9% . 11.1% with almost identical in s in bo eatmen for  musculoskeletal  and  c ective  t e  disord which  w e  more  f quent  in e  linaglip metformin  g 11.1% ee tabl elow). injury oisoning nd  proc complications (2.3% v were  slightly  mor )  and r iratory, t racic and ediastina isorders .8% vs. 4.8%) Conversely,  m nutrition sorders  w lly  less quent  in e  linaglip metformin group than in vs. 10 ) main e to a r incide hyperglycaemia (16.4% vs. combination therapy than 1%). Al hypoglyca ia was le frequent ith linagli n + metf vs. 4.0%) and psychiatric metformin a vs. 0.8 were less  requent w h the com ination th than with mparin of adv events e linag n + metf group  of  the  pivo ith  thos f  the  lin liptin  gro in  the agliptin  m no  subm demonstrates s s acros stem org classes.

<div style=\"page-break-after: always\"></div>

e events occurring in more tha f patients in eatment group eferred t leve n SA and/ FSOCs quencie e  2 ith tm p -C d  by e linagliptin+metformin group of SAF-C5 - TS Table 46. Advers n 2% o either tr on the pr with  fre erm s  abov l  with their S %  in  e OCs i er  trea F-C1 ent  grou or SA in  SAF C5 and 5,  sorte frequency in th

|                                         | SAF-C1          | SAF-C1                 | SAF-C5            | SAF-C5                 | SEA-2             | SEA-2                  |
|-----------------------------------------|-----------------|------------------------|-------------------|------------------------|-------------------|------------------------|
|                                         | Met N (%)       | linagliptin +Met N (%) | Met N (%)         | linagliptin +Met N (%) | Met N (%)         | linagliptin +Met N (%) |
| Patients (100.0%)                       | 177             | 523                    | 583               | 1388                   | 583               | 1322                   |
| Patients with any adverse events        | 101 (57.1)      | 282 (53.9)             | 295 (50.6)        | 660 (47.6)             | 295 (50.6)        | 632 (47.8)             |
| Infections and infestations             | 39 (22.0)       | 113 (21.6)             | 113 (19.4)        | 257 (18.5)             | 113 (19.4)        | 247 (18.7)             |
| Nasopharyngitis Urinary tract infection | 9 (5.1) 9 (5.1) | 27 (5.2) 16 (3.1)      | 23 (3.9) 18 (3.1) | 61 (4.4) 39 (2.8)      | 23 (3.9) 18 (3.1) | 57 (4.3) 37 (2.8)      |
| Upper resp. tract infection*            | 4 (2.3)         | 15 (2.9)               | 13 (2.2)          | 32 (2.3)               | 13 (2.2)          | 32 (2.4)               |
| Influenza                               | 5 (2.8)         | 18 (3.4)               | 18 (3.1)          | 28 (2.0)               | 18 (3.1)          | 28 (2.1)               |
| Gastrointestinal disorders              | 21 (11.9)       | 58 (11.1)              | 68 (11.7)         | 155                    | 68 (11.7)         | 147                    |
| Diarrhoea                               | 4 (2.3)         | 15 (2.9)               | 20 (3.4)          | (11.2) 43 (3.1)        | 20 (3.4)          | (11.1) 41 (3.1)        |
| Nausea                                  | 3 (1.7)         | 6 (1.1)                | 12 (2.1)          | 24 (1.7)               | 12 (2.1)          | 21 (1.6)               |
| Abdominal pain                          | 4 (2.3)         | 2 (0.4)                | 5 (0.9)           | 4 (0.3)                | 5 (0.9)           | 4 (0.3)                |
| Musculoskeletal and                     | 14 (7.9)        | 58 (11.1)              | 45 (7.7)          | 127 (9.1)              | 45 (7.7)          | 124 (9.4)              |
| connective tissue disorders Back pain   |                 |                        | 12 (2.1)          |                        | 12 (2.1)          |                        |
| Arthralgia                              | 5 (2.8) 3 (1.7) | 12 (2.3) 11 (2.1)      | 11 (1.9)          | 32 (2.3) 24 (1.7)      | 11 (1.9)          | 32 (2.4) 24 (1.8)      |

|                                                     | SAF-C1     | SAF-C1                 | SAF-C5     | SAF-C5                 | SEA-2      | SEA-2                  |
|-----------------------------------------------------|------------|------------------------|------------|------------------------|------------|------------------------|
|                                                     | Met N (%)  | linagliptin +Met N (%) | Met N (%)  | linagliptin +Met N (%) | Met N (%)  | linagliptin +Met N (%) |
| Patients (100.0%)                                   | 177        | 523                    | 583        | 1388                   | 583        | 1322                   |
| Patients with any adverse events                    | 101 (57.1) | 282 (53.9)             | 295 (50.6) | 660 (47.6)             | 295 (50.6) | 632 (47.8)             |
| Metabolism and nutrition disorders                  | 42 (23.7)  | 53 (10.1)              | 74 (12.7)  | 96 (6.9)               | 74 (12.7)  | 95 (7.2)               |
| Hyperglycaemia                                      | 29 (16.4)  | 32 (6.1)               | 46 (7.9)   | 49 (3.5)               | 46 (7.9)   | 49 (3.7)               |
| Hypoglycaemia                                       | 5 (2.8)    | 3 (0.6)                | 12 (2.1)   | 14 (1.0)               | 12 (2.1)   | 14 (1.1)               |
| Hypertriglyceridaemia                               | 5 (2.8)    | 2 (0.4)                | 9 (1.5)    | 4 (0.3)                | 9 (1.5)    | 4 (0.3)                |
| Nervous system disorders                            | 9 (5.1)    | 35 (6.7)               | 37 (6.3)   | 87 (6.3)               | 37 (6.3)   | 85 (6.4)               |
| Headache                                            | 7 (4.0)    | 15 (2.9)               | 19 (3.3)   | 33 (2.4)               | 19 (3.3)   | 33 (2.5)               |
| General disorders and administration site conditons | 7 (4.0)    | 19 (3.6)               | 37 (6.3)   | 51 (3.7)               | 37 (6.3)   | 46 (3.5)               |
| Investigations                                      | 15 (8.5)   | 21 (4.0)               | 37 (6.3)   | 51 (3.7)               | 37 (6.3)   | 48 (3.6)               |
| Blood glucose increased                             | 7 (4.0)    | 5 (1.0)                | 9 (1.5)    | 6 (0.4)                | 9 (1.5)    | 5 (0.4)                |
| Injury, poisoning and procedural complications      | 4 (2.3)    | 26 (5.0)               | 13 (2.2)   | 50 (3.6)               | 13 (2.2)   | 49 (3.7)               |
| Respiratory, thoracic and mediastinal disorders     | 5 (2.8)    | 25 (4.8)               | 14 (2.4)   | 49 (3.5)               | 14 (2.4)   | 47 (3.6)               |
| Cough                                               | 3 (1.7)    | 11 (2.1)               | 5 (0.9)    | 24 (1.7)               | 5 (0.9)    | 23 (1.7)               |
| Vascular disorders                                  | 7 (4.0)    | 23 (4.4)               | 22 (3.8)   | 39 (2.8)               | 22 (3.8)   | 38 (2.9)               |
| Hypertension                                        | 6 (3.4)    | 17 (3.3)               | 17 (2.9)   | 29 (2.1)               | 17 (2.9)   | 28 (2.1)               |
| Skin and subcutaneous tissue disorders              | 5 (2.8)    | 18 (3.4)               | 18 (3.1)   | 39 (2.8)               | 18 (3.1)   | 37 (2.8)               |

Jentadueto

CHMP assessment report

<div style=\"page-break-after: always\"></div>

| Cardiac disorders           | 2 (1.1)   | 12 (2.3)   | 8 (1.4)   | 29 (2.1)   | 8 (1.4)   | 26 (2.0)   |
|-----------------------------|-----------|------------|-----------|------------|-----------|------------|
| Renal and urinary disorders | 5 (2.8)   | 13 (2.5)   | 14 (2.4)  | 29 (2.1)   | 14 (2.4)  | 25 (1.9)   |
| Psychiatric disorders       | 5 (2.8)   | 4 (0.8)    | 13 (2.2)  | 13 (0.9)   | 13 (2.2)  | 11 (0.8)   |

*Upper respiratory tract infection

SAF-C1: Linagliptin was administered as 5 mg qd; metformin was given as background medication.

SAF-C5 and SEA-2 are identical except for 66 patients excluded from SEA-2 because they had taken 10 mg linagliptin.

The  profile  of  adverse  events  with  the  combination  therapy  with  linagliptin  +  metformin  +  SU  was consistent with that observed for linagiptin in combination with metformin. Overall, 61.2% (metformin + SU) and 67.3% (linagliptin + metformin + SU) of patients were reported with an adverse event. The frequency  of  patients  with  adverse  events  of  severe  intensity  (1.5%  vs.  2.5%),  of  adverse  events leading to treatment discontinuation (1.9% vs. 3.2%), and of adverse events of special interest (0.4% vs.  1.3%)  were  generally  low  but  slightly  lower  in  the  metformin  +  SU  than  in  the  linagliptin  + metformin + SU groups. The incidence of serious adverse events was comparable between treatment groups (metformin + SU 4.2% vs. linagliptin + metformin + SU 3.2%). The percentage of patients with drug-related adverse events was higher in the linagliptin + metformin + SU group (18.3%) than was  mainly  due  to  a  higher  incidence  of  hypoglycemia linagliptin + metformin+ SU 14.5%). Due to the mode of action of insulin in  the  metformin  +  SU  group  (12.2%).  This (metformin + SU 7.6% vs. secretagogues such as SUs, patients on combination therapy are known to be at risk of hypoglycaemic events.

## Clinical laboratory evaluation and vital signs

ely. Fluctuations in amylase values were noted at subsequent time points, but ultimately the differences from baseline at week 78 were similar to those n 2.1, 3.8, and 8.6 U/L respectively). In  general,  no  clinically  relevant  findings  or  significant  differences  between  linagliptin  and  control groups were observed for any of the measured parameters. In the trials with a duration shorter than 24  weeks,  there  were  no  changes  in  amylase  levels.  A  comparison  of  changes  in  amylase  values (normalized reference range: 30-110 U/L) over a 72 week period in patients dosed continuously with either  metformin  1000  mg  twice  daily,  linagliptin  2.5  mg  plus  metformin  500  mg  twice  daily,  or linagliptin 2.5 mg plus metformin 1000 mg twice daily reveals that at week 12 the mean differences from baseline were 5.7, 5.1, and 9.9 U/L respectiv at weeks 12 and 24 (mea

Blood pressure and pulse rates at baseline were comparable between treatment groups. Over the 24week treatment period only minimal changes in mean values were observed both treatment groups (&lt;1 mmHg for blood pressure and &lt;1 bpm for pulse rate).

<div style=\"page-break-after: always\"></div>

## Hypoglycaemic events

The  analysis  of  hypoglycaemic  events  was  based  on  investigator-reporting.  In  the  pivotal  study ia  was  higher  in  the  metformin  group  (2.8%)  than  in  the of linagliptin + metformin + SU (23.7%).  In  trial  1218.20,  the  difference  between  both  treatment  groups  in  hypoglycaemic  events ormin 7.5% vs. glimepiride + metformin 36.1%) was significant and in favour of 1218.17,  the  incidence  of  hypoglycaem linagliptin + metformin group (0.6%) and this was corroborated in the set of all metformin-controlled studies SAF-C5 (metformin 2.5% vs. linagliptin + metformin 1.4%). As shown by the analysis of trial 1218.18, the addition of an SU to metformin led to a substantially higher frequency of hypoglycaemic events (16.0%) which was even higher in the triple combination group (linagliptin  +  metf linagliptin  (p&lt;0.0001).  The  majority  of  patients  in  all  SAFs  did  not  require  assistance  in  case  of  a hypoglycaemic episode, and large proportions of patients in all SAFs had an onset of a first episode after  28  days.  With  combination  therapy  of  linagliptin  +  metformin  only  1  patient  had  a  severe hypoglycaemic  event  (requiring  assistance)  during  long-term  treatment.  However,  in  the  triple combination  of  linagliptin  +  metformin  +  SU  the  incidence  also  of  severe  hypoglycaemic  events appears to be increased.

## Pancreatic disorders

In  total,  10  cases  of  pancreas  disorders  were  reported:  8  cases  occurring  during  treatment  with linagliptin  +  metformin,  and  2  cases  during  treatment  with  glimepiride  +  metformin.  In  the  posttreatment  period,  2  cases  of  pancreas  disorders  were  reported.  None  of  the  cases  has  been necrotising,  haemorrhagic,  or  fatal.  All  of  these  cases  but  one  (on  patient  in  trial  1218.20  with pancreatic  carcinoma)  were  included  in  the  linagliptin  monotherapy  SCS.  In  clinical  trials  with linagliptin in combination with metformin, the incidence rate per 1000 patient-years in 3463 patients was 1.4. When the linagliptin plus metformin combination was compared to placebo plus metformin, the incidence rate per 1000 patient-years in 1322 patients treated with linagliptin plus metformin was 2.0. No events of pancreatitis were reported in the placebo plus metformin cohort of 483 patients. The incidence rate of pancreatitis for linagliptin plus metformin is similar to the data found in the linagliptin monotherapy development program. The risk of pancreatitis associated with linagliptin treatment has been added in section 4.4 of the Jentadueto SmPC.

## Cardiovascular safety

Eight trials with a total of 5239 patients with T2DM were included in a cardiovascular meta-analysis in the MAA for Trajenta (linagliptin). The primary endpoint was based on adjudicated events and was a r death (including fatal stroke and fatal MI), non-fatal MI, non-fatal stroke, and hospitalisation due to unstable angina. This analysis indicated that treatment rdial ischaemia (2 vs 0 patients). Linagliptin was not associated composite endpoint consisting of cardiovascula with  linagliptin  was  not  associated  with  an  increased  cardiovascular  risk  compared  with  a  pooled comparator  group.  However,  linagliptin  in  combination  with  metformin  was  associated  with  angina pectoris (4 vs. 0 patients) and myoca with an increase in CV risk, and the primary endpoint for linagliptin was significantly lower than for the total comparators, so this may be a chance finding.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Patients at high cardiovascular risk

A  cardiovascular  outcome  study  (study  1218.74)  is  currently  ongoing.  Patients  are  planned  to  be treated with randomised study medication for up to 400 weeks (i.e. 8 years), an interim analysis is planned to be performed based on a number of at least 80 adjudicated primary outcome events and a minimum duration of 1.5 years after randomisation of the first patient.

## Elderly patients

Elderly patients might be at a higher risk of cardiovascular events. During the evaluation, a study in elderly patients was submitted (study 1218.63), where only patients of at least 70 years of age are included. Overall, 60 patients (75.9%) were reported with AEs in the placebo group and 123 patients (75.9%)  were  reported  with  AEs  in  the  linagliptin  group.  The  majority  of  the  AEs  were  of  mild  or moderate  intensity.  Severe  AEs  were  reported  for  3  patients  (3.8%)  treated  with  placebo  and  9 patients (5.6%) treated with linagliptin. Serious adverse events (SAEs) were reported for 5 patients (6.3%) in the placebo group and 14 patients (8.6%) in the linagliptin group. No patients died during the study. Two patients, both in the linagliptin group, had confirmed cardiac or cerebrovascular events adjudicated by the CEC. One patient had a non-fatal ischaemic stroke, and 1 patient was hospitalised due to coronary artery disease (unstable angina). None of the SAEs were considered drug-related. No ed  &gt;75  years  had  severe  hypoglycaemia.  The  proportion  of  patients  reported  with investigator-defined hypoglycaemia by age group was similar for the two treatment groups in patients roup  was  not  associated  with  a  significant lin)  was significant (p = 0.0005). In this study in elderly individuals, it was also noted that more patients in the linagliptin group had increase in amylase compared to the placebo but  it  was  not  clear  whether  the  event  was nd  causality  between  this  event  and  study  drug  has  not  been established. patients  ag younger than 75 years of age (23.3% placebo; 25.3% linagliptin), but was lower in the placebo group in  patients  aged  75  years  or  older  (8.3%  placebo;  22.5%  linagliptin).  Logistic  regression  of  the occurrence  of  hypoglycaemia  indicated  that  treatment  g difference in the odds of having a hypoglycaemic event (odds ratio 1.577, p = 0.2083). Age was not a significant  factor  (odds  ratio  1.490,  p  =  0.2414),  whereas  background  anti-diabetes  medication (particularly SU and insu group  (3.2%  versus  1.3%).  Increase  in  amylase  levels  is  included  in  section  4.8  of  the  Jentadueto SmPC. One case with  contact  dermatitis  was  reported contact  dermatitis  or  urticaria,  a

## 2.6.1. Discussion on clinical safety

The evaluation of the safety of linagliptin and linagliptin/ metformin FDC for the treatment of patients with T2DM was based on 6 phase I studies, 2 phase II studies, and 6 phase III studies. Data were analysed in several study groupings.

Analysis  of  the  safety  of  linagliptin  with  metformin  combination  therapy  was  initially  based  on  the pivotal studies (study 1218.17). This analysis was compared with data obtained from a pooled analysis of all metformin-controlled trials.

<div style=\"page-break-after: always\"></div>

## Most frequent adverse events

bstantially less frequent in afety profile of individual In the pivotal study, the most frequent adverse events were infections and infestations. Gastrointestinal  disorders  also  occurred  with  almost  identical  incidences  in  both  treatment  groups. Differences of 2% or more were observed for musculoskeletal and connective tissue disorders which were  more  frequent  in  the  linagliptin  +  metformin  group.  Also  injury,  poisoning  and  procedural complications and respiratory, thoracic and mediastinal disorders were more frequent in the linagliptin + metformin group. Conversely, metabolism and nutrition disorders were su the  linagliptin  +  metformin  group  than  in  the  metformin  group  mainly  due  to  a  lower  incidence  of hyperglycaemia.  Also  hypoglycaemia  was  less  frequent  with  linagliptin  +  metformin  combination therapy  than  with  metformin  alone.  Furthermore,  investigations  and  psychiatric  disorders  were  less frequent with the combination therapy than in the metformin group. The comparison of the adverse event incidences in the pivotal trial with the incidences in the pooled analysis of all placebo-controlled trials  with  metformin  background  indicated  a  similar  safety  profile  of  the  linagliptin  +  metformin combination. The observed adverse events profile is in accordance with the s components  such  as  gastrointestinal  disorders  (e.g.  decreased  appetite,  nausea,  vomiting,  and diarrhoea) and pruritus associated with metformin; and nasopharyngitis, hypersensitivity, cough, and pancreatitis with linagliptin linagliptin. Hypoglycemia is identified as a side effect only when linagliptin and  metformin  are  combined  with  sulfonylureas.  This  is  addressed  in  sections  4.2  and  4.4  of  the SmPC.

## Subgroups

pairment, or metformin dose. The  analysis  of  the  safety  by  relevant  subgroups  indicated  that  the  safety  profile  of  the  linagliptin metformin  combination  was  not  influenced  by  age,  gender,  race  (White  and  Asian),  ethnicity, geographic region, renal im too  low  to  yield  any  relevant  information  in  a th  linagliptin.  This  issue  is  sufficiently The number of patients with hepatic impairment was subgroup  analysis;  these  patients  should  not  be  treated  wi addressed in the SmPC.

The assessment of safety in the study in elderly patients (1218.63) did not reveal any major concerns for treatment with linagliptin in the elderly population.

## Adverse events of special interest

e values (normalized reference range: 30-110 U/L) over a 72 week ce daily, linagliptin  2.5 mg 1000 mg twice daily reveals ients in the linagliptin group had increase in amylase compared to the placebo group. Increase in amylase levels is included otal, 10 cases of pancreas disorders were reported. Although none of the cases has been necrotising, haemorrhagic, or fatal, this is an important issue. In clinical trials with ed in the placebo plus metformin cohort of 483  patients.  The  incidence  rate  of  pancreatitis  for  linagliptin  plus  metformin  is  similar  to  the  data found in  the  linagliptin  monotherapy  development  program.  The  risk  of  pancreatitis  is  appropriately covered in section 4.4 of the SmPC. A comparison of changes in amylas period in patients dosed continuously with either metformin 1000 mg twi plus metformin 500 mg twice daily, or linagliptin 2.5 mg plus metformin that  at  week  12  the  mean  differences  from  baseline  were  5.7,  5.1,  and  9.9  U/L  respectively. Fluctuations in amylase values were noted at subsequent time points, but ultimately the differences from  baseline  at  week  78  were  similar  to  those  at  weeks  12  and  24  (mean  2.1,  3.8,  and  8.6  U/L respectively). In the study in elderly individuals, it was also noted that more pat in section 4.8 of the SmPC. In t linagliptin  (used  in  combination  with  metformin),  the  incidence  rate  per  1000  patient-years  in  3463 patients  was  1.4.  When  the  linagliptin  plus  metformin  combination  was  compared  to  placebo  plus metformin,  the  incidence  rate  per  1000  patient-years  in  1322  patients  treated  with  linagliptin  plus metformin was 2.0. No events of pancreatitis were report

<div style=\"page-break-after: always\"></div>

ts:  3  cases  occurring  during  treatment  with rmin m 1 event  was  considered a  was  rep treatment  with linagliptin  +  metformi was  serious,  both  events  were  not  assessed  as  drug-related. Regarding AE of special interest one case with contact dermatitis was reported in the study in elderly t clear whether the event was contact dermatitis or urticaria, and causality nt and she Photosensitivity  reactions  were  reported  by  4  patien linagliptin + metfo and 1 case during treatment with drug-related.  Angioedem n;  one  event etformin. None of the events was serious, orted  by  2  patients  during patients. However, it was no between this eve study drug has not been establi d.

As for linagliptin mono tion in was associated with angina pectoris  (4  vs.  0  pati and  myocardial  ischaemia  (2 metaanalysis  of  all  randomised  linagliptin  studies  demonstrat ith cardiovascular  risk,  cardiovascular  safety  remains  an  im important missing  information  in  the  RMP.  Higher  frequencies  of  hypertension  (0.1%)  and  hypertensive  crisis (0.1%)  were  observed  in  the  linagliptin  group.  A  CV  outcome  study  (study  1218.74)  is  currently ongoing. The results of this study will be submitted to the therapy, linagliptin in combina ents) with metform vs  0  patients).  Although  a  formal ed  that  linagliptin  was  not  associated  w portant  issue  and  is  included  as CHMP for review.

A  higher  incidence  of  infections  has  been  described  w long-term consequences of DPP-4 inhibition and its effects on other DPP-4 substrates, particularly with respect to immune  function,  are  unknown.  Although  the  incidence with  linagliptin  was  similar  to placebo (19.1% vs. 20.6%) and linagliptin was not associ phocyte count, it is important to realize that these observations w ort term trials, and ects rema ito ith  other  DPP-4  inhibitors.  The of  infections ated with a decrease in absolute lym ere done in relatively sh long term eff in a concern. This should be mon red closely post marketing.

Metformin is contraind elow nd this contraindication is also applicable  for  metfor combination  with  linaglipti tly addressed in the SmPC. icated for patients with GFR b min  in 60 ml/min a n.  This  issue  is  considered  as  sufficien

## usion 2.6.2. Concl s on the clinical safety

Overall, in the phase I ies the incidence of adverse ery similar across studies, with linagliptin being mostly comparable to placebo and active ty profile  appears  comparable  with  other  DPP-4  inhibitors. between linagliptin 2.5 mg twice daily and linagliptin 5 mg once dai II stud events was v comparator groups. In general, the safe Adverse  events  are  not  different ly.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilan ce system

The  CHMP  considered  that  the  Pharmacovigilance  system  as  descri cant  fulfills  the legislative  requirements  and  provides  adequate  evidence  that  the  applicant  has  the  services  of  a qualified person responsible for Pharmacovigilance and ha on of any adverse reaction suspected to occur either in the Unio bed  by  the  appli s the necessary means for the notificati n or in a third country.

## Risk Management Plan

The applicant submitted a risk management plan (version ased on the  RMP  for  the  single  component  linagliptin  (Trajenta)  and  complemented  with  relevant  safety information for metformin. The identified and potentials ris ation that are proposed by the applicant are considered acceptable. 4.0, dated 15 May 2012), which is b ks and the areas of missing inform

<div style=\"page-break-after: always\"></div>

mmary Table 47. Su of the risk management plan

| Safety concern            | e ties (routine and Proposed pharmacovigilanc activi additional)      | Proposed risk minimization activities (routine and additional)                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risk | Important identified risk                                             | Important identified risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hypoglycaemia             | Routine pharmacovigilance and analysis of clinical trial safety data  | When Jentadueto is used with SU, a n of SU may be considered Section 4.4 dose d to poglycaemia Hypoglycaemia is listed as adverse reaction for Jentadueto. Appropriate labelling in SmPC Section 4.2 dose reductio to reduce risk of hypoglycaemia When Jentadueto is used with SU, reduction of SU may be considere reduce risk of hy Section 4.8                                                                                                                                                                             |
| Pancreatitis              | Routine pharmacovigilance and analysis of clinical trial safety data  | Appropriate labelling in SmPC Section 4.8 Pancreatitis is listed as adverse reaction for Jentadueto.                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactic acidosis           | Routine pharmacovigilance and is of clinical trial safety analys data | Appropriate labelling in SmPC Section 4.2 nal function is necessary to aid in prevention of metformin- associated lactic acidosis, particularly in elderly Section 4.4 ntinuation of treatment and hospitalisation in case sis provided r lactic acidosis in acute alcohol intoxication is a listed side effect igh monitoring of re information on diagnosis, disco of lactic acido Section 4.5 information on increased risk fo provided Section 4.8 lactic acidosis is Section 4.9 lactic acidosis may occour in h overdose |
| Important potential risks | Important potential risks                                             | Important potential risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Skin lesions                             | Routine pharmacovigilance and analysis of clinical trial safety data                                                | Not applicable.                                                                                                                                                                                                                                                                              |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypersensitivity reactions               | e pharmacovigilance and analysis of clinical trial safety data Routin                                               | s is listed as side effect for Jentadueto. Hypersensitivity is specified (e.g. dema, bronchial hyperreactivity Appropriate labelling in SmPC Section 4.3 Hypersensitivity to the active substance of Jentadueto is listed as contraindication Section 4.8 Hypersensitivity urticaria, angioe |
| Infections                               | e pharmacovigilance and Routin analysis of clinical trial safety data                                               | Not applicable.                                                                                                                                                                                                                                                                              |
| Worsening of renal function              | ne pharmacovigilance and 74 [U10-2169]) Routi analysis of clinical trial safety data (planned CV-safety study 1218. | Not applicable.                                                                                                                                                                                                                                                                              |
| Important missing information            | Important missing information                                                                                       | Important missing information                                                                                                                                                                                                                                                                |
| Safety in subpopulations                 | Safety in subpopulations                                                                                            | Safety in subpopulations                                                                                                                                                                                                                                                                     |
| High risk patients with recent CV events | Routine pharmacovigilance and analysis of clinical trial safety data. Planned CV-safety study [U10-2169] 1218.74    | Not applicable.                                                                                                                                                                                                                                                                              |
| Elderly patients (> 80 years)            | Routine pharmacovigilance and analysis of clinical trial s data (planned CV-safety 1218.74 [U10-2169]) afety study  | n of age is available and care should be exercised. our times a year. Sections 4.2 Limited safety data for Jentadueto i Appropriate labelling in SmPC patients >75 years Section 4.4 Serum creatinine should be be determined in elderly at least two to f                                   |
| Paediatric use                           | Routine pharmacovigilance                                                                                           | Appropriate labelling in SmPC Sections 4.2 No data on safety and efficacy in children aged 0 to 18 years is available                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                        |                                                                      | for Jentadueto.                                                                                                                                                                                                                                                        |
|----------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pregnant and lactating patients        | Routine pharmacovigilance and analysis of clinical trial safety data | Appropriate labelling in SmPC Section 4.6 As a precautionary measure, it is preferable to avoid the use of Jentadueto during pregnancy. When becoming, or being pregnant, diabetes should be treated with insulin. Jentadueto should not be used during breastfeeding. |
| Oncological adverse reactions          | Routine pharmacovigilance and analysis of clinical trial safety data | Not applicable.                                                                                                                                                                                                                                                        |
| Idiosyncratic adverse reactions        | Routine pharmacovigilance and analysis of clinical trial safety data | Not applicable.                                                                                                                                                                                                                                                        |
| Immunological adverse reactions        | Routine pharmacovigilance and analysis of clinical trial safety data | Not applicable.                                                                                                                                                                                                                                                        |
| Concomitant P-gp and CYP3A4 inhibitors | Routine pharmacovigilance and analysis of clinical trial safety data | Not applicable.                                                                                                                                                                                                                                                        |

The CHMP, having considered the data submitted, was of the opinion that the below Pharmacovigilance activity in addition to the use of routine pharmacovigilance is needed to investigate further some of the safety concerns:

| Description                                           | Due date                                                                                                                                                                                                                                                          |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. RMP Ongoing CV safety study (study 1218.74)        | Interim analysis (DMC safety assessment only): event driven, ≥ 80 adjudicated primary outcome events, and minimum duration of 1.5 years: December 2012 Final analysis due date event driven, 631 adjudicated primary outcome events. Final report: December 2018. |
| 2. RMP Ongoing meta-analysis of phase 3 and 4 studies | A meta-analysis of phase 3 and 4 studies is ongoing to further investigate card iovascular safety. The final hs of the Commission Decision. protocol should be submitted to CHMP for review within two mont                                                       |

No  additional  risk  minimisation  activities  were  required  beyond  those  included  in  the  product information.

<div style=\"page-break-after: always\"></div>

## 2.8. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

that lowers blood glucose levels by augmenting the glucose-stimulated insulin release through GLP-1. Linagliptin 5 mg has been plus sulphonylurea. In addition,  linagliptin  5  mg  has  been  approved  for  use  as  monotherapy  in  patients  inadequately Linagliptin is a selective, orally administered, xanthine-based DPP-4 inhibitor approved in the EU as Trajenta in combination with metformin and metformin controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.

For other DPP-4 inhibitors sitagliptin (Januvia), vildagliptin (Galvus) and saxagliptin (Onglyza), fixed dose combinations with metformin (Janumet, Eucras and Komboglyze, respectively) have previously been approved in the European Union.

Because the pharmacokinetics of metformin require an at least twice daily dosing, for the development of the FDC the once daily dosing of 5 mg linagliptin (which is the posology of Trajenta) was split into 2 daily  doses  of  2.5  mg.  In  healthy  individuals,  linagliptin  2.5  mg  twice  daily  was  bioequivalent  to linagliptin  5  mg  once daily with respect to the exposure data over 24 hours AUC0-24 hours  and DPP-4 inhibition (study 1218.47). In its Scientific Advice from 2008, the CHMP requested a clinical study to show equivalence of twice daily dosing of linagliptin 2.5 mg with once daily dosing of linagliptin 5 mg (EMEA/CHMP/SAWP/472394/2008). Therefore, new clinical data were submitted. Study 1218.62 was a placebo-controlled  study  over  12  weeks  that  showed  comparable  efficacy  of  the  linagliptin  2.5  mg twice daily regimen and the linagliptin 5 mg once daily regimen when added to metformin.

An additional  phase  III  study  for  the  establishment  of  efficacy  of  linagliptin  2.5  mg  twice  daily  was study 1218.46.  This study tested 2 linagliptin 2.5 mg-metformin combinations versus metformin. The combination of linagliptin with metformin 500 mg twice daily as well as with metformin 1000 mg twice daily demonstrated a relevant effect on HbA1c in comparison to metformin only.

thnicity,  geographical  region,  and baseline BMI did not have an influence on the treatment effect. Furthermore, the presence of washout negatively influence the treatment effect of The efficacy of linagliptin and metformin over metformin could also be shown in relevant subgroups of patients.  Factors  such  as  age,  gender,  race  (White  vs.  Asian),  e of prior OADs and the time since diagnosis of diabetes did linagliptin metformin combination therapy, but efficacy was acceptable.

The clinical study in elderly patients (&gt;70 years) showed that the glucose lowering effect of linagliptin in the elderly population is similar to that in younger patients.

<div style=\"page-break-after: always\"></div>

ical  studies  in  the  application  dossier  were  conducted  with  linagliptin  2.5  mg  tablets  in combination with metformin tablets (1000 mg, 500 mg and 850 mg tablets). The Applicant conducted studies 1288.1,1288.2 and 1288.3) with the to be registered FDC tablets to justify the extrapolation of the results of the studies performed with the mono components to the Most  clin three bioequivalence studies ( FDC tablets. Based on the bioequivalence studies linagliptin 2.5 mg/metformin 1000 mg, linagliptin 2.5 mg/metformin 850 mg, linagliptin 2.5 mg/metformin 500 mg can be considered bioequivalent with the single dose formulation with linagliptin 2.5mg tablet and EU Glucophage 1000 mg, 500 mg and 850 mg respectively.

ntadueto and of the use of metformin 500 mg bid in clinical practice taking into account effects on HbA1C, clinical outcome and intolerance of higher dosages of metformin. Justification for the linagliptin 2.5 mg/metformin 500 mg strength was requested by the CHMP on the basis  of  the  clinical  data  of  Je The Applicant decided to withdraw this lower strength during the evaluation.

## Uncertainty in the knowledge about the beneficial effects

linagliptin  2.5  mg  twice  daily  in The  treatment  effect  of  linagliptin  2.5  mg  twice  daily  in  combination  with  metformin  as  dual combination  therapy  was  investigated.  The  triple  combination  of combination with metformin and SU was not investigated as such.

up  to  54  weeks,  mean roup.  In  addition,  the  proportion  of  patients  who required rescue medication up to Week 78 was lower in the linagliptin 2.5 + metformin1000 mg bid Long term efficacy of linagliptin was investigated in several trials. First, linagliptin 5 mg in combination with metformin or metformin with SU was investigated in study 1218.40, the open-label extension of studies  1218.17  and  1218.18.  Interim  analyses  were  presented  with  this  application.  New  interim analyses  provided  efficacy  data  for  linagliptin  over  up  to  102  weeks.  The  decrease  in  HbA1c  was maintained in the individuals that continued the use of linagliptin with metformin. However, 38.7% of the patients using linagliptin in combination with metformin required rescue medication, and 33.8% of the patients using linagliptin in combination with metformin and SU required rescue medication. The relatively large proportion of patients requiring rescue medication in the extension trials in comparison to the initial trials was a concern. However, it is conceivable that this is explained by the low threshold for the initiation of rescue therapy, the long study duration and the fact that the extension trials also allowed entry for patients who already received rescue medication in the initial trials. Second, longterm  data  (78  weeks)  are  available  from  study  1218.52,  which  is  a  double-blind  metformin monotherapy-controlled  extension  trial  in  patients  who  completed  the  24-week  treatment  period  of study  1218.46  without  requiring  rescue  medication.  In  the  extension  study, HbA1c levels remained fairly stable in all 3 treatment groups. Throughout the entire treatment duration of 78 weeks, the linagliptin 2.5 mg + metformin 1000 mg combination achieved greater reductions in mean  HbA1c  than  the  metformin  1000  mg  bid  g group (12.6%) than in the metformin 1000 mg bid group (22.9%).

The amount of patients with hepatic impairment was low.

1218.46  suggest  the  opposite:  the  treatment  effect  of  linagliptin  2.5  mg Factors such as age, gender, race (White vs. Asian), ethnicity, geographical region, and baseline BMI did  not  have  an  influence  on  the  treatment  effect.  The  results  with  respect  to  race  were  divergent Previous studies suggested that the treatment effect of linagliptin was lower in Whites than in Asians, while  the  results  of  study twice daily was smaller in Asians compared to Whites (-0.42% vs. -0.65%, respectively in combination with metformin 500 mg;-0. 39% vs. -0.59% respectively in combination with metformin 1000 mg).

<div style=\"page-break-after: always\"></div>

## Risks

## Unfavourable effects

Overall,  in  the  phase  III  studies  the  overall  incidence  of  adverse  events  were  very  similar  across ng  mostly  comparable  to  placebo  and  active  comparator  groups.  The observed adverse events profile is in accordance with the safety profile of individual components such ng, and diarrhoea) and pruritus associated with metformin; and nasopharyngitis, hypersensitivity, cough, and pancreatitis for studies,  with  linagliptin  bei as gastrointestinal disorders (e.g., decreased appetite, nausea, vomiti linagliptin.  Hypoglycaemia  is  identified  as  a  side  effect  only  when  linagliptin  and  metformin  are combined with sulfonylureas.

It  is  well  known  that  metformin  is  contraindicated  for  patients  with  GFR  below  60  ml/min.  This contraindication is also applicable for metformin in combination with linagliptin.

The analysis of the safety by relevant subgroups indicated that the safety profile of the linagliptin/metformin  combination  was  not  influenced  by  age,  gender,  race  (White  and  Asian), ethnicity, geographic region, renal impairment, or metformin dose.

d 24 (mean 2.1, 3.8, and 8.6 U/L respectively). In the study in elderly individuals, it e incidence rate of pancreatitis for linagliptin plus metformin is A comparison of changes in amylase values over a 72 week period in patients dosed continuously with either  metformin  1000  mg  twice  daily,  linagliptin  2.5  mg  plus  metformin  500  mg  twice  daily,  or linagliptin 2.5 mg plus metformin 1000 mg twice daily reveals that at week 12 the mean differences from baseline were 5.7, 5.1, and 9.9 U/L respectively. Fluctuations in amylase values were noted at subsequent time points, but ultimately the differences from baseline at week 78 were similar to those at weeks 12 an was also noted that more patients in the linagliptin group had increase in amylase compared to the placebo group. This increase in amylase levels has been included in the SmPC. In total, 10 cases of pancreas disorders were reported. Although none of the cases has been necrotising, haemorrhagic, or fatal,  this  is  an  important  issue.  When  the  linagliptin  plus  metformin  combination  was  compared  to placebo  plus  metformin,  the  incidence  rate  per  1000  patient-years  in  1322  patients  treated  with linagliptin  plus  metformin  was  2.0.  No  events  of  pancreatitis  were  reported  in  the  placebo  plus metformin cohort of 483 patients. Th similar to the data found in the linagliptin monotherapy development program. The risk of pancreatitis has been added to paragraph 4.4 'Special warnings and precautions for use'.

The Safety analyses of the study in elderly patients revealed no new unexpected safety issues. The overall rate of AEs was higher than in most previous clinical trials with linagliptin, but the differences between placebo and treatment group were small.

## Uncertainty in the knowledge about the unfavourable effects

th events were not assessed as drug-related. Long term effects are unclear. Photosensitivity  reactions  were  reported  by  4  patients:  3  cases  occurring  during  treatment  with linagliptin + metformin and 1 case during treatment with metformin. None of the events was serious, 1 event  was  considered  drug-related.  Angioedema  was  reported  by  2  patients  during  treatment  with linagliptin + metformin; one event was serious, bo tin  treatment  in  combination  with  metformin.  A  formal  meta-analysis  of  all  randomised linagliptin  studies  was  submitted.  This  meta-analysis  demonstrated  that  overall  linagliptin  was  not associated  with  cardiovascular  risk.  Somewhat  higher  frequencies  of  hypertension  and  hypertensive crisis were observed in the linagliptin group. Angina pectoris (4 vs. 0 patients) and myocardial ischaemia (2 vs 0 patients) were associated with linaglip

<div style=\"page-break-after: always\"></div>

ne  in A  higher  incidence  of  infections  has  been  described  with  other  DPP-4  inhibitors.  The  long-term consequences of DPP-IV inhibition and its effects on other DPP-IV substrates, particularly with respect to  immune  function,  are  unknown.  It  is  important  to  realize  that  these  observations  were  do relatively short term trials.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

gliptin and metformin was a logical next step. Fixed-dose combinations may decrease the risk of medication non-compliance and The most important favourable effect of linagliptin were added to treatment with metformin is lowering of HbA1c. This effect is relatively small in comparison to the effects of other drug classes, such as GLP1 agonists, insulin and SU preparations. A fixed dose combination of lina this may translate into better clinical outcomes.

The triple combination of linagliptin 2.5 mg twice daily in combination with metformin and SU was not problem if SU influences the efficacy and/or safety of linagliptin 2.5 mg twice  daily  differently  than  it  influences  linagliptin  5  mg  once  daily,  which  is  unlikely.  In  healthy investigated. This may be a individuals, bioequivalence of the linagliptin 2.5 mg/metformin fixed dose combination posology versus the  separate  components  has  been  demonstrated.  In  addition,  it  has  been  demonstrated  that  the efficacy  of  linagliptin  2.5  mg  twice  daily  was  similar  to  the  efficacy  of  linagliptin  5  mg  once  daily  in patients on metformin. Therefore the CHMP considered that data submitted which include a linagliptin 5 mg qd triple combination study sufficiently support the use of Jentadueto in triple combination with a sulphonylurea.

The fact that at least half of the patients were not treated with oral antidiabetic drugs before inclusion in study 1218.46 is not in line with the requested indication for linagliptin/metformin in patients that are  insufficiently  controlled  with  metformin  or  metformin  in  combination  with  SU.  The  inclusion  of treatment naive patients resulted in an overestimation of the treatment effects of metformin in this study. Nevertheless, the treatment effects of linagliptin were similar in patients that were pretreated and those that were treatment naive.

1000  mg combination achieved greater reductions in mean HbA1c than the metformin 1000 mg bid group. In cue medication up to Week 78 was lower in the linagliptin  2.5  +  metformin1000  mg  bid  group  (12.6%)  than  in  the  metformin  1000  mg  bid  group While T2DM is a progressive disease and the long term effects of linagliptin are relatively modest, longterm  data  from  study  1218.52  demonstrated  that  the  linagliptin  2.5  mg  +  metformin addition, the proportion of patients who required res (22.9%).

ancreatitis in the long term are considered cluded in section 4.4 of the SmPC and as an important potential risk in the RMP. In line with the SmPC guideline, increase in amylase levels The increase in amylase levels and the increased risk for p important concerns. The incidence rate of pancreatitis for linagliptin plus metformin is similar to the data found in the linagliptin monotherapy development program. Although none of the cases has been necrotising, haemorrhagic, or fatal, the risk of pancreatitis has in has also been included in section 4.8 of the SmPC.

ioedema  were  observed  rarely.  Angioedema  (hypersensitivity reactions) is included in section 4.8 of the SmPC and is included in the RMP as an important potential risk. Photosensitivity  reactions  and  ang

<div style=\"page-break-after: always\"></div>

served with linagliptin in combination with metformin although the absolute numbers of CV events were very low. This emphasizes the need for a cardiovascular safety utcome study is currently ongoing (study 1218.74) and is also included in the RMP. A low number of CV events were ob study. A CV o re unknown. If present, this is likely to be a class effect of DPP-IV inhibitors. Immunological adverse  reactions  are  included  as  important  missing  information  in  the  RMP  and  will  be  monitored The possible increased risk of infections and skin reactions and worsening of renal function have been included  as  important  potential  risk  in  the  RMP.  Long-term  consequences  of  linagliptin  on  immune function a closely post marketing.

tformin has a relatively low risk for hypoglycaemia. The low propensity of linagliptin to cause hypoglycaemia when compared to SU and Due to its mechanism of action, linagliptin in combination with me insulin may be relevant in patients more prone to hypoglycaemic events.

sulins  and  SU  the  addition  of  linagliptin  to  metformin  does  not increase body weight. In an overweight population, this can be considered a valuable advantage. Furthermore  compared  to  most  in

## nce Benefit-risk bala

twice  daily  is  comparable  to linagliptin 5 mg once daily in combination with metformin. Linagliptin 2.5 mg twice daily was shown to AUC0-24 hours and DPP-4 inhibition. In addition it has been demonstrated that the to be registered linagliptin 2.5 mg/metformin 1000 mg and linagliptin 2.5 5  mg  tablet  given concomitantly with EU metformin 1000 mg and 850 mg respectively. The  clinical  short  term  effect  of  linagliptin  2.5  mg  with  metformin be bioequivalent to linagliptin 5 mg once daily for mg  /  metformin  850  mg  FDC  tablets  are  bioequivalent  with  the  linagliptin  2.

Several  possible  side-effects  were  identified,  but  the  risks  were  in  general  only  mildly  elevated  in r comparison to placebo and comparators. Cardiovascular risk and pancreatitis are of particular interest. A cardiovascular outcome study is currently ongoing and the results will be submitted for the CHMP fo review (as stated in the RMP). Furthermore, an increased incidence of pancreatitis is of concern, as this is a potential serious life threatening disease. The risk of pancreatitis has been included in section 4.4 of the SmPC and will be further monitored.

In  conclusion  the  CHMP  considers  that  the  benefits  outweigh  the  risks  of  Jentadueto  (linagliptin  2.5 mg/metformin 850 mg and linagliptin 2.5 mg/metformin 1000 mg) in the claimed indication.

## Discussion on the benefit-risk balance

The overall benefit/risk of Jentadueto is considered positive for the indication:

'Treatment of adult patients with type 2 diabetes mellitus:

Jentadueto  is  indicated  as  an  adjunct  to  diet  and  exercise  to  improve  glycaemic  control  in  adult on their maximal tolerated dose of metformin alone, or those already patients inadequately controlled being treated with the combination of linagliptin and metformin.

Jentadueto  is  indicated  in  combination  with  a  sulphonylurea  (i.e.  triple  combination  therapy)  as  an nd exercise in adult patients inadequately controlled on their maximal tolerated dose adjunct to diet a of metformin and a sulphonylurea.'

<div style=\"page-break-after: always\"></div>

## 4. 3 B Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that  the  risk-benefit  balance  of  Jentadue  in  the  treatment  of  adult  patients  with  type  2  diabetes mellitus:

Jentadueto  is  indicated  as  an  adjunct  to  diet  and  exercise  to  improve  glycaemic  control  in  adult patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of linagliptin and metformin.

Jentadueto is  indicated  in  combination  with  a  sulphonylurea  (i.e.,  triple  combination  therapy)  as  an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

is  favourable  and  therefore  recommends  the  granting  of  the  marketing  authorisation  subject  to  the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Conditions and requirements of the Marketing Authorisation

## Risk Management System and PSUR cycle

The  MAH  must  ensure  that  the  system  of  pharmacovigilance,  presented  in  Module  1.8.1  of  the marketing authorisation, is in place and functioning before and whilst the product is on the market.

The  MAH  shall  perform  the  pharmacovigilance  activities  detailed  in  the  Pharmacovigilance  Plan,  as agreed in the Risk Management Plan (RMP) presented in Module 1.8.2 of the marketing authorisation and any subsequent updates of the RMP agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).

In addition, an updated RMP should be submitted:

-  When  new  information  is received that may  impact  on  the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
-  Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
-  At the request of the EMA.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

Not applicable.

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.